var docs;if (!docs) docs =[]; docs["77"]={"7700":"<p><b>Title</b> Angiotensin II Receptor Blockers / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving angiotensin II antagonists in combination with low molecular weight heparins.</p>\n<div>\n <p><b>Angiotensin II Receptor Blockers Interacting Members</b> Azilsartan, Candesartan, Eprosartan, Fimasartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan</p>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> The U.K. summary of product characteristics for heparin states that its use in combination with angiotensin II antagonists may elevate the risk of hyperkalemia.<sup>1</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and angiotensin II antagonists has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Heparin. Buckinghamshire, UK: Leo Laboratories Limited, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7701":"<p><b>Title</b> Potassium-Sparing Diuretics / Heparins (Low Molecular Weight)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving potassium-sparing diuretics in combination with low molecular weight heparins. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n <p><b>Potassium-Sparing Diuretics Interacting Members</b> AMILoride, Eplerenone, Spironolactone, Triamterene</p>\n</div> \n<p><b>Discussion</b> Spironolactone U.S. prescribing information warns that its combination with other drugs associated with hyperkalemia could result in severe hyperkalemia.<sup>1</sup> Heparin and low molecular weight heparins are specifically listed as potential contributors to such effects, and have been widely reported as potential causes of hyperkalemia (likely related to suppression of adrenal aldosterone secretion), although the magnitude of any interaction between these agents and spironolactone or other potassium sparing diuretics has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aldactone (spironolactone). New York, NY: Pfizer Inc, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7702":"<p><b>Title</b> Eplerenone / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Eplerenone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving eplerenone in combination with low molecular weight heparins.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> Eplerenone is an aldosterone antagonist, with one of its actions being to decrease sodium and water retention in the kidney, which results in greater potassium retention.<sup>1</sup> Its combination with potassium supplements or other medications that can increase serum potassium may increase the risk of hyperkalemia. Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and eplerenone has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Inspra (eplerenone). New York, NY: Pfizer Inc., February 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7703":"<p><b>Title</b> Aliskiren / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Aliskiren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving aliskiren in combination with low molecular weight heparins.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> The U.K. summary of product characteristics for aliskiren states that its use in combination with other drugs that may increase serum potassium may elevate the risk of hyperkalemia, specifically listing heparin as a potential contributor to such effects.<sup>1</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and aliskiren has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Rasilez (aliskiren). Surrey, UK: Novartis Pharmaceuticals UK Ltd, February 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7704":"<p><b>Title</b> Canagliflozin / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Canagliflozin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving canagliflozin in combination with low molecular weight heparins.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n</div> \n<p><b>Discussion</b> Canagliflozin U.S. prescribing information states that its coadministration with medications that reduce potassium excretion (e.g., potassium sparing diuretics and medications that inhibit the renin-angiotensin-aldosterone system) may predispose patients to development of hyperkalemia.<sup>1</sup> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion, although the magnitude of any interaction between these agents and canagliflozin has not been characterized clinically. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Invokana (canagliflozin). Titusville, NJ: Janssen Pharmaceuticals, Inc., March 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7705":"<p><b>Title</b> Potassium Salts / Heparins (Low Molecular Weight)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Heparins (Low Molecular Weight) may enhance the hyperkalemic effect of Potassium Salts. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum potassium concentrations closely in patients receiving potassium salts in combination with low molecular weight heparins.</p>\n<div>\n <p><b>Heparins (Low Molecular Weight) Interacting Members</b> Bemiparin, Dalteparin, Enoxaparin, Nadroparin, Tinzaparin</p>\n <p><b>Potassium Salts Interacting Members</b> Potassium Acetate, Potassium Chloride, Potassium Citrate, Potassium Gluconate, Potassium Iodate, Potassium Iodide, Potassium Phosphate</p>\n</div> \n<p><b>Discussion</b> Heparin and low molecular weight heparins have been widely reported as potential causes of hyperkalemia, likely related to suppression of adrenal aldosterone secretion.<sup>1</sup> Use of these agents in combination with potassium supplements or other medications that can increase serum potassium may therefore increase the risk of hyperkalemia. Closely monitor serum potassium in patients receiving these agents in combination, particularly patients who may be at further elevated risk for hyperkalemia (e.g., those with diabetes, advanced age, chronic kidney disease, or metabolic acidosis, or those receiving other medications associated with increases in serum potassium concentrations).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Summary of product characteristics. Heparin. Buckinghamshire, UK: Leo Laboratories Limited, June 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7706":"<p><b>Title</b> Vitamin K Antagonists / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for increased vitamin K antagonist effectiveness (increased INR, signs/symptoms of bleeding) when used together with one of these types of multivitamin. Both the vitamin E and vitamin A (particularly at higher doses) components may increase anticoagulant effectiveness. The specific effect(s) of individual multivitamin products may be better predicted by evaluating the specific amount of these components in the particular multivitamin product. The likelihood of a clinically significant is greater with products containing larger amounts of any of these specific vitamins.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A warfarin-treated patient exhibited a prolonged prothrombin time (PT) and began to bleed within 2 months of initiating vitamin E therapy (1200 IU/day).<sup>1</sup> A subsequent challenge with 800 IU of vitamin E daily (for 7 weeks) showed a 41% increase in prothrombin time at 7 weeks (changes began at week 4), the development of ecchymoses on extremities, and decreased serum concentrations of blood clotting factors. Warfarin serum concentrations remained unchanged. The patient's coagulation status (including signs of over-anticoagulation) normalized within one week of discontinuing the vitamin E. The prothrombin activity (36 hours postdose) in 3 dicumarol-treated (150 mg single dose) healthy subjects was decreased from 52% to 33% when administered following a 30-day course of vitamin E (42 IU/day).<sup>2</sup> Of note, the author states that “similar results” were obtained using vitamin A (25,000 IU/day) instead of vitamin E, suggesting that higher doses of vitamin A may interact in a similar manner. In contrast, two studies involving 37 patients showed no significant changes in response to warfarin during concomitant administration of vitamin E (doses up to 1200 IU/day).<sup>3,4</sup> The mechanism of this interaction is unknown. One author group has postulated that vitamin E may interfere with the vitamin K-dependent process of clotting factor production.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Corrigan JJ and Marcus FI, “Coagulopathy Associated With Vitamin E Ingestion,” <i>JAMA</i>, 1974, 230:1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479598\">[PubMed 4479598]</a></p>\n<p>2. Schrogie JJ, “Coagulopathy and Fat-Soluble Vitamins,” <i>JAMA</i>, 1975, 232:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172961\">[PubMed 1172961]</a></p>\n<p>3. Kim JM and White RH, “Effect of Vitamin E on the Anticoagulant Response to Warfarin,” <i>Am J Cardiol</i>, 1996, 77:545-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=86296604\">[PubMed 86296604]</a></p>\n<p>4. Corrigan JJ and Ulfers LL, “Effect of Vitamin E on Prothrombin Levels in Warfarin-Induced Vitamin K Deficiency,” <i>Am J Clin Nutr</i>, 1981, 34:1701-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7282596\">[PubMed 7282596]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7707":"<p><b>Title</b> Retinoic Acid Derivatives / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the adverse/toxic effect of Retinoic Acid Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming vitamin A-containing supplements while taking retinoic acid derivatives. If supplements containing vitamin A are used, ensure vitamin A consumption does not exceed the recommended daily allowance of 4,000 to 5,000 units daily due to the risk for vitamin A toxicity.</p>\n<div>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Adapalene, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), Bexarotene (Topical), ISOtretinoin (Systemic), Tretinoin (Systemic), Tretinoin (Topical)</p>\n</div> \n<p><b>Discussion</b> Due to the concern for an increased risk of vitamin A toxicity (eg, nausea, vomiting, headache, dizziness, blurred vision, skin and mucous disturbances), prescribing information for retinoic acid derivatives recommends to either strictly avoid all vitamin A supplements<sup>1,2,3,4</sup> or generally avoid vitamin A supplements, and if used, to not exceed the recommended daily allowance of 4,000 to 5,000 units daily.<sup>5</sup> <br><br>The likely mechanism of this potential interaction is retinoid overload resulting from the intake of both the specific retinoid derivative and vitamin A.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Soriatane</i> (acitretin) [prescribing information]. Research Triangle Park, NC: Stiefel Laboratories Inc; May 2014.</p>\n<p>2. <i>Accutane</i> (isotretinoin) [prescribing information]. Nutley, NJ: Roche Laboratories Inc; January 2010.</p>\n<p>3. Tretinoin [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; December 2011.</p>\n<p>4. <i>Toctino</i> (alitretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2013.</p>\n<p>5. <i>Targretin</i> (bexarotene) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7709":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Orlistat</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only oral preparations of fat soluble vitamins are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, orlistat may impair absorption of fat-solube vitamins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins.</p> \n<p><b>Discussion</b> Orlistat prescribing information describes reduced absorption of supplemental beta carotene (30%) and vitamin E (60%) associated with its concomitant use.<sup>1</sup> The influence of orlistat on the absorption of other fat soluble vitamins including diet-derived vitamin K or supplemental vitamin A and D has not been demonstrated. As orlistat inhibits gastric and pancreatic lipase, it would seem prudent to anticipate a similar effect on the absorption of these fat soluble vitamins as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenical (orlistat). South San Francisco, CA: Genentech USA, Inc., May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7710":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Bile Acid Sequestrants</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Applies only to oral administration of these agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Fluoride (with ADE). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant oral administration of multivitamins and bile acid sequestrants (eg, cholestyramine). Specific recommendations regarding separating the administration of these agents are not defined; however, it would be prudent to separate the administration of these agents by several hours to minimize the potential for a significant interaction. The manufacturer of colesevelam recommends that drugs with a known interaction or uncertain interaction potential should be administered at least 4 hours before colesevelam..</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n</div> \n<p><b>Discussion</b> In one report, children with hypercholesterolemia (n=5) who had good adherence to treatment with colestipol plus a low-cholesterol diet had significantly decreased vitamin A and vitamin E concentrations.<sup>1</sup> A controlled study of 14 healthy volunteers similarly reported that administration of cholestyramine (12 g) with a vitamin A-containing test meal was associated with an approximate 60% decrease in the expected rise in vitamin A concentrations.<sup>2</sup><br><br>Two case reports and several animal studies support the theory that bile acid sequestrants can impair vitamin D absorption. Both case reports describe patients with prior ileal resections who developed osteomalacia that was attributed to cholestyramine therapy.<sup>3,4</sup> Studies in rats have shown that steatorrhea-inducing doses of cholestyramine impaired vitamin D3 absorption and was associated with altered calcium handling.<sup>5,6</sup> Conversely, two separate long-term clinical studies found that cholestyramine (24 g/d) treatment for up to 7-10 years was not associated with any changes in plasma concentrations of calcium, phosphorous, calcifediol, 25-hydroxy-vitamin D2, or calcitriol.<sup>7,8</sup> Another study in children with hypercholesterolemia found that diet plus colestipol therapy did not negatively impact plasma 25-hydroxycholecalciferol concentrations or calcium metabolism.<sup>1</sup><br><br>Approximately 98% of niacin was bound to colestipol in an in vitro study.<sup>9</sup> A much lower amount (10% to 30%) was bound to cholestyramine,<sup>9</sup> suggesting there may be some differences among the individual bile acid sequestrants.<br><br>This suspected effect of bile acid sequestrants on the absorption of fat-soluble vitamins and possibly niacin could be the result of direct binding of the vitamin by the bile acid-binding resin, resin removal of bile acids that are necessary for fat-soluble vitamin absorption, and/or the impaired absorption could be secondary to drug-induced steatorrhea.<sup>5,10</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schwarz KB, Goldstein PD, Witztum JL, et al, “Fat-Soluble Vitamin Concentrations in Hypercholesterolemic Children Treated with Colestipol,” <i>Pediatrics</i>, 1980, 65(2):243-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7354970\">[PubMed 7354970]</a></p>\n<p>2. Barnard DL, Heaton KW, “Bile Acids and Vitamin A Absorption in Man: The Effects of Two Bile Acid-Binding Agents, Cholestyramine and Lignin,” <i>Gut</i>, 1973, 14(4):316-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4706914\">[PubMed 4706914]</a></p>\n<p>3. Heaton KW, Lever JV, Barnard D, “Osteomalacia Associated with Cholestyramine Therapy for Postileectomy Diarrhea,” <i>Gastroenterology</i>, 1972, 62(4):642-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5020877\">[PubMed 5020877]</a></p>\n<p>4. Compston JE, Horton LW, “Oral 25-Hydroxyvitamin D3 in Treatment of Osteomalacia Associated with Ileal Resection and Cholestyramine Therapy,” <i>Gastroenterology</i>, 1978, 74(5 Pt 1):900-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=640344\">[PubMed 640344]</a></p>\n<p>5. Thompson WG, Thompson GR, “Effect of Cholestyramine on the Absorption of Vitamin D3 and Calcium,” <i>Gut</i>, 1969, 10:717-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4318526\">[PubMed 4318526]</a></p>\n<p>6. Watkins DW, Khalafi R, Cassidy MM, et al, “Alterations in Calcium, Magnesium, Iron, and Zinc Metabolism by Dietary Cholestyramine,” <i>Dig Dis Sci</i>, 1985, 30(5):477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3987479\">[PubMed 3987479]</a></p>\n<p>7. Ismail F, Corder CN, Epstein S, et al, “Effects of Pravastatin and Cholestyramine on Circulating Levels of Parathyroid Hormone and Vitamin D Metabolites,” <i>Clin Ther</i>, 1990, 12(5):427-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2125243\">[PubMed 2125243]</a></p>\n<p>8. Hoogwerf BJ, Hibbard DM, Hunninghake DB, “Effects of Long-Term Cholestyramine Administration on Vitamin D and Parathormone Levels in Middle-Aged Men with Hypercholesterolemia,” <i>J Lab Clin Med</i>, 1992, 119(4):407-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1583392\">[PubMed 1583392]</a></p>\n<p>9. Prescribing information. Niaspan (niacin). Cranbury, NJ: Kos Pharmaceuticals, 12/2010.</p>\n<p>10. West RJ, Lloyd JK, “The Effect of Cholestyramine on Intestinal Absorption,” <i>Gut</i>, 1975, 16:93-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1168607\">[PubMed 1168607]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7711":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Aluminum Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: The significance of this interaction is greater among patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may increase the serum concentration of Aluminum Hydroxide. Aluminum Hydroxide may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, aluminum hydroxide may impair fluoride absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> To minimize the impact of this potential interaction, avoid administration of aluminum hydroxide within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination of agents, and in all patients avoid chronic and/or excessive use of aluminum and aluminum-containing products in patients who are also taking multivitamins containing vitamin D. Monitor for toxic effects of aluminum if a vitamin D- and/or vitamin C-containing multivitamin product is coadministered with aluminum hydroxide.</p> \n<p><b>Discussion</b> Modest doses of aluminum hydroxide (30 mL three times/day) have been shown to increase fecal fluoride excretion and decrease the net fluoride absorption.<sup>1</sup> It is suspected that this interaction is due to the formation of a poorly absorbed aluminum-fluoride complex, similar to the reported interaction between fluoride and calcium.<sup>1,2</sup> Clinical significance of this interaction is unclear.<br><br>A small study demonstrated an average 3-fold increase in urinary aluminum excretion when subjects received aluminum hydroxide (900 mg 3 times/day) with concomitant vitamin C (2 g/day).<sup>3</sup> Animal studies have similarly demonstrated increased aluminum concentrations in the liver, brains, and bones of rats given aluminum hydroxide with vitamin C.<sup>4</sup> The mechanism of this interaction is unknown, but has been suggested to be related to the formation of a soluble aluminum-citrate complex.<sup>5</sup><br><br>Several human studies and animal studies have also shown that vitamin D enhances aluminum absorption,<sup>6,7,8,9,10,11,12</sup> and this risk is expected to extend to all vitamin D analogs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” Clin Pharmacol Ther, 1980, 28(4):529-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408412\">[PubMed 7408412]</a></p>\n<p>2. Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002.</p>\n<p>3. Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” <i>Lancet</i>, 1991, 338(8780):1467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1683458\">[PubMed 1683458]</a></p>\n<p>4. Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” <i>Kidney Int</i>, 1991, 39(4):598-601. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2051716\">[PubMed 2051716]</a></p>\n<p>5. Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” <i>Am J Kid Dis</i>, 1991, 17(6):708-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2042654\">[PubMed 2042654]</a></p>\n<p>6. Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” <i>CMAJ</i>, 1992, 147(9):1308, 1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1340782\">[PubMed 1340782]</a></p>\n<p>7. Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” <i>Clin Nephrol</i>, 1989, 31(3):123-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706809\">[PubMed 2706809]</a></p>\n<p>8. Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” <i>Clin Nephrol</i>, 1986, 26(3):146-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769230\">[PubMed 3769230]</a></p>\n<p>9. Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i>, 1985, 21:390-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3991529\">[PubMed 3991529]</a></p>\n<p>10. Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” <i>Am J Physiol</i>, 1985, 249(2 Pt 1):G209-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4025548\">[PubMed 4025548]</a></p>\n<p>11. Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” <i>J Environ Sci Health B</i>, 1986, 21(2):191-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3011882\">[PubMed 3011882]</a></p>\n<p>12. Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” <i>J Lab Clin Med</i>, 1986, 108(2):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755457\">[PubMed 3755457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7712":"<p><b>Title</b> Cardiac Glycosides / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum calcium concentrations closely and watch for signs and symptoms of cardiac glycoside toxicity (e.g., loss of appetite, nausea and vomiting, etc.) in patients receiving a multivitamin and a cardiac glycoside together. In particular, multivitamins containing vitamin D and/or higher amounts of calcium are those with the highest potential to interact. Hypercalcemia enhances the conduction effects of cardiac glycosides.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> Multivitamins containing vitamin D and/or calcium can contribute to hypercalcemia, particularly with higher doses or in high-risk patients. Existing data show that hypercalcemia and cardiac glycosides, such as digoxin, have similar effects on cardiac conduction.<sup>1,2</sup> Consequently, clinically significant adverse effects on cardiac conduction can occur even at therapeutic concentrations of cardiac glycosides in the setting of hypercalcemia.<sup>1</sup> Similarly, cardiac glycosides can exacerbate the negative cardiovascular effects of hypercalcemia. A case report describing an elderly patient who experienced a clinically significant bradyarrhythmia attributed to hypercalcemia (total calcium = 3.0 mmol/L [normal: 2.2-2.5 mmol/L]) and digoxin therapy (digoxin concentration = 1.5 ng/mL [normal/therapeutic: 0.5-2.0 ng/mL]) exemplifies this risk.<sup>1</sup> Other case reports describe cardiac arrhythmias that occurred during concomitant administration of cardiac glycosides and a calcium preparation (primarily IV calcium).<sup>3,4</sup> Though deaths were reported in one citation, a causal relationship was not firmly established.<sup>3</sup><br><br>The mechanism by which hypercalcemia and cardiac glycosides augment one another's effects on conduction involves both the Na+/K+-ATPase and the Ca2+/Na+-antiporter. Cardiac glycosides are known to inhibit Na+/K+-ATPase,<sup>2</sup> increasing intracellular sodium concentrations. This increase in intracellular sodium inhibits action of the Ca2+/Na+-antiporter, which normally transports sodium into the cell as it transports calcium out of the cell. The net effect of inhibiting this antiporter is increased intracellular calcium.<sup>1</sup> Both the cardiac glycosides and excess calcium (i.e., hypercalcemia) decrease the cardiac excitation threshold, shorten the effective refractory period, and increase the refractoriness of the AV node.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vella A, Gerber TC, Hayes DL, et al, “Digoxin, Hypercalcemia, and Cardiac Conduction,” <i>Postgrad Med J</i>, 1999, 75:554-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616693\">[PubMed 10616693]</a> </p>\n<p>2. Kelly RA, Smith TW, “Pharmacological Treatment of Heart Failure,” In: Hardman JG, Limbird LE, Molinoff PB, et al, eds, Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996:809-38.]</p>\n<p>3. Bower Jo and Mengle HAK, “The Additive Effects of Calcium and Digitalis. A Warning With a Report of Two Deaths,” <i>JAMA</i>, 1936, 106:1151.</p>\n<p>4. Nola GT, Pope S, and Harrison DC, “Assessment of the Synergistic Relationship Between Serum Calcium and Digitalis,” <i>Am Heart J</i>, 1970, 79(4):499-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5418023\">[PubMed 5418023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7713":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Calcium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride. Additionally, though concurrent use of vitamin D and calcium salts is often recommended, patients receiving higher supplemental calcium doses together with a multivitamin that contains vitamin D and/or calcium should receive regular monitoring of serum calcium (and phosphate, iPTH, etc., as appropriate) and for signs/symptoms of hypercalcemia.</p>\n<div>\n <p><b>Calcium Salts Interacting Members</b> Calcium Acetate, Calcium Carbonate, Calcium Chloride, Calcium Citrate, Calcium Glubionate, Calcium Gluconate, Calcium Lactate, Polycarbophil</p>\n</div> \n<p><b>Discussion</b> According to the sodium fluoride prescribing information, ingestion of calcium-containing products within one hour of fluoride administration may impair fluoride absorption due to the formation of poorly absorbed calcium fluoride.<sup>1</sup> Clinical significance of this interaction is unclear.<br><br>Also, concurrent use of high doses of calcium-containing products with a multivitamin containing a vitamin D analog and/or calcium may increase the risk for hypercalcemia and other toxicities (e.g., nephrolithiasis, cardiovascular disease, etc.).<sup>2,3,4</sup> It is important to note that the risk for such adverse effects is generally limited to those patients whose calcium and/or vitamin D intake is considerably above dietary reference intake levels, and even with such higher intake, toxicity may not be common. Patients who are also using thiazide diuretics or those with conditions such as renal failure, granulomatous disease, or other conditions associated with hypercalcemia are at greatest risk.<sup>2,3,4</sup><br><br>Vitamin D is an important regulator of calcium absorption and handling, generally working to enhance serum calcium levels.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002.</p>\n<p>2. Hathcock JN, Shao A, Vieth R, et al, “Risk Assessment for Vitamin D,” <i>Am J Clin Nutr</i>, 2007, 85(1):6-18. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17209171\">[PubMed 17209171]</a></p>\n<p>3. Peacock M, “Calcium Metabolism in Health and Disease,” <i>Clin J Am Soc Nephrol</i>, 2010, 5 Suppl 1:S23-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20089499\">[PubMed 20089499]</a></p>\n<p>4. Bjelakovic G, Gluud LL, Nikolova D, et al, “Vitamin D Supplementation for Prevention of Mortality in Adults,” <i>Cochrane Database Syst Rev</i>, 2011, (7):CD007470. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21735411\">[PubMed 21735411]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7714":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Mineral Oil</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mineral Oil may decrease the serum concentration of Multivitamins/Fluoride (with ADE). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant administration of mineral oil with a multivitamin to minimize the risk for an interaction, though specific recommendations regarding how much to separate administration of these agents are not available. If the multivitamin is being used to increase/maintain concentrations of a specific vitamin or mineral, increased monitoring of serum concentrations may be warranted after initiation of regular mineral oil use.</p> \n<p><b>Discussion</b> The prescribing information for several vitamin D analogs warn that mineral oil may interfere with their absorption.<sup>1,2,3,4</sup> Though specific recommendations regarding administration are not provided in the manufacturer labeling, it would seem prudent to separate the administration of vitamin D, and possibly other fat-soluble vitamins, from mineral oil by several hours to minimize the potential for an interaction. Similarly, the mineral oil prescribing information warns that chronic and abusive use may lead to potentially serious adverse events (e.g., bleeding, metabolic).<sup>5</sup><br><br>In contrast, a published case report describes a 17-year-old female with normal values for prothrombin time, vitamin A and E, alkaline phosphatase, calcium, and phosphorus, despite consuming mineral oil (up to 400 mL/day) for at least 5 months.<sup>6</sup> A study of 25 children who were treated with mineral oil (between meals) for up to 4 months for constipation similarly reported only minimal to moderate effects on serum concentrations of various fat-soluble vitamins.<sup>7</sup> Serum beta-carotene concentrations were reduced by an average of 35%, alpha-tocopherol concentrations were not significantly changed, and serum retinol concentrations were increased by an average of 50%. Others have also questioned the evidence supporting this potential interaction.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, February 2011.</p>\n<p>2. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, March 2007.</p>\n<p>3. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, June 2010. </p>\n<p>4. Product monograph. One-Alpha (alfacalcidol). Thornhill, Ontario:LEO Pharma Inc., March 2010.</p>\n<p>5. Prescribing information. Mineral oil. Greensville, SC: Pharmaceutical Associates, Inc., November 2002.</p>\n<p>6. Gal-Ezer S, Shaoul R, “The Safety of Mineral Oil in the Treatment of Constipation- A Lesson from Prolonged Overdose,” Clin Pediatr, 2006, 45:856-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17041175\">[PubMed 17041175]</a></p>\n<p>7. Clark JH, Russell GJ, Fitzgerald JF, et al, “Serum Beta-Carotene, Retinol, and Alpha-Tocopherol Levels During Mineral Oil Therapy for Constipation,” <i>Am J Dis Child</i>, 1987, 141(11):1210-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3673974\">[PubMed 3673974]</a></p>\n<p>8. Abi-Hanna A, Lake AM, “Constipation and Encopresis in Childhood,” <i>Pediatr Rev</i>, 1998, 19(1):23-30 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9439166\">[PubMed 9439166]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7715":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Sucralfate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum may be increased. Sucralfate may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, sucralfate may impair the absorption of fluoride. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> To minimize the impact of this potential interaction, avoid administration of aluminum-containing products (such as sucralfate) within at least 1-2 hours of fluoride administration. In patients with severe renal dysfunction, consider avoiding this combination of agents, and in all patients avoid chronic and/or excessive use of aluminum-containing products in patients who are also taking multivitamins containing vitamin D. Monitor for toxic effects of aluminum if a vitamin D- and/or vitamin C-containing multivitamin product is coadministered with aluminum hydroxide.</p> \n<p><b>Discussion</b> Due to its aluminum content, interactions associated with other aluminum products are expected to be of similar concern with sucralfate.<br><br>Modest doses of aluminum hydroxide (30 mL three times/day) have been shown to increase fecal fluoride excretion and decrease the net fluoride absorption.<sup>1</sup> It is suspected that this interaction is due to the formation of a poorly absorbed aluminum-fluoride complex, similar to the reported interaction between fluoride and calcium.<sup>1,2</sup> Clinical significance of this interaction is unclear.<br><br>The prescribing information for the vitamin D analog paricalcitol specifically cautions that excessive and/or chronic concurrent use of aluminum salts and other aluminum-containing products, such as sucralfate, should be avoided due to an increased risk for aluminum accumulation/toxicity.<sup>3</sup> Several human studies and animal studies have shown that vitamin D enhances aluminum absorption,<sup>4,5,6,7,8,9,10</sup> and this risk likely extends to all vitamin D analogs.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” <i>Clin Pharmacol Ther</i>, 1980, 28(4):529-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408412\">[PubMed 7408412]</a></p>\n<p>2. Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002.</p>\n<p>3. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 3/2011.</p>\n<p>4. Moon J, Davison A, Bandy B, “Vitamin D and Aluminum Absorption,” <i>CMAJ</i>., 1992, 147(9):1308, 1313. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1340782\">[PubMed 1340782]</a></p>\n<p>5. Demontis R, Reissi D, Noel C, et al, “Indirect Clinical Evidence that 1 Alpha OH Vitamin D3 Increases the Intestinal Absorption of Aluminum,” <i>Clin Nephrol</i>, 1989, 31(3):123-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2706809\">[PubMed 2706809]</a></p>\n<p>6. Demontis R, Leflon A, Fournier A, et al, “1 Alpha(OH) Vitamin D3 Increases Plasma Aluminum in Hemodialized Patients Taking AI(OH)3,” <i>Clin Nephrol</i>, 1986, 26(3):146-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3769230\">[PubMed 3769230]</a></p>\n<p>7. Fournier A, Demontis R, Tahiri Y, et al, “1 Alpha OH Vitamin D3 Increases Plasma Aluminium in Haemodialysed Patients Taking Al (OH)3,” <i>Proc Eur Dial Transplant Assoc Eur Ren Assoc</i>, 1985, 21:390-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3991529\">[PubMed 3991529]</a></p>\n<p>8. Adler AJ, Berlyne GM, “Duodenal Aluminum Absorption in the Rat: Effect of Vitamin D,” <i>Am J Physiol</i>, 1985, 249(2 Pt 1):G209-13. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4025548\">[PubMed 4025548]</a></p>\n<p>9. Anthony J, Fadl S, Mason C, et al, “Absorption, Deposition and Distribution of Dietary Aluminium in Immature Rats: Effects of Dietary Vitamin D3 and Food-Borne Chelating Agent,” <i>J Environ Sci Health B</i>, 1986, 21(2):191-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3011882\">[PubMed 3011882]</a></p>\n<p>10. Burnatowska-Hledin MA, Doyle TM, Eadie MJ, et al, “1,25-Dihydroxyvitamin D3 Increases Serum and Tissue Accumulation of Aluminum in Rats,” <i>J Lab Clin Med</i>, 1986, 108(2):96-102. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3755457\">[PubMed 3755457]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7716":"<p><b>Title</b> Vitamin D Analogs / Multivitamins/Fluoride (with ADE)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Multivitamin products with higher doses of vitamin D pose a higher risk than those products with smaller doses of vitamin D.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the adverse/toxic effect of Vitamin D Analogs. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid combined use of multiple vitamin D analogs (at pharmacologic doses). Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against such combined use. Though not specified in the prescribing information for calcipotriene, cholecalciferol, and ergocalciferol, each contains warnings regarding the potential for vitamin D toxicity. Multivitamin products with higher doses of vitamin D pose a higher risk than those products with smaller doses of vitamin D.</p>\n<div>\n <p><b>Vitamin D Analogs Interacting Members</b> Alfacalcidol, Calcifediol, Calcipotriene, Calcitriol (Systemic), Calcitriol (Topical), Cholecalciferol, Doxercalciferol, Ergocalciferol, Paricalcitol, Tacalcitol</p>\n</div> \n<p><b>Discussion</b> Prescribing information for calcitriol, doxercalciferol, paricalcitol, and alfacalcidol each specifically cautions against combined use with pharmacologic doses of other vitamin D analogs due to the risk for vitamin D toxicity.<sup>1,2,3,4</sup> Though the prescribing information for other vitamin D analogs do not specifically warn against such concurrent use, they do contain warnings regarding the potential for vitamin D toxicity.<sup>5,6,7</sup> Even with relatively low systemic absorption, calcipotriene prescribing information contains cautions about systemic toxicities such as vitamin D toxicity and hypercalcemia.<sup>7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, 01/2009.</p>\n<p>2. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, 06/2010.</p>\n<p>3. Prescribing information. Calcijex (calcitriol). North Chicago, IL: Abbott Laboratories, 2004.</p>\n<p>4. Prescribing information. One-Alpha (alfacalcidol). Thornhill, Ontario: LEO Pharma Inc., March 2010.</p>\n<p>5. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: sanofi-aventis U.S. LLC, March 2007.</p>\n<p>6. Prescribing information. Fosamax Plus D (alendronate/cholecalciferol). Whitehouse Station, NJ: Merck &amp; Co., Inc., March 2010.</p>\n<p>7. Prescribing information. Dovonex (calcipotriene). Princeton, NJ: Bristol-Myers Squibb Company, 04/2006.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7717":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the hypercalcemic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for evidence of calcium-related toxicities as well as both serum calcium concentrations and response to vitamin D closely in all patients receiving a multivitamin containing vitamin D and/or calcium together with a thiazide diuretic.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The product labeling for both ergocalciferol and calcitriol recommend caution with concomitant use of a thiazide diuretic due to the risk of hypercalcemia.<sup>1,2</sup> Studies regarding the effect of thiazide diuretics in combination with either of these agents are relatively lacking. One small study of 6 healthy volunteers fed a low-calcium diet found that those receiving calcitriol differed very little in their response to thiazides from those not receiving calcitriol with regard to measures of calcium balance and vitamin D/parathyroid hormone systems.<sup>3</sup> Thiazides have been shown to decrease urinary calcium excretion in both healthy volunteers and children on long-term calcitriol treatment.<sup>3,4</sup> However, no change in urinary calcium excretion was reported in patients with hypoparathyroidism being treated with vitamin D,<sup>5</sup> leading the study authors to conclude that parathyroid hormone is required for thiazides to have their anti-calciuric effects. This ability to diminish urinary calcium excretion has stimulated interest in using thiazide diuretics with calcitriol to prevent/treat hypocalcemia in certain patients, and one such study reported less hypocalcemia following thyroidectomy in patients receiving calcitriol plus hydrochlorothiazide (n=22) than those receiving placebo (n=20) (4.5% vs. 50%).<sup>6</sup><br><br>Studies examining the effects of thiazide diuretics on calcium and vitamin D metabolism without concurrent calcitriol treatment have reported variable findings. While thiazides have been shown to decrease urinary calcium excretion in healthy volunteers<sup>7,8,9</sup> and patients with idiopathic hypercalciuria,<sup>10</sup> the net effect on calcium concentrations has ranged from increased concentrations<sup>5,7</sup> to no change<sup>8,10</sup> to decreased concentrations.<sup>6,11,12</sup> The reported effects of thiazides on concentrations of endogenous calcitriol and various vitamin D metabolites have been similarly mixed.<sup>7,8,9,10,11,12</sup><br><br>As hypercalcemia is a potential adverse event associated with vitamin D therapy, it would seem prudent to closely monitor serum calcium concentrations in patients receiving concomitant thiazide diuretic therapy.<br><br>Additionally, case reports describe hypercalcemia, and signs and symptoms of the milk-alkali syndrome (including dizziness, weakness, hypercalcemia, metabolic and alkalosis with respiratory compensation), developing in conjunction with concomitant use of thiazide diuretics and calcium supplementation.<sup>13,14,15,16</sup> Thiazide diuretics inhibit the excretion of calcium, as well as bicarbonate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, November 2009. </p>\n<p>2. Prescribing information Rocaltrol (calcitriol). Parsippany, NJ: Validus Pharmaceuticals LLC, July 2009.</p>\n<p>3. Lemann J, Jr., Gray RW, Maierhofer WJ, et al., “Hydrochlorothiazide Inhibits Bone Resorption in Men Despite Experimentally Elevated Serum 1,25-Dihydroxyvitamin D Concentrations,” <i>Kidney Int</i>, 1985, 28:951-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3003445\">[PubMed 3003445]</a></p>\n<p>4. Santos F, Smith MJ,Chan JC, “Hypercalciuria Associated with Long-Term Administration of Calcitriol (1,25-Dihydroxyvitamin D3). Action of Hydrochlorothiazide,” <i>Am J Dis Child</i>, 1986, 140:139-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3753816\">[PubMed 3753816]</a></p>\n<p>5. Brickman AS, Massry SG,Coburn JW, “Changes in Serum and Urinary Calcium During Treatment with Hydrochlorothiazide: Studies on Mechanisms,” <i>J Clin Invest</i>, 1972, 51:945-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4552338\">[PubMed 4552338]</a></p>\n<p>6. Testa A, Fant V, De Rosa A, et al., “Calcitriol Plus Hydrochlorothiazide Prevents Transient Post-Thyroidectomy Hypocalcemia,” <i>Horm Metab Res</i>, 2006, 38:821-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17163358\">[PubMed 17163358]</a></p>\n<p>7. Krause U, Zielke A, Schmidt-Gayk H, et al., “Direct Tubular Effect on Calcium Retention by Hydrochlorothiazide,” <i>J Endocrinol Invest</i>, 1989, 12:531-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2592738\">[PubMed 2592738]</a></p>\n<p>8. Rejnmark L, Vestergaard P, Heickendorff L, et al., “Effects of Thiazide- and Loop-Diuretics, Alone or in Combination, on Calcitropic Hormones and Biochemical Bone Markers: A Randomized Controlled Study,” <i>J Intern Med</i>, 2001, 250:144-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11489064\">[PubMed 11489064]</a></p>\n<p>9. Riis B,Christiansen C, “Actions of Thiazide on Vitamin D Metabolism: A Controlled Therapeutic Trial in Normal Women Early in the Postmenopause,” <i>Metabolism</i>, 1985, 34:421-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3887100\">[PubMed 3887100]</a></p>\n<p>10. Coe FL, Parks JH, Bushinsky DA, et al., “Chlorthalidone Promotes Mineral Retention in Patients with Idiopathic Hypercalciuria,” <i>Kidney Int</i>, 1988, 33:1140-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3404813\">[PubMed 3404813]</a></p>\n<p>11. Nowack R, Hofner MC, Reichel H, et al., “Subacute Effects of Thiazide Administration on Renal Hemodynamics and Calcium Metabolism,” <i>Clin Investig</i>, 1992, 70:686-91. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1392446\">[PubMed 1392446]</a></p>\n<p>12. Rejnmark L, Vestergaard P, Pedersen AR, et al., “Dose-Effect Relations of Loop- and Thiazide-Diuretics on Calcium Homeostasis: A Randomized, Double-Blinded Latin-Square Multiple Cross-over Study in Postmenopausal Osteopenic Women,” <i>Eur J Clin Invest</i>, 2003, 33:41-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12492451\">[PubMed 12492451]</a></p>\n<p>13. Drinka PJ and Nolten WE, “Hazards of Treating Osteoporosis and Hypertension Concurrently With Calcium, Vitamin D, and Distal Diuretics,” <i>J Am Geriat Soc</i>, 1984, 32(5):405-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6715769\">[PubMed 6715769]</a></p>\n<p>14. Hakim R, Tolis G, Goltzman D, et al, “Severe Hypercalcemia Associated With Hydrochlorothiazide and Calcium Carbonate Therapy,” <i>Can Med Assoc J</i>, 1979, 121(5):591-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=497950\">[PubMed 497950]</a></p>\n<p>15. Gora ML, Seth SK, Bay WH, et al, “Milk-Alkali Syndrome Associated With Use of Cholorothiazide and Calcium Carbonate,” <i>Clin Pharm</i>, 1989, 8(3):227-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27006898\">[PubMed 27006898]</a></p>\n<p>16. Parfitt AM, “Chlorothiazide-Induced Hypercalcemia in Juvenile Osteoporosis and Hyperparathyroidism,” <i>N Engl J Med</i>, 1969, 281(2):55-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5305802\">[PubMed 5305802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7718":"<p><b>Title</b> Agents with Antiplatelet Properties / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased platelet inhibition (e.g., bruising, bleeding) in patients receiving a vitamin E-containing multivitamin together with antiplatelet agents.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachadonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein IIb expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7719":"<p><b>Title</b> CycloSPORINE (Systemic) / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum cyclosporine concentrations with initiation/dose increase of a vitamin E-containing multivitamin.</p> \n<p><b>Discussion</b> In three clinical studies of cyclosporine maintained transplant recipients, antioxidant regimens containing 267-500 mg/day vitamin E were associated with 24-30% lower trough cyclosporine concentrations compared to baseline values or placebo treatment.<sup>1,2,3</sup> All regimens also contained ascorbic acid (500-1000 mg/day), and one contained beta carotene (6 mg/day). The mechanism of this interaction is unknown, and it is unclear whether the observed changes may be attributable to vitamin E or the other supplements.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lake KD, Aaronson KD, Gorman LE, et al, “Effect of Oral Vitamin E and C Therapy on Calcineurin Inhibitor Levels in Heart Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2005, 24(8):990-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16102431\">[PubMed 16102431]</a></p>\n<p>2. Blackhall ML, Fassett RG, Sharman JE, et al, “Effects of Antioxidant Supplementation on Blood Cyclosporine A and Glomerular Filtration Rate in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2005, 20(9):1970-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15998657\">[PubMed 15998657]</a></p>\n<p>3. de Vries AP, Oterdoom LH, Gans RO, et al, “Supplementation With Anti-oxidants Vitamin C and E Decreases Cyclosporine A Trough-Levels in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2006, 21(1):231-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115840\">[PubMed 16115840]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7720":"<p><b>Title</b> Iron Salts / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may diminish the therapeutic effect of Iron Salts. Multivitamins/Fluoride (with ADE) may increase the serum concentration of Iron Salts. Specifically, vitamin C-containing multivitamins may increase iron absorption. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferric Carboxymaltose, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Ferumoxytol, Iron Acetyltransferrin, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exception</b> Ferric Citrate</p>\n</div> \n<p><b>Discussion</b> Ascorbic acid (vitamin C)-containing multivitamins may increase the absorption of iron. Ascorbic acid supplementation has been shown to increase iron absorption from foods/meals in several studies,<sup>1,2</sup> though the magnitude and significance of this effect has been questioned.<sup>3</sup><br><br>In addition, the hematologic response to iron administration (iron dextran 5 mg/kg/day for 3 days, then oral ferrous sulfate beginning day 7) was decreased in anemic children who were also administered oral vitamin E (200 units) on iron days 1 through 3.<sup>4</sup> The reticulocyte response in patients receiving vitamin E was 4.4% versus 14.4% in those not receiving vitamin E. The mechanism of this interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Thankachan P, Walczyk T, Muthayya S, et al, “Iron Absorption in Young Indian Women: The Interaction of Iron Status with the Influence of Tea and Ascorbic Acid,” <i>Am J Clin Nutr</i>, 2008, 87(4):881-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18400710\">[PubMed 18400710]</a></p>\n<p>2. Fidler MC, Davidsson L, Zeder C, et al, “Iron Absorption from Ferrous Fumarate in Adult Women is Influenced by Ascorbic Acid but Not by Na2EDTA,” <i>Br J Nutr</i>, 2003, 90(6):1081-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14641967\">[PubMed 14641967]</a></p>\n<p>3. Hunt JR, Gallagher SK, Johnson LK, “Effect of Ascorbic Acid on Apparent Iron Absorption by Women with Low Iron Stores,” <i>Am J Clin Nutr</i>, 1994, 59(6):1381-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8198064\">[PubMed 8198064]</a></p>\n<p>4. Melhorn DK and Gross S, “Relationships Between Iron-Dextran and Vitamin E in Iron Deficiency Anemia in Children,” <i>J Lab Clin Med</i>, 1969, 74:789-802. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5350205\">[PubMed 5350205]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7721":"<p><b>Title</b> Altretamine / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may diminish the therapeutic effect of Altretamine. Specifically, vitamin B6 (pyridoxine) supplementation may diminish the response to altretamin/cisplatin treatment. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In spite of its beneficial effects on altretamine-associated neurotoxicity, the potential reduction in response duration may warrant consideration of not using multivitamins containing pyridoxine (vitamin B6) with an altretamine/cisplatin regimen.</p> \n<p><b>Discussion</b> An Eastern Cooperative Oncology Group (ECOG) study in 248 patients receiving altretamine and cisplatin for ovarian carcinoma showed both positive and negative effects of adding pyridoxine to the regimen. Pyridoxine use was associated with a significant reduction in neurotoxicity, but concurrent pyridoxine was also one of several factors identified as having an adverse effect on clinical response duration.<sup>1</sup> The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiernik PH, Yeap B, Vogl SE, et al, “Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group,” <i>Cancer Invest</i>, 1992, 10(1):1-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1735009\">[PubMed 1735009]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7722":"<p><b>Title</b> Barbiturates / Multivitamins/Fluoride (with ADE)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been suggested at high pyridoxine doses (80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may decrease the serum concentration of Barbiturates. Specifically, it has been reported that pyridoxine may decrease barbiturate concentrations. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required since this interaction is thought to be limited to high-dose pyridoxine (e.g., 80-200 mg/day). If patients may be receiving multiple pyridoxine-containing supplements, consider monitoring serum concentrations/effects of barbiturates more closely.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Serum phenobarbital concentrations were approximately halved in 5 patients (also receiving chronic phenytoin therapy) following 4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenobarbital metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentrations of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7723":"<p><b>Title</b> Fosphenytoin-Phenytoin / Multivitamins/Fluoride (with ADE)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been suggested at high pyridoxine doses (80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may decrease the serum concentration of Fosphenytoin-Phenytoin. Specifically, it has been reported that pyridoxine may decrease phenytoin concentrations. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required since this interaction is thought to be limited to high-dose pyridoxine (e.g., 80-200 mg/day). If patients may be receiving multiple pyridoxine-containing supplements, consider monitoring serum concentrations/effects of phenytoin more closely.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Serum phenytoin concentrations were approximately halved in patients (also receiving chronic phenobarbital therapy) following 2-4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenytoin metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentrations of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7724":"<p><b>Title</b> Levodopa / Multivitamins/Fluoride (with ADE)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Carbidopa): The significance of this interaction is substantially diminished with concurrent carbidopa (which is almost always used with levodopa).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may diminish the therapeutic effect of Levodopa. Specifically, pyridoxine may diminish the effects of levodopa, when used in the absence of a dopa decarboxylase inhibitor. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Multiple reported cases, but no apparent mechanism or confirmatory studies </p> \n<p><b>Patient Management</b> If levodopa is being used in the absence of a dopa decarboxylase inhibitor (DDI), concomitant use of a multivitamin containing pyridoxine (vitamin B6) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will largely eliminate the risk of this interaction.</p> \n<p><b>Discussion</b> The therapeutic effects of levodopa have been abolished in patients receiving concomitant pyridoxine in doses from 5-1000 mg/day.<sup>1,2,3,4,5</sup> When levodopa is administered with carbidopa (a dopa-decarboxylase inhibitor), no such interaction with pyridoxine occurs.<sup>6</sup> Pyridoxine enhances the conversion of levodopa to dopamine by increasing the concentration of a necessary cofactor, pyridoxal-5-phosphate. Excess pyridoxine increases the rate of conversion, and thus decreases the amount of levodopa available to cross the blood-brain barrier, and thus exert its therapeutic, anti-Parkinson's effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Carter AB, “Pyridoxine and Parkinsonism,” <i>Br Med J</i>, 1973, 4:236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4758412\">[PubMed 4758412]</a></p>\n<p>2. Cotzias GC and Papavasiliou PS, “Blocking the Negative Effects of Pyridoxine on Patients Receiving Levodopa,” <i>JAMA</i>, 1971, 215:1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107638\">[PubMed 5107638]</a></p>\n<p>3. Duvoisin RC, Yahr MD, and Cote LD, “Pyridoxine Reversal of L-Dopa Effects in Parkinsonism,” <i>Trans Am Neurol Ass</i>, 1969, 94:81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5374494\">[PubMed 5374494]</a></p>\n<p>4. Hildick-Smith M, “Pyridoxine in Parkinsonism,” <i>Lancet</i>, 1973, ii:1029.</p>\n<p>5. Yahr MD and Duvoisin RC, “Pyridoxine and Levodopa in the Treatment of Parkinsonism,” <i>JAMA</i>, 1972, 220:861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5067358\">[PubMed 5067358]</a></p>\n<p>6. Papavasiliou PS, Cotzias GC, Duby SE, et al, “Levodopa in Parkinsonism: Potentiation of Central Effects With a Peripheral Inhibitor,” <i>N Engl J Med</i>, 1972, 285:8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4550085\">[PubMed 4550085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7725":"<p><b>Title</b> Amphetamines / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may decrease the serum concentration of Amphetamines. More specifically, the ascorbic acid (vitamin C) in many multivitamins may decrease amphetamine concentrations. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with vitamin C-containing multivitamins as reduced absorption of amphetamines may result, possibly leading to decreased concentration and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> Concurrent use of amphetamines with ascorbic acid is expected to decrease the absorption of amphetamines from the GI tract, leading to reduced serum amphetamine concentrations and possibly to reduced efficacy.<sup>1,2</sup><br><br>The prescribing information for some amphetamine products also suggests that ascorbic acid may acidify the urine, resulting in increased urinary excretion of the amphetamine and reduced serum concentrations.<sup>3</sup> Despite this claim, many studies have concluded that ascorbic acid (at doses from 1-2 g administered as single doses or up to four times per day, and including oral or IV) has no significant impact on urinary pH.<sup>4,5,6,7,8,9,10,11</sup> It has also been proposed that the potentially relevant change in urine pH with ascorbic acid reported in a few studies of patients with a UTI<sup>12,13,14,15</sup> is likely the result of inhibition of bacterial urease, making the results more a reflection of decreased alkalinization than any true acidification.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adderall (dextroamphetamine and amphetamine). Wayne, PA: Shire US Inc., 3/07.</p>\n<p>2. Prescribing information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, July 2008.</p>\n<p>3. Prescribing information. Vyvanse (lisdexamfetamine). Wayne, PA: Shire US Inc., June 2013.</p>\n<p>4. Traxer O, Huet B, Poindexter J, et al, “Effect of Ascorbic Acid Consumption on Urinary Stone Risk Factors,” <i>J Urol</i>, 2003, 170(2 Pt 1):397-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12853784\">[PubMed 12853784]</a></p>\n<p>5. Baxmann AC, De O G Mendonca C, et al, “Effect of Vitamin C Supplements on Urinary Oxalate and pH in Calcium Stone-Forming Patients,” <i>Kidney Int</i>, 2003, 63(3):1066-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12631089\">[PubMed 12631089]</a></p>\n<p>6. Strom JG Jr, Jun HW, “Effect of Urine pH and Ascorbic Acid on the Rate of Conversion of Methenamine to Formaldehyde,” <i>Biopharm Drug Dispos</i>, 1993, 14(1):61-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8427945\">[PubMed 8427945]</a></p>\n<p>7. Wall I, Tiselius HG, “Long-Term Acidification of Urine in Patients Treated for Infected Renal Stones,” <i>Urol Int</i>, 1990, 45(6):336-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2288050\">[PubMed 2288050]</a></p>\n<p>8. Axelrod DR. “Ascorbic Acid and Urinary pH,” <i>JAMA</i>, 1985, 254(10):1310-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4021006\">[PubMed 4021006]</a></p>\n<p>9. Trang JM, Blanchard J, Conrad KA, et al, “Effect of Dietary Ascorbic Acid Restriction and Supplementation on Urine pH in Elderly Males,” <i>JAMA</i>, 1984, 252(21):2960-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502855\">[PubMed 6502855]</a></p>\n<p>10. Barton CH, Sterling ML, Thomas R, et al, “Ineffectiveness of Intravenous Ascorbic Acid as an Acidifying Agent in Man,” <i>Arch Intern Med</i>, 1981, 141(2):211-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7458517\">[PubMed 7458517]</a></p>\n<p>11. Naccarto DV, Bell CJ, Lamy PP, “Appraisal of Ascorbic Acid for Acidifying the Urine of Methenamine-Treated Geriatric Patients,” <i>J Am Geriatr Soc</i>, 1979, 27(1):34-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32196\">[PubMed 32196]</a></p>\n<p>12. Nahata MC, Cummins BA, McLeod DC, “Effect of Ascorbic Acid on Urine pH,” <i>Am J Hosp Pharm</i>, 1981, 38(1):33, 36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211868\">[PubMed 7211868]</a></p>\n<p>13. Hetey SK, Kleinberg ML, Parker WD, et al, “Effect of Ascorbic Acid on Urine pH in Patients with Injured Spinal Cords,” <i>Am J Hosp Pharm</i>, 1980, 37(2):235-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7361797\">[PubMed 7361797]</a></p>\n<p>14. Nahata MC, Shrimp L, Lampman T, et al, “Effect of Ascorbic Acid on Urine pH in Man,” <i>Am J Hosp Pharm</i>, 1977, 34(11):1234-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22245\">[PubMed 22245]</a></p>\n<p>15. Houston JB, Levy G, “Modification of Drug Biotransformation by Vitamin C in Man,” <i>Nature</i>, 1975, 255(5503):78-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1128674\">[PubMed 1128674]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7726":"<p><b>Title</b> Bortezomib / Multivitamins/Fluoride (with ADE)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may diminish the therapeutic effect of Bortezomib. Specifically, the vitamin C (ascorbic acid) found in many multivitamins may impair the clinical effects of bortezomib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy. It is probably unnecessary, though, to advise patients to avoid foods/beverages that contain vitamin C (e.g., citrus fruits, etc.).</p> \n<p><b>Discussion</b> In one study, the addition of plasma from healthy volunteers who were taking vitamin C (1 g/d) was associated with decreased bortezomib-induced multiple myeloma cell death in vitro.<sup>1</sup> In the same study, using a mouse model of human multiple myeloma, vitamin C also interfered with the bortezomib inhibition of multiple myeloma cell growth. In another study, vitamin C inhibited bortezomib-mediated cell death in an endometrial carcinoma cell line.<sup>2</sup> A third in vitro study also reported that vitamin C interfered with bortezomib actions, and reported findings consistent with a direct chemical interaction between ascorbic acid and bortezomib.<sup>3</sup><br><br>In contrast to these findings, other reports describe the use of this combination as part of a regimen used in treatment of patients with multiple myeloma -- one using bortezomib/ascorbic acid/melphalan in newly diagnosed multiple myeloma,<sup>4</sup> and another using arsenic trioxide/bortezomib/ascorbic acid in patients with refractory or relapsed multiple myeloma.<sup>5</sup><br><br>One commentary on the issue emphasized the need for additional data in order to accurately determine the clinical significance of this apparent interaction, particularly given that such an interaction with vitamin C may either protect patients from toxicity or interfere with bortezomib effectiveness.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perrone G, Hideshima T, Ikeda H, et al, “Ascorbic Acid Inhibits Antitumor Activity of Bortezomib in Vivo,” <i>Leukemia</i>, 2009, 23:1679-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19369963\">[PubMed 19369963]</a></p>\n<p>2. Llobet D, Eritja N, Encinas M, et al, “Antioxidants Block Proteasome Inhibitor Function in Endometrial Carcinoma Cells,” <i>Anticancer Drugs</i>, 2008, 19:115-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18176107\">[PubMed 18176107]</a></p>\n<p>3. Zou W, Yue P, Lin N, et al, “Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells,” <i>Clin Cancer Res</i>, 2006, 12:273-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16397052\">[PubMed 16397052]</a></p>\n<p>4. Berenson JR, Yellin O, Woytowitz D, et al, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients with Newly Diagnosed Multiple Myeloma: An Effective and Well-Tolerated Frontline Regimen,” <i>Eur J Haematol</i>, 2009, 82:433-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226361\">[PubMed 19226361]</a></p>\n<p>5. Berenson JR, Matous J, Swift RA, et al, “A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” <i>Clin Cancer Res</i>, 2007, 13:1762-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17363530\">[PubMed 17363530]</a></p>\n<p>6. Catley L,Anderson KC, “Velcade and Vitamin C: Too Much of a Good Thing?,” <i>Clin Cancer Res</i>, 2006, 12:3-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16397016\">[PubMed 16397016]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7727":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Magnesium Salts</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour.</p>\n<div>\n <p><b>Magnesium Salts Interacting Members</b> Almagate, Diomagnite, Magaldrate, Magnesium Aspartate, Magnesium Carbonate, Magnesium Chloride, Magnesium Citrate, Magnesium Glucoheptonate, Magnesium Gluconate, Magnesium Glycerophosphate, Magnesium Hydroxide, Magnesium L-aspartate Hydrochloride, Magnesium L-lactate, Magnesium Oxide, Magnesium Salicylate, Magnesium Sulfate, Magnesium Trisilicate</p>\n</div> \n<p><b>Discussion</b> Studies in rats have found that low dietary magnesium enhanced fluoride absorption, whereas higher dietary magnesium significantly reduced fluoride absorption.<sup>1</sup> Further, data showed that this interaction likely occurred in the intestine, suggesting that the interaction may be similar to both the aluminum-fluoride and calcium-fluoride interactions that are thought to involve formation of poorly absorbed fluoride-cation complexes.<sup>2,3</sup><br><br>In contrast, others have reported that concurrent magnesium does not have a significant effect on fluoride absorption.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cerklewski FL, “Influence of Dietary Magnesium on Fluoride Bioavailability in the Rat,” <i>J Nutr</i>, 117(3):496-500. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3572562\">[PubMed 3572562]</a></p>\n<p>2. Spencer H, Kramer L, Norris C, et al, “Effect of Aluminum Hydroxide on Fluoride Metabolism,” <i>Clin Pharmacol Ther</i>, 1980, 28(4):529-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7408412\">[PubMed 7408412]</a></p>\n<p>3. Prescribing information. EtheDent (Sodium Fluoride). St. Louis, MO: Ethex Corporation, 2002.</p>\n<p>4. Spencer H, Kramer L, Osis D, et al, “Effect of Calcium, Phosphorus, Magnesium, and Aluminum on Fluoride Metabolism in Man,” <i>Ann N Y Acad Sci</i>, 1980, 355:181-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6940475\">[PubMed 6940475]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7728":"<p><b>Title</b> Multivitamins/Fluoride (with ADE) / Colchicine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Colchicine may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to cyanocobalamin supplementation in patients receiving long-term colchicine.</p> \n<p><b>Discussion</b> Several reports describe pernicious anemia and/or vitamin B12 malabsorption in patients receiving colchicine.<sup>1,2,3</sup><br><br>Animal studies suggest that colchicine interferes with the expression of the intrinsic factor-vitamin B12 receptor, contributing to deficient vitamin B12 absorption.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Palopoli J, Waxman J, “Recurrent Aphthous Stomatitis and Vitamin B12 Deficiency,”<i> South Med J</i>, 1990, 83(4):475-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2321075\">[PubMed 2321075]</a></p>\n<p>2. Webb DI, Chodos RB, Mahar CQ, et al, “Mechanism of Vitamin B12 Malabsorption in Patients Receiving Colchicine,” <i>N Engl J Med</i>, 1968, 279(16):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5677718\">[PubMed 5677718]</a></p>\n<p>3. Race TF, Paes IC, Faloon WW, “Intestinal Malabsorption Induced by Oral Colchicine. Comparison with Neomycin and Cathartic Agents,” <i>Am J Med Sci</i>, 1970, 259(1):32-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5416781\">[PubMed 5416781]</a></p>\n<p>4. Polliotti BM, Panigel M, Miller RK, “Free Vitamin B12 and Transcobalamin II-Vitamin B12 Complex Uptake by the Visceral Yolk Sac of the Sprague-Dawley Rat: Effect of Inhibitors,” <i>Reprod Toxicol</i>, 1997, 11(4):617-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241684\">[PubMed 9241684]</a></p>\n<p>5. Ramanujam KS, Seetharam S, Dahms NM, et al, “Functional Expression of Intrinsic Factor-Cobalamin Receptor by Renal Proximal Tubular Epithelial Cells,” <i>J Biol Chem</i>, 1991, 266(20):13135-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1649178\">[PubMed 1649178]</a></p>\n<p>6. Stopa EG, O'Brien R, Katz M, “Effect of Colchicine on Guinea Pig Intrinsic Factor-Vitamin B12 Receptor,” <i>Gastroenterology</i>, 1979, 76(2):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=759260\">[PubMed 759260]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7729":"<p><b>Title</b> Deferoxamine / Multivitamins/Fluoride (with ADE)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Ascorbic acid (vitamin C) -- ascorbic acid may be used at doses of 200 mg/day or less under certain circumstances. Avoid ascorbic acid doses greater than 200 mg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the adverse/toxic effect of Deferoxamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid ascorbic acid/vitamin C doses greater than 200 mg/day in patients receiving deferoxamine, due to a potential risk of diminished left ventricular function. Though most multivitamins do not contain this amount of ascorbic acid, some products do contain close to or in excess of 200 mg per recommended dose. Ascorbic acid doses 200 mg/day or less may be administered to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump. Monitor cardiac function.</p> \n<p><b>Discussion</b> Ascorbic acid has been administered concomitantly with deferoxamine in some patients to increase the excretion of iron. However, prescribing information for deferoxamine recommends avoiding its use with ascorbic acid doses exceeding 200 mg/day.<sup>1</sup> Reports have been published of patients receiving 500 mg/day of ascorbic acid who experienced clinically important, transient deterioration of left ventricular function.<sup>2,3,4,5</sup><br><br>In contrast to the above cases, in a clinical study of 16 patients receiving iron chelation therapy with deferoxamine, 10 of the patients were given supplemental ascorbic acid (200 mg daily) 9-12 months after starting therapy, 9 of whom actually experienced increases in left ventricular ejection fraction (LVEF).<sup>6</sup> The one additional patient whose LVEF decreased while on ascorbic acid supplementation had pre-existing ischemic heart disease.<br><br>The reason for these effects has not been investigated. One group proposed that enhanced iron release from reticuloendothelial cells at higher ascorbic acid doses could enhance cardiac oxidative stress.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Desferal (deferoxamine mesylate). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p>2. Nienhaus AW, “Vitamin C and Iron,” <i>N Engl J Med</i>, 1981, 304:170-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442737\">[PubMed 7442737]</a></p>\n<p>3. Cohen A, Cohen U, and Schwartz E, “Scurvy and Altered Iron Stores in Thalassaemia Major,” <i>N Engl J Med</i>, 1981, 304(3):158-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442735\">[PubMed 7442735]</a></p>\n<p>4. Henry W, “Echocardiographic Evaluation of the Heart in Thalassaemia Major,” <i>Ann Intern Med</i>, 1978:892-4.</p>\n<p>5. Schafer AI, Rabinowe S, LeBoff MS, et al, “Long-term Efficacy of Deferoxamine Iron Chelation Therapy in Patients With Acquired Transfusional Iron Overload,” <i>Arch Intern Med</i>, 1985, 145(7):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3925909\">[PubMed 3925909]</a></p>\n<p>6. Jensen P, Olsen N, Bagger J, et al. “Cardiac Function During Iron Chelation Therapy in Adult Non-thalassaemic Patients With Transfusional Iron Overload,” <i>Eur J Haematol</i>, 1997, 59(4):221-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9338620\">[PubMed 9338620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7730":"<p><b>Title</b> Dofetilide / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer CYP3A4 inhibitors cautiously with dofetilide, carefully monitoring for signs and symptoms of increased dofetilide exposure.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> Dofetilide U.S. prescribing information advises cautious use in combination with CYP3A4 inhibitors due to the potential for increases in dofetilide exposure.<sup>1</sup> Specific agents associated with this warning include strong (e.g., nefazodone), moderate (e.g., diltiazem) and weak (e.g., amiodarone) inhibitors of CYP3A4.<sup>1</sup> <br><br>CYP3A4 mediated metabolism is expected to make a minor contribution to total dofetilide clearance.<sup>1,2</sup> Therefore the magnitude of interaction of dofetilide with CYP3A4 inhibitors is expected to be small. Concomitant use of the moderate CYP3A4 inhibitor verapamil (80 mg three times daily) increased dofetilide (0.5 mg twice daily) maximum concentration and AUC in the first 4 hours after dosing by 43% and 26%, respectively, without affecting total AUC in the first 8 hours after dosing.<sup>1,3</sup> The concomitant administration of these drugs, however, was associated with an increased incidence of torsades de pointes in clinical trials, and is listed as a contraindication to use of dofetilide.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer Inc, February 2011.</p>\n<p>2. Walker DK, Alabaster CT, Congrave GS, et al, “Significance of Metabolism in the Disposition and Action of the Antidysrhythmic Drug, Dofetilide. In Vitro Studies and Correlation With In Vivo Data,” <i>Drug Metab Dispos</i>, 1996, 24(4):447-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8801060\">[PubMed 8801060]</a></p>\n<p>3. Johnson BF, Cheng SL and Venitz J, “Transient Kinetic and Dynamic Interactions Between Verapamil and Dofetilide, a Class III Antiarrhythmic,” <i>J Clin Pharmacol</i>, 2001, 41(11):1248-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11697758\">[PubMed 11697758]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7731":"<p><b>Title</b> Dofetilide / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer CYP3A4 inhibitors cautiously with dofetilide, carefully monitoring for signs and symptoms of increased dofetilide exposure.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> Dofetilide U.S. prescribing information advises cautious use in combination with CYP3A4 inhibitors due to the potential for increases in dofetilide exposure.<sup>1</sup> Specific agents associated with this warning include strong (e.g., nefazodone), moderate (e.g., diltiazem) and weak (e.g., amiodarone) inhibitors of CYP3A4.<sup>1</sup> <br><br>CYP3A4 mediated metabolism is expected to make a minor contribution to total dofetilide clearance.<sup>1,2</sup> Therefore the magnitude of interaction of dofetilide with CYP3A4 inhibitors is expected to be small. Concomitant use of the moderate CYP3A4 inhibitor verapamil (80 mg three times daily) increased dofetilide (0.5 mg twice daily) maximum concentration and AUC in the first 4 hours after dosing by 43% and 26%, respectively, without affecting total AUC in the first 8 hours after dosing.<sup>1,3</sup> The concomitant administration of these drugs, however, was associated with an increased incidence of torsades de pointes in clinical trials, and is listed as a contraindication to use of dofetilide.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer Inc, February 2011.</p>\n<p>2. Walker DK, Alabaster CT, Congrave GS, et al, “Significance of Metabolism in the Disposition and Action of the Antidysrhythmic Drug, Dofetilide. In Vitro Studies and Correlation With In Vivo Data,” <i>Drug Metab Dispos</i>, 1996, 24(4):447-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8801060\">[PubMed 8801060]</a></p>\n<p>3. Johnson BF, Cheng SL and Venitz J, “Transient Kinetic and Dynamic Interactions Between Verapamil and Dofetilide, a Class III Antiarrhythmic,” <i>J Clin Pharmacol</i>, 2001, 41(11):1248-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11697758\">[PubMed 11697758]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7732":"<p><b>Title</b> Dofetilide / CYP3A4 Inhibitors (Weak)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer CYP3A4 inhibitors cautiously with dofetilide, carefully monitoring for signs and symptoms of increased dofetilide exposure.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Weak) Interacting Members</b> ALPRAZolam, Amiodarone, AmLODIPine, AtorvaSTATin, Bicalutamide, Bitter Orange, Cilostazol, Cimetidine, Ciprofloxacin (Systemic), Clotrimazole (Oral), CycloSPORINE (Systemic), Danazol, Dasatinib, Delavirdine, Everolimus, FluvoxaMINE, Fosaprepitant, Glecaprevir and Pibrentasvir, Goldenseal, Grazoprevir, Iloperidone, Isoniazid, Ivacaftor, Lapatinib, Lomitapide, Lurasidone, NiCARdipine, Palbociclib, PAZOPanib, Peppermint, Piperaquine, Propiverine, Propofol, QuiNIDine, Quinupristin, Ranolazine, Resveratrol, Roxithromycin, Ticagrelor, Tofisopam</p>\n</div> \n<p><b>Discussion</b> Dofetilide U.S. prescribing information advises cautious use in combination with CYP3A4 inhibitors due to the potential for increases in dofetilide exposure.<sup>1</sup> Specific agents associated with this warning include strong (e.g., nefazodone), moderate (e.g., diltiazem) and weak (e.g., amiodarone) inhibitors of CYP3A4.<sup>1</sup> <br><br>CYP3A4 mediated metabolism is expected to make a minor contribution to total dofetilide clearance.<sup>1,2</sup> Therefore the magnitude of interaction of dofetilide with CYP3A4 inhibitors is expected to be small. Concomitant use of the moderate CYP3A4 inhibitor verapamil (80 mg three times daily) increased dofetilide (0.5 mg twice daily) maximum concentration and AUC in the first 4 hours after dosing by 43% and 26%, respectively, without affecting total AUC in the first 8 hours after dosing.<sup>1,3</sup> The concomitant administration of these drugs, however, was associated with an increased incidence of torsades de pointes in clinical trials, and is listed as a contraindication to use of dofetilide.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tikosyn (dofetilide). New York, NY: Pfizer Inc, February 2011.</p>\n<p>2. Walker DK, Alabaster CT, Congrave GS, et al, “Significance of Metabolism in the Disposition and Action of the Antidysrhythmic Drug, Dofetilide. In Vitro Studies and Correlation With In Vivo Data,” <i>Drug Metab Dispos</i>, 1996, 24(4):447-55. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8801060\">[PubMed 8801060]</a></p>\n<p>3. Johnson BF, Cheng SL and Venitz J, “Transient Kinetic and Dynamic Interactions Between Verapamil and Dofetilide, a Class III Antiarrhythmic,” <i>J Clin Pharmacol</i>, 2001, 41(11):1248-56. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11697758\">[PubMed 11697758]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7733":"<p><b>Title</b> Ziprasidone / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> FLUoxetine may enhance the QTc-prolonging effect of Ziprasidone. Ziprasidone may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The concomitant use of fluoxetine with ziprasidone is expected to substantially increase the risk for serious toxicities, including the development of torsades de pointes or other significant ventricular tachyarrhythmias and should be avoided. Patients with other risk factors present (e.g., older age, female sex, bradycardia, hypokalemia, hypomagnesemia, heart disease, and higher drug concentrations), would be at an even higher risk for these potentially life-threatening effects.</p> \n<p><b>Discussion</b> Ziprasidone U.S. prescribing information lists concomitant use with drugs that have demonstrated QT interval prolongation as contraindicated due to the potential for additive QT prolonging effects.<sup>1</sup> Although published clinical studies have found no evidence of QT interval prolongation when fluoxetine was given to patients or healthy volunteers at average doses of 20-37 mg/day,<sup>2,3,4</sup> numerous cases of significant QT prolongation and/or associated arrhythmias in patients treated with fluoxetine have been reported.<sup>5,6,7,8,9,10,11,12</sup> In vitro data also support a possible mechanism for QT interval prolongation by fluoxetine and its major active metabolite, norfluoxetine, via inhibition of hERG channel function and its localization to the cell surface.<sup>13</sup> Fluoxetine prescribing information consequently also states that its use in combination with other QT prolonging drugs should be avoided.<sup>5</sup><br><br>In addition to the potential for additive QT lengthening effects of ziprasidone and fluoxetine, concomitant administration could theoretically increase the risk of serotonin toxicity and neuroleptic malignant syndrome.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Geodon (ziprasidone). New York, NY: Pfizer Inc, July 2013.</p>\n<p>2. Zhao Q, Wojcik MA, Parier JL, et al, “Influence of Coadministration of Fluoxetine on Cisapride Pharmacokinetics and QTc Intervals in Healthy Volunteers,” <i>Pharmacotherapy</i>, 2001, 21(2):149-57. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11213850\">[PubMed 11213850]</a></p>\n<p>3. Pohl R, Balon R, Jayaraman A, et al, “Effect of Fluoxetine, Pemoline and Placebo on Heart Period and QT Variability in Normal Humans,” <i>J Psychosom Res</i>, 2003, 55(3):247-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12932798\">[PubMed 12932798]</a></p>\n<p>4. Baker B, Dorian P, Sandor P, et al, “Electrocardiographic Effects of Fluoxetine and Doxepin in Patients With Major Depressive Disorder,” <i>J Clin Psychopharmacol</i>, 1997, 17(1):15-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9004052\">[PubMed 9004052]</a></p>\n<p>5. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Lilly USA, LLC, 7/2013.</p>\n<p>6. Buchanan Keller K and Lemberg L, “Torsade,” <i>Am J Crit Care</i>, 2008, 17(1):77-81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18158394\">[PubMed 18158394]</a></p>\n<p>7. Adetunji B, Basil B, Mathews M, et al, “Should the Physician's Desk Reference Contraindicate the Use of Chlorpromazine-Fluoxetine Combination? A Case Report,” <i>J Clin Psychopharmacol</i>, 2006, 26(4):438. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16855470\">[PubMed 16855470]</a></p>\n<p>8. Wilting I, Smals OM, Holwerda NJ, et al, “QTc Prolongation and Torsades de Pointes in an Elderly Woman Taking Fluoxetine,” <i>Am J Psychiatry</i>, 2006, 163(2):325. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16449492\">[PubMed 16449492]</a></p>\n<p>9. Dubnov G, Fogelman R and Merlob P, “Prolonged QT Interval in an Infant of a Fluoxetine Treated Mother,” <i>Arch Dis Child</i>, 2005, 90(9):972-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16113135\">[PubMed 16113135]</a></p>\n<p>10. Nykamp DL, Blackmon CL, Schmidt PE, et al, “QTc Prolongation Associated With Combination Therapy of Levofloxacin, Imipramine, and Fluoxetine,” <i>Ann Pharmacother</i>, 2005, 39(3):543-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15687478\">[PubMed 15687478]</a></p>\n<p>11. Appleby M, Mbewu A and Clarke B, “Fluoxetine and Ventricular Torsade--Is There a Link?” <i>Int J Cardiol</i>, 1995, 49(2):178-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7628890\">[PubMed 7628890]</a></p>\n<p>12. Graudins A, Vossler C and Wang R, “Fluoxetine-Induced Cardiotoxicity With Response to Bicarbonate Therapy,” <i>Am J Emerg Med</i>, 1997, 15(5):501-3. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9270390\">[PubMed 9270390]</a></p>\n<p>13. Rajamani S, Eckhardt LL, Valdivia CR, et al, “Drug-Induced Long QT Syndrome: hERG K+ Channel Block and Disruption of Protein Trafficking by Fluoxetine and Norfluoxetine,” <i>Br J Pharmacol</i>, 2006, 149(5):481-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16967046\">[PubMed 16967046]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7734":"<p><b>Title</b> Afatinib / P-glycoprotein/ABCB1 Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between U.S. and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of afatinib toxicity during concomitant treatment with P-glycoprotein inhibitors. The U.S prescribing information recommends to reduce the afatinib dose by 10 mg if not tolerated and to increase back to the original afatinib dose following discontinuation of P-glycoprotein inhibitors as tolerated. The Canadian product monograph recommends avoiding concurrent use. If such a combination is needed, the P-glycoprotein inhibitor should be given simultaneously with or after the afatinib dose.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir*, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In clinical studies summarized in afatinib U.S. prescribing information, coadministration of ritonavir (200 mg twice daily for 3 days) increased the maximum concentration and AUC of afatinib in a time-dependent manner: by 39% and 48%, respectively, when ritonavir was given 1 h before afatinib (20 mg single dose); by 4% and 19%, respectively, when ritonavir was given simultaneously with afatinib (40 mg single dose); and by and 5% and 11%, respectively, when ritonavir was given 6 hours after afatinib (40 mg single dose).<sup>1</sup><br><br>The suspected primary mechanism of this interaction is ritonavir inhibition of P-glycoprotein-mediated efflux of afatinib. Considering the differences in the interaction magnitude with different administration times, the Canadian product monograph recommends that if such concurrent use is required, the P-glycoprotein inhibitor should be given simultaneously with or after the dose of afatinib.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Gilotrif</i> (afatinib) [Prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., July 2013.</p>\n<p>2. <i>Giotrif</i> (afatinib) [Product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd., November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7735":"<p><b>Title</b> Afatinib / P-glycoprotein/ABCB1 Inducers</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>International labeling</b>: Recommendations regarding the significance and management of this interaction varies between U.S. and Canadian labeling.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The U.S prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-glycoprotein inducers with afatinib. The dose should then be reduced back to the original afatinib dose 2-3 days after discontinuation of the P-glycoprotein inducers. The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inducers Interacting Members</b> Apalutamide, Fosphenytoin, Phenytoin, RifAMPin*, St John's Wort</p>\n <p style=\"font-size: 75%; font-style: italic;\">* Denotes agent(s) specifically implicated in clinical data. Unmarked agents are listed because they have properties similar to marked agents, and may respond so within the context of the stated interaction.</p>\n</div> \n<p><b>Discussion</b> In a clinical study summarized in afatinib U.S. prescribing information, coadministration of rifampin (600 mg daily for 7 days) decreased the maximum concentration and AUC of afatinib by 22% and 34%, respectively.<sup>1</sup> The suspected primary mechanism of this interaction is rifampin induction of P-glycoprotein-mediated efflux of afatinib.<br><br>The U.S prescribing information recommends increasing the afatinib dose by 10 mg as tolerated in patients requiring chronic coadministration of P-glycoprotein inducers with afatinib, with subsequent reduction back to the original afatinib dose 2-3 days after discontinuation of the P-glycoprotein inducers.<sup>1</sup> The Canadian product monograph recommends avoiding concurrent use if possible, and no specific dose adjustments are specified for patients in whom concurrent use is necessary.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Gilotrif</i> (afatinib) [Prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc., July 2013.</p>\n<p>2. <i>Giotrif</i> (afatinib) [Product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd., November 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7736":"<p><b>Title</b> Triazolam / Dexamethasone (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Dexamethasone (Systemic) may decrease the serum concentration of Triazolam. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for reduced effects of triazolam in patients receiving systemic dexamethasone.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, pretreatment with dexamethasone (1.5 mg daily for 4 days) decreased the average triazolam AUC by 19%.<sup>1</sup> The suspected primary mechanism of this interaction is dexamethasone induction of CYP3A4 mediated triazolam metabolism. Based on this mechanism, the interaction between these agents may be more significant under some circumstances, particularly when dexamethasone is administered for a greater period of time or at higher doses.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Villikka K, Kivisto KT and Neuvonen PJ, “The Effect of Dexamethasone on the Pharmacokinetics of Triazolam,” <i>Pharmacol Toxicol</i>, 1998, 83(3):135-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9783333\">[PubMed 9783333]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7737":"<p><b>Title</b> Altretamine / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may diminish the therapeutic effect of Altretamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In spite of its beneficial effects on altretamine-associated neurotoxicity, the potential reduction in response duration may warrant consideration of not using multivitamins containing pyridoxine (vitamin B6) with an altretamine/cisplatin regimen.</p> \n<p><b>Discussion</b> An Eastern Cooperative Oncology Group (ECOG) study in 248 patients receiving altretamine and cisplatin for ovarian carcinoma showed both positive and negative effects of adding pyridoxine to the regimen. Pyridoxine use was associated with a significant reduction in neurotoxicity, but concurrent pyridoxine was also one of several factors identified as having an adverse effect on clinical response duration.<sup>1</sup> The mechanism of this potential interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wiernik PH, Yeap B, Vogl SE, et al, “Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group,” <i>Cancer Invest</i>, 1992, 10(1):1-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1735009\">[PubMed 1735009]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7738":"<p><b>Title</b> Aluminum Hydroxide / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: The significance of this interaction is greater among patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may increase the serum concentration of Aluminum Hydroxide. Specifically, vitamin C may enhance aluminum absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients with severe renal dysfunction, consider avoiding this combination of agents. Administering agents at least 2 hours apart may help minimize the interaction(s). Monitor for toxic effects of aluminum if a multivitamin is coadministered.</p> \n<p><b>Discussion</b> A small study demonstrated an average 3-fold increase in urinary aluminum excretion when subjects received aluminum hydroxide (900 mg 3 times/day) with concomitant vitamin C (2 g/day).<sup>1</sup> Animal studies have similarly demonstrated increased aluminum concentrations in the liver, brains, and bones of rats given aluminum hydroxide with vitamin C.<sup>2</sup> The mechanism of this interaction is unknown, but has been suggested to be related to the formation of a soluble aluminum-citrate complex.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Domingo JL, Gomez M, Llobet JM, et al, “Effect of Ascorbic Acid on Gastrointestinal Aluminum Absorption,” <i>Lancet</i>, 1991, 338(8780):1467. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1683458\">[PubMed 1683458]</a></p>\n<p>2. Domingo JL, Gomez M, Llobet JM, et al, “Influence of Some Dietary Constituents on Aluminum Absorption and Retention in Rats,” <i>Kidney Int</i>, 1991, 39(4):598-601. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2051716\">[PubMed 2051716]</a></p>\n<p>3. Coburn JW, Mischel MG, Goodman WG, et al, “Calcium Citrate Markedly Enhances Aluminum Absorption From Aluminum Hydroxide,” <i>Am J Kid Dis</i>, 1991, 17(6):708-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2042654\">[PubMed 2042654]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7739":"<p><b>Title</b> Amphetamines / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Amphetamines. Specifically, vitamin C may impair absorption of amphetamines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to amphetamines when used together with vitamin C-containing multivitamins as reduced absorption of amphetamines may result, possibly leading to decreased concentration and diminished clinical response.</p>\n<div>\n <p><b>Amphetamines Interacting Members</b> Amphetamine, Benzphetamine, Dextroamphetamine, Lisdexamfetamine, Methamphetamine, Phendimetrazine, Phentermine</p>\n</div> \n<p><b>Discussion</b> Concurrent use of amphetamines with ascorbic acid is expected to decrease the absorption of amphetamines from the GI tract, leading to reduced serum amphetamine concentrations and possibly to reduced efficacy.<sup>1,2</sup><br><br>The prescribing information for some amphetamine products also suggests that ascorbic acid may acidify the urine, resulting in increased urinary excretion of the amphetamine and reduced serum concentrations.<sup>3</sup> Despite this claim, many studies have concluded that ascorbic acid (at doses from 1-2 g administered as single doses or up to four times per day, and including oral or IV) has no significant impact on urinary pH.<sup>4,5,6,7,8,9,10,11</sup> It has also been proposed that the potentially relevant change in urine pH with ascorbic acid reported in a few studies of patients with a UTI<sup>12,13,14,15</sup> is likely the result of inhibition of bacterial urease, making the results more a reflection of decreased alkalinization than any true acidification.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Adderall (dextroamphetamine and amphetamine). Wayne, PA: Shire US Inc., 3/07.</p>\n<p>2. Prescribing information. Dexedrine (dextroamphetamine). Research Triangle Park, NC: GlaxoSmithKline, July 2008.</p>\n<p>3. Prescribing information. Vyvanse (lisdexamfetamine). Wayne, PA: Shire US Inc., June 2013.</p>\n<p>4. Traxer O, Huet B, Poindexter J, et al, “Effect of Ascorbic Acid Consumption on Urinary Stone Risk Factors,” <i>J Urol</i>, 2003, 170(2 Pt 1):397-401. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12853784\">[PubMed 12853784]</a></p>\n<p>5. Baxmann AC, De O G Mendonca C, et al, “Effect of Vitamin C Supplements on Urinary Oxalate and pH in Calcium Stone-Forming Patients,” <i>Kidney Int</i>, 2003, 63(3):1066-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12631089\">[PubMed 12631089]</a></p>\n<p>6. Strom JG Jr, Jun HW, “Effect of Urine pH and Ascorbic Acid on the Rate of Conversion of Methenamine to Formaldehyde,” <i>Biopharm Drug Dispos</i>, 1993, 14(1):61-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8427945\">[PubMed 8427945]</a></p>\n<p>7. Wall I, Tiselius HG, “Long-Term Acidification of Urine in Patients Treated for Infected Renal Stones,” <i>Urol Int</i>, 1990, 45(6):336-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2288050\">[PubMed 2288050]</a></p>\n<p>8. Axelrod DR. “Ascorbic Acid and Urinary pH,” <i>JAMA</i>, 1985, 254(10):1310-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4021006\">[PubMed 4021006]</a></p>\n<p>9. Trang JM, Blanchard J, Conrad KA, et al, “Effect of Dietary Ascorbic Acid Restriction and Supplementation on Urine pH in Elderly Males,” <i>JAMA</i>, 1984, 252(21):2960-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6502855\">[PubMed 6502855]</a></p>\n<p>10. Barton CH, Sterling ML, Thomas R, et al, “Ineffectiveness of Intravenous Ascorbic Acid as an Acidifying Agent in Man,” <i>Arch Intern Med</i>, 1981, 141(2):211-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7458517\">[PubMed 7458517]</a></p>\n<p>11. Naccarto DV, Bell CJ, Lamy PP, “Appraisal of Ascorbic Acid for Acidifying the Urine of Methenamine-Treated Geriatric Patients,” <i>J Am Geriatr Soc</i>, 1979, 27(1):34-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32196\">[PubMed 32196]</a></p>\n<p>12. Nahata MC, Cummins BA, McLeod DC, “Effect of Ascorbic Acid on Urine pH,” <i>Am J Hosp Pharm</i>, 1981, 38(1):33, 36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7211868\">[PubMed 7211868]</a></p>\n<p>13. Hetey SK, Kleinberg ML, Parker WD, et al, “Effect of Ascorbic Acid on Urine pH in Patients with Injured Spinal Cords,” <i>Am J Hosp Pharm</i>, 1980, 37(2):235-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7361797\">[PubMed 7361797]</a></p>\n<p>14. Nahata MC, Shrimp L, Lampman T, et al, “Effect of Ascorbic Acid on Urine pH in Man,” <i>Am J Hosp Pharm</i>, 1977, 34(11):1234-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22245\">[PubMed 22245]</a></p>\n<p>15. Houston JB, Levy G, “Modification of Drug Biotransformation by Vitamin C in Man,” <i>Nature</i>, 1975, 255(5503):78-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1128674\">[PubMed 1128674]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7740":"<p><b>Title</b> Quinolones / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This applies specifically to orally administered quinolone antibiotics.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Quinolones. Specifically, minerals in the multivitamin/mineral product may impair absorption of quinolone antibiotics. <b>Severity</b> Major <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Interactions can be minimized by administering the oral quinolone at least 2 hours before, or 6 hours after, the dose of a multivitamin that contains polyvalent cations (i.e., calcium, iron, magnesium, selenium, zinc). Monitor for decreased therapeutic effects of oral quinolones if administered with polyvalent cation-containing multivitamins.</p>\n<div>\n <p><b>Quinolones Interacting Members</b> Ciprofloxacin (Systemic), Delafloxacin, Gemifloxacin, LevoFLOXacin (Systemic), Lomefloxacin, Moxifloxacin (Systemic), Nalidixic Acid, Norfloxacin, Ofloxacin (Systemic), Pefloxacin, Pipemidic Acid, Sparfloxacin<br><b>Exception</b> LevoFLOXacin (Oral Inhalation)</p>\n</div> \n<p><b>Discussion</b> The ability of multivalent cations to reduce the absorption of oral quinolones is well-established. It is believed that the 3-carbonyl and 4-oxo functional groups on the antibiotic forms a chelate with the cations resulting in inactive antimicrobials.<sup>1,2,3</sup> This interaction appears most significant with aluminum and magnesium ions, to a lesser extent with calcium ions, and probably nonexistent with sodium ions. The reduction in quinolone absorption can significantly affect Cmax and percent bioavailability, at times inhibiting the therapeutic effectiveness of the antibiotic. Calcium-containing antacids have been reported to reduce quinolone bioavailability to the following percentages: Ciprofloxacin (59%); levofloxacin (97%); lomefloxacin (98%); and norfloxacin (37%).<sup>4,5,6,7,8,9,10</sup> Calcium acetate has been reported to decrease the AUC of oral ciprofloxacin by 51%.<sup>11</sup> Calcium administration appears to affect the rate, but not the extent, of moxifloxacin absorption.<sup>12</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Hoffken G, Borner K, Glatzel PD, et al, “Reduced Enteral Absorption of Ciprofloxacin in the Presence of Antacids,” <i>Eur J Clin Microbiol</i>, 1985, 4:345. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3160584\">[PubMed 3160584]</a></p>\n<p>2. Schentag JJ, Watson WA, Nix DE, et al, “Time-Dependent Interactions Between Antacids and Quinolone Antibiotics,” <i>Clin Pharmacol Ther</i>, 1988, 43:135.</p>\n<p>3. Shimada J, Shiba K, Oguma T, et al, “Effect of Antacid on Absorption of the Quinolone Lomefloxacin,” <i>Antimicrob Agents Chemother</i>, 1992, 36:1219-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1329615\">[PubMed 1329615]</a></p>\n<p>4. Shiba K, Sakai O, Shimada J, et al, “Effects of Antacids, Ferrous Sulphate and Ranitidine on Absorption of DR-3355 in Humans,” <i>Antimicrob Agents Chemother</i>, 1992, 36:2270-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1444308\">[PubMed 1444308]</a></p>\n<p>5. Sahai J, Healey DP, Stotka J, et al, “The Influence of Chronic Administration of Calcium Carbonate on the Bioavailability of Oral Ciprofloxacin,” <i>Br J Clin Pharmacol</i>, 1993, 35:302-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8471407\">[PubMed 8471407]</a></p>\n<p>6. Frost RW, Lettieri JT, Noe A, et al, “Effect of Aluminum Hydroxide and Calcium Carbonate Antacids on Ciprofloxacin Bioavailability,” <i>Clin Pharmacol Ther</i>, 1989, 45:165.</p>\n<p>7. Lehto PL and Kivisto KT, “Different Effects of Products Containing Metal Ions on the Absorption of Lomefloxacin,” <i>Clin Pharmacol Ther</i>, 1994, 56:477-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7955811\">[PubMed 7955811]</a></p>\n<p>8. Nix DE, Wilton JH, Ronald B, et al, “Inhibition of Norfloxacin Absorption by Antacids,” <i>Antimicrob Agents Chemother</i>, 1990, 34:432-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2334155\">[PubMed 2334155]</a></p>\n<p>9. Nix DE, Wilton JH, Schentag JJ, et al, “Inhibition of Norfloxacin Absorption by Antacids and Sucralfate,” <i>Rev Infect Dis</i>, 1989, II(Suppl 5):S1096.</p>\n<p>10. Okhamafe AO, Akerele JO, and Chukuka CS, “Pharmacokinetic Interactions of Norfloxacin With Some Metallic Medicinal Agents,” <i>Int J Pharm</i>, 1991, 68:11-18.</p>\n<p>11. Kays MB, Overholser BR, Mueller BA, et al, “Effects of Sevelamer Hydrochloride and Calcium Acetate on the Oral Bioavailability of Ciprofloxacin,”<i> Am J Kidney Dis</i>, 2003, 42(6):1253-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14655198\">[PubMed 14655198]</a></p>\n<p>12. Staff H, Wandel C, Delesen H, et al, “Effect of Calcium Supplements on the Oral Bioavailability of Moxifloxacin in Healthy Male Volunteers,” <i>Clin Pharmacokinet</i>, 2001, 40(Suppl 1):27-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11352439\">[PubMed 11352439]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7741":"<p><b>Title</b> Tetracyclines / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to use of oral tetracyclines.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Tetracyclines. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In general, the coadministration of oral polyvalent cations (i.e., calcium, magnesium, zinc, iron) and oral tetracycline derivatives should be avoided. Interactions may be minimized by administering the polyvalent cation-containing multivitamin at least 2 hours before or 4 hours after the dose of the oral tetracycline derivative. Even with dose separation, therapy may still be compromised. Monitor for decreased therapeutic effect of oral tetracycline derivatives.</p>\n<div>\n <p><b>Tetracyclines Interacting Members</b> Demeclocycline, Doxycycline, Lymecycline, Minocycline, Oxytetracycline, Tetracycline (Systemic)</p>\n</div> \n<p><b>Discussion</b> Several studies have shown that the absorption/bioavailability of tetracycline, minocycline, doxycycline, and oxytetracycline were significantly reduced by the concurrent use of the polyvalent cations calcium, magnesium, or iron.<sup>1,2,3,4,5,6,7</sup> Similarly, serum concentrations and AUC of the tetracyclines have been shown to be reduced by as much as 40-50% with concurrent ingestion of magnesium and zinc salts.<sup>8,9,10,11</sup><br><br>This interaction is likely the result of formation of a non-absorbable cation-tetracycline complex in the GI tract.<sup>12</sup> Separating the doses of the cation and the tetracycline by 2-4 hours appears to have a minimizing effect on the interaction.<sup>3,4</sup> However, even with the recommended dose separation, use of such a combination may still result in significant decreases in tetracycline derivative absorption.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Tetracycline. Sellersville, PA: Teva Pharmaceuticals USA, 6/2009.</p>\n<p>2. Prescribing information. Minocin (minocycline). Cranford, NJ: Triax Pharmaceuticals, LLC, 08/2010.</p>\n<p>3. Prescribing information. Vibramycin (doxycycline). New York, NY: Pfizer Inc, April 2007.</p>\n<p>4. Jung H, Peregrina AA, Rodriguez JM, et al, “The Influence of Coffee with Milk and Tea with Milk on the Bioavailability of Tetracycline,” Biopharm Drug Dispos, 1997, 18(5):459-63. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9210983\">[PubMed 9210983]</a></p>\n<p>5. Garty M and Hurwitz A, “Effect of Cimetidine and Antacids on Gastrointestinal Absorption of Tetracycline,” <i>Clin Pharmacol Ther</i>, 1980, 28(2):203-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7398187\">[PubMed 7398187]</a></p>\n<p>6. Leyden JJ, “Absorption of Minocycline Hydrochloride and Tetracycline Hydrochloride. Effects of Food, Milk and Iron,” <i>J Am Acad Dermatol</i>, 1985, 12:308-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3838321\">[PubMed 3838321]</a></p>\n<p>7. Neuvonen PJ, Gothoni G, Hackman R, et al, “Interference of Iron With the Absorption of Tetracyclines in Man,” <i>Br Med J</i>, 1970, 4:532. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5483323\">[PubMed 5483323]</a></p>\n<p>8. Healy DP, Dansereau RJ, Dunn AB, et al, “Reduced Tetracycline Bioavailability Caused by Magnesium Aluminum Silicate in Liquid Formulations of Bismuth Subsalicylate,” <i>Ann Pharmacother</i>, 1997, 31(12):1460-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9416381\">[PubMed 9416381]</a></p>\n<p>9. Penttila O, Hurme H, and Neuvonen PJ, “Effect of Zinc Sulphate on the Absorption of Tetracycline and Doxycycline in Man,” <i>Eur J Clin Pharmacol</i>, 1975, 9:131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=786686\">[PubMed 786686]</a></p>\n<p>10. Andersson KE, Bratt L, Dencker H, et al, “Inhibition of Tetracycline Absorption by Zinc,” <i>Eur J Clin Pharmacol</i>, 1976, 10:59.</p>\n<p>11. Mapp RK and McCarthy TJ, “The Effect of Zinc Sulphate and of Bicitropeptide on Tetracycline Absorption,” <i>S Afr Med J</i>, 1976, 50:1829. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=996681\">[PubMed 996681]</a></p>\n<p>12. Prescribing information. PhosLo (calcium acetate). Waltham, MA: Fresenius Medical Care North America, 3/2011.</p>\n<p>13. Mattila MJ, Neuvonen PJ, Gothoni G, et al, “Interference of Iron Preparations and Milk With the Absorption of Tetracyclines,” <i>Excerpta Medica Int Congr Series No. 254</i>, 1972. Toxicological Problems of Drug Combinations, 128.</p>\n<p>14. Neuvonen PJ and Penttila O, “Effect of Oral Ferrous Sulphate on the Half-Life of Doxycycline in Man,” <i>Eur J Clin Pharmacol</i>, 1974, 7:361. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4607747\">[PubMed 4607747]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7742":"<p><b>Title</b> Vitamin K Antagonists / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for increased vitamin K antagonist effectiveness (increased INR, signs/symptoms of bleeding) when used together with one of these types of multivitamin. Both the vitamin E and vitamin A (particularly at higher doses) components may increase anticoagulant effectiveness. The specific effect(s) of individual multivitamin products may be better predicted by evaluating the specific amount of these components in the particular multivitamin product. The likelihood of a clinically significant is greater with products containing larger amounts of any of these specific vitamins.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A warfarin-treated patient exhibited a prolonged prothrombin time (PT) and began to bleed within 2 months of initiating vitamin E therapy (1200 IU/day).<sup>1</sup> A subsequent challenge with 800 IU of vitamin E daily (for 7 weeks) showed a 41% increase in prothrombin time at 7 weeks (changes began at week 4), the development of ecchymoses on extremities, and decreased serum concentrations of blood clotting factors. Warfarin serum concentrations remained unchanged. The patient's coagulation status (including signs of over-anticoagulation) normalized within one week of discontinuing the vitamin E. The prothrombin activity (36 hours postdose) in 3 dicumarol-treated (150 mg single dose) healthy subjects was decreased from 52% to 33% when administered following a 30-day course of vitamin E (42 IU/day).<sup>2</sup> Of note, the author states that “similar results” were obtained using vitamin A (25,000 IU/day) instead of vitamin E, suggesting that higher doses of vitamin A may interact in a similar manner. In contrast, two studies involving 37 patients showed no significant changes in response to warfarin during concomitant administration of vitamin E (doses up to 1200 IU/day).<sup>3,4</sup> The mechanism of this interaction is unknown. One author group has postulated that vitamin E may interfere with the vitamin K-dependent process of clotting factor production.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Corrigan JJ and Marcus FI, “Coagulopathy Associated With Vitamin E Ingestion,” <i>JAMA</i>, 1974, 230:1300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4479598\">[PubMed 4479598]</a></p>\n<p>2. Schrogie JJ, “Coagulopathy and Fat-Soluble Vitamins,” <i>JAMA</i>, 1975, 232:19. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1172961\">[PubMed 1172961]</a></p>\n<p>3. Kim JM and White RH, “Effect of Vitamin E on the Anticoagulant Response to Warfarin,” <i>Am J Cardiol</i>, 1996, 77:545-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=86296604\">[PubMed 86296604]</a></p>\n<p>4. Corrigan JJ and Ulfers LL, “Effect of Vitamin E on Prothrombin Levels in Warfarin-Induced Vitamin K Deficiency,” <i>Am J Clin Nutr</i>, 1981, 34:1701-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7282596\">[PubMed 7282596]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7743":"<p><b>Title</b> Multivitamins/Minerals (with AE, No Iron) / Bile Acid Sequestrants</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Bile Acid Sequestrants may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant administration of multivitamins and bile acid sequestrants (e.g., cholestyramine). Specific recommendations regarding separating the administration of these agents are not defined; however, it would be prudent to separate the administration of these agents by several hours to minimize the potential for a significant interaction. The manufacturer of colesevelam recommends that drugs should be administered at least 1 hour before or 4 hours after colesevelam.</p>\n<div>\n <p><b>Bile Acid Sequestrants Interacting Members</b> Cholestyramine Resin, Colesevelam, Colestipol</p>\n</div> \n<p><b>Discussion</b> In one report, children with hypercholesterolemia (n=5) who had good adherence to treatment with colestipol plus a low-cholesterol diet had significantly decreased vitamin A and vitamin E concentrations.<sup>1</sup> A controlled study of 14 healthy volunteers similarly reported that administration of cholestyramine (12 g) with a vitamin A-containing test meal was associated with an approximate 60% decrease in the expected rise in vitamin A concentrations.<sup>2</sup><br><br>Approximately 98% of niacin was bound to colestipol in an in vitro study.<sup>3</sup> A much lower amount (10% to 30%) was bound to cholestyramine,<sup>9</sup> suggesting there may be some differences among the individual bile acid sequestrants.<br><br>This suspected effect of bile acid sequestrants on the absorption of fat-soluble vitamins and possibly niacin could be the result of direct binding of the vitamin by the bile acid-binding resin, resin removal of bile acids that are necessary for fat-soluble vitamin absorption, and/or the impaired absorption could be secondary to drug-induced steatorrhea.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schwarz KB, Goldstein PD, Witztum JL, et al, “Fat-Soluble Vitamin Concentrations in Hypercholesterolemic Children Treated with Colestipol,” <i>Pediatrics</i>, 1980, 65(2):243-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7354970\">[PubMed 7354970]</a></p>\n<p>2. Barnard DL, Heaton KW, “Bile Acids and Vitamin A Absorption in Man: The Effects of Two Bile Acid-Binding Agents, Cholestyramine and Lignin,” <i>Gut</i>, 1973, 14(4):316-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4706914\">[PubMed 4706914]</a></p>\n<p>3. Prescribing information. Niaspan (niacin). Cranbury, NJ: Kos Pharmaceuticals, 12/2010.</p>\n<p>4. West RJ, Lloyd JK, “The Effect of Cholestyramine on Intestinal Absorption,” <i>Gut</i>, 1975, 16:93-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1168607\">[PubMed 1168607]</a></p>\n<p>5. Thompson WG, Thompson GR, “Effect of Cholestyramine on the Absorption of Vitamin D3 and Calcium,” <i>Gut</i>, 1969, 10:717-22. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4318526\">[PubMed 4318526]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7744":"<p><b>Title</b> Agents with Antiplatelet Properties / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may enhance the antiplatelet effect of Agents with Antiplatelet Properties. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased platelet inhibition (e.g., bruising, bleeding) in patients receiving a vitamin E-containing multivitamin together with antiplatelet agents.</p>\n<div>\n <p><b>Agents with Antiplatelet Properties Interacting Members</b> Abciximab, Aceclofenac, Acemetacin, Anagrelide, Aspirin, Cangrelor, Cilostazol, Citalopram, Clopidogrel, Dapoxetine, Defibrotide, Desvenlafaxine, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dilazep, Dipyridamole, Dipyrone, DULoxetine, Eptifibatide, Escitalopram, Etodolac, Etofenamate, Fenoprofen, Floctafenine, FLUoxetine, Flurbiprofen (Systemic), FluvoxaMINE, Ibuprofen, Ibuprofen (Topical), Indobufen, Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Levomilnacipran, Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Milnacipran, Nabumetone, Naproxen, Oxaprozin, PARoxetine, Pelubiprofen, Phenylbutazone, Piracetam, Piroxicam (Systemic), Piroxicam (Topical), Prasugrel, Propyphenazone, Sarpogrelate, Sertraline, Sulfinpyrazone, Sulindac, Tenoxicam, Tiaprofenic Acid, Ticagrelor, Ticlopidine, Tirofiban, Tolfenamic Acid, Tolmetin, Triflusal, Venlafaxine, Vilazodone, Vorapaxar, Vortioxetine, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachadonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein IIb expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7745":"<p><b>Title</b> Aspirin / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The impact of aspirin on ascorbic acid absorption has only been demonstrated with aspirin doses 600 mg or greater.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, aspirin may decrease the absorption of ascorbic acid. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased platelet inhibition (e.g., bruising, bleeding) in patients receiving a multivitamin that contains vitamin E together with aspirin.</p> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachadonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein IIb expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.<br><br>In addition, several observational and clinical studies, in both healthy volunteers and patients, have shown decreased ascorbate absorption and/or systemic concentrations during aspirin administration (from 600 mg single dose up to 3.9 g/day).<sup>59,60,61,62</sup> In contrast, one week of aspirin (3 g/day) had no effect on plasma ascorbate concentrations in healthy volunteers receiving varying dietary ascorbic acid content.<sup>63</sup><br><br>The mechanism and clinical importance of this interaction are unknown. Aspirin may decrease ascorbate absorption,<sup>59</sup> cause depletion of systemic ascorbate stores (e.g., in the gastric mucosa),<sup>60</sup> or both. Gastric ascorbate stores may be used in the process of neutralizing reactive oxygen species generated during aspirin treatment, which suggests a possible role in mediating the risk of aspirin induced gastric mucosal damage.<sup>64,65,66</sup> Ascorbic acid also may also decrease serum aspirin esterase activity,<sup>67</sup> but the clinical impact of this is likely low based on a study of choline salicylate.<sup>68</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p>59. Basu TK, “Vitamin C-Aspirin Interactions,” <i>Int J Vitam Nutr Res Suppl</i>, 1982, 23:83-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6811490\">[PubMed 6811490]</a></p>\n<p>60. Schulz HU, Schurer M, Krupp S, et al, “Effects of Acetylsalicylic Acid on Ascorbic Acid Concentrations in Plasma, Gastric Mucosa, Gastric Juice and Urine--A Double-Blind Study in Healthy Subjects,” <i>Int J Clin Pharmacol Ther</i>, 2004, 42(9):481-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15487806\">[PubMed 15487806]</a></p>\n<p>61. Sahud MA and Cohen RJ, “Effect of Aspirin Ingestion on Ascorbic-Acid Levels in Rheumatoid Arthritis,” <i>Lancet</i>, 1971, 1(7706):937-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102269\">[PubMed 4102269]</a></p>\n<p>62. Loh HS, Watters K and Wilson CW, “The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings,” <i>J Clin Pharmacol</i>, 1973, 13(11):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4490672\">[PubMed 4490672]</a></p>\n<p>63. Johansson U and Akesson B, “Interaction Between Ascorbic Acid and Acetylsalicylic Acid and Their Effects on Nutritional Status in Man,” <i>Int J Vitam Nutr Res</i>, 1985, 55(2):197-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4040504\">[PubMed 4040504]</a></p>\n<p>64. Pohle T, Brzozowski T, Becker JC, et al, “Role of Reactive Oxygen Metabolites in Aspirin-Induced Gastric Damage in Humans: Gastroprotection by Vitamin C,” <i>Aliment Pharmacol Ther</i>, 2001, 15(5):677-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11328262\">[PubMed 11328262]</a></p>\n<p>65. Konturek PC, Kania J, Hahn EG, et al, “Ascorbic Acid Attenuates Aspirin-Induced Gastric Damage: Role of Inducible Nitric Oxide Synthase,” <i>J Physiol Pharmacol</i>, 2006, 57 Suppl 5:125-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17218764\">[PubMed 17218764]</a></p>\n<p>66. Dammann HG, Saleki M, Torz M, et al, “Effects of Buffered and Plain Acetylsalicylic Acid Formulations With and Without Ascorbic Acid on Gastric Mucosa in Healthy Subjects,” <i>Aliment Pharmacol Ther</i>, 2004, 19(3):367-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984384\">[PubMed 14984384]</a></p>\n<p>67. Gupta JD, Gruca M and Ablett W, “Effect of Other Drugs and Chemicals on the Degradation of Aspirin in Vitro: Possible Extrapolation to In Vivo Metabolism of Aspirin,” <i>Eur J Drug Metab Pharmacokinet</i>, 1979, 4(2):103-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=488131\">[PubMed 488131]</a></p>\n<p>68. Hansten PD and Hayton WL, “Effect of Antacid and Ascorbic Acid on Serum Salicylate Concentration,” <i>J Clin Pharmacol</i>, 1980, 20(5-6 Pt 1):326-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7400368\">[PubMed 7400368]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7746":"<p><b>Title</b> Barbiturates / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction has only been suggested at high pyridoxine doses (80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Barbiturates. Specifically, it has been reported that high-dose pyridoxine may decrease barbiturate concentrations. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required since this interaction is thought to be limited to high-dose pyridoxine (e.g., 80-200 mg/day). If patients may be receiving multiple pyridoxine-containing supplements, consider monitoring serum concentrations/effects of barbiturates more closely.</p>\n<div>\n <p><b>Barbiturates Interacting Members</b> Amobarbital, Butabarbital, Butalbital, Methohexital, PENTobarbital, PHENobarbital, Primidone, Secobarbital, Thiopental</p>\n</div> \n<p><b>Discussion</b> Serum phenobarbital concentrations were approximately halved in 5 patients (also receiving chronic phenytoin therapy) following 4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenobarbital metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentrations of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7747":"<p><b>Title</b> Bisphosphonate Derivatives / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: Only oral preparations of bisphosphonate derivatives and multivitamin products are expected to participate in this interaction.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.</p>\n<div>\n <p><b>Bisphosphonate Derivatives Interacting Members</b> Alendronate, Clodronate, Etidronate, Ibandronate, Risedronate, Tiludronate<br><b>Exceptions</b> Pamidronate, Zoledronic Acid</p>\n</div> \n<p><b>Discussion</b> The manufacturers of all oral bisphosphonate derivatives caution that absorption may be impaired by concomitant oral intake of polyvalent cations such as calcium and magnesium.<sup>1,2,3,4,5,6</sup> The likely primary mechanism of this interaction is binding of the bisphosphonate derivative to polyvalent cations to form a nonabsorbable (or very poorly absorbable) chelate.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Skelid (tiludronate disodium) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; March 2010.</p>\n<p>2. Actonel (risedronate sodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>3. Fosamax (alendronate sodium) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; February 2015.</p>\n<p>4. Bonefos (clodronate disodium) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; September 2011.</p>\n<p>5. Didronel (etidronate disodium) [prescribing information]. North Norwich, NY: Norwich Pharmaceuticals Inc; April 2015.</p>\n<p>6. Boniva (ibandronate sodium) [prescribing information]. South San Francisco, CA: Genentech USA Inc; April 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7748":"<p><b>Title</b> Bortezomib / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may diminish the therapeutic effect of Bortezomib. Specifically, vitamin C may decrease bortezomib therapeutic effects. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Patients should avoid taking extra vitamin C supplements and vitamin C-containing multivitamins during their bortezomib therapy. It is probably unnecessary, though, to advise patients to avoid foods/beverages that contain vitamin C (e.g., citrus fruits, etc.).</p> \n<p><b>Discussion</b> In one study, the addition of plasma from healthy volunteers who were taking vitamin C (1 g/d) was associated with decreased bortezomib-induced multiple myeloma cell death in vitro.<sup>1</sup> In the same study, using a mouse model of human multiple myeloma, vitamin C also interfered with the bortezomib inhibition of multiple myeloma cell growth. In another study, vitamin C inhibited bortezomib-mediated cell death in an endometrial carcinoma cell line.<sup>2</sup> A third in vitro study also reported that vitamin C interfered with bortezomib actions, and reported findings consistent with a direct chemical interaction between ascorbic acid and bortezomib.<sup>3</sup><br><br>In contrast to these findings, other reports describe the use of this combination as part of a regimen used in treatment of patients with multiple myeloma -- one using bortezomib/ascorbic acid/melphalan in newly diagnosed multiple myeloma,<sup>4</sup> and another using arsenic trioxide/bortezomib/ascorbic acid in patients with refractory or relapsed multiple myeloma.<sup>5</sup><br><br>One commentary on the issue emphasized the need for additional data in order to accurately determine the clinical significance of this apparent interaction, particularly given that such an interaction with vitamin C may either protect patients from toxicity or interfere with bortezomib effectiveness.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Perrone G, Hideshima T, Ikeda H, et al, “Ascorbic Acid Inhibits Antitumor Activity of Bortezomib in Vivo,” <i>Leukemia</i>, 2009, 23:1679-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19369963\">[PubMed 19369963]</a></p>\n<p>2. Llobet D, Eritja N, Encinas M, et al, “Antioxidants Block Proteasome Inhibitor Function in Endometrial Carcinoma Cells,” <i>Anticancer Drugs</i>, 2008, 19:115-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18176107\">[PubMed 18176107]</a></p>\n<p>3. Zou W, Yue P, Lin N, et al, “Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells,” <i>Clin Cancer Res</i>, 2006, 12:273-80. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16397052\">[PubMed 16397052]</a></p>\n<p>4. Berenson JR, Yellin O, Woytowitz D, et al, “Bortezomib, Ascorbic Acid and Melphalan (BAM) Therapy for Patients with Newly Diagnosed Multiple Myeloma: An Effective and Well-Tolerated Frontline Regimen,” <i>Eur J Haematol</i>, 2009, 82:433-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19226361\">[PubMed 19226361]</a></p>\n<p>5. Berenson JR, Matous J, Swift RA, et al, “A Phase I/II Study of Arsenic Trioxide/Bortezomib/Ascorbic Acid Combination Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma,” <i>Clin Cancer Res</i>, 2007, 13:1762-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17363530\">[PubMed 17363530]</a></p>\n<p>6. Catley L,Anderson KC, “Velcade and Vitamin C: Too Much of a Good Thing?,” <i>Clin Cancer Res</i>, 2006, 12:3-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16397016\">[PubMed 16397016]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7749":"<p><b>Title</b> Cardiac Glycosides / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may enhance the arrhythmogenic effect of Cardiac Glycosides. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor serum calcium concentrations closely and watch for signs and symptoms of cardiac glycoside toxicity (e.g., loss of appetite, nausea and vomiting, etc.) in patients receiving a multivitamin and a cardiac glycoside together. In particular, multivitamins containing higher amounts of calcium likely have a higher potential to interact. Hypercalcemia enhances the conduction effects of cardiac glycosides.</p>\n<div>\n <p><b>Cardiac Glycosides Interacting Members</b> Digitoxin, Digoxin</p>\n</div> \n<p><b>Discussion</b> Multivitamins containing calcium can contribute to hypercalcemia, particularly with higher doses or in high-risk patients. Existing data show that hypercalcemia and cardiac glycosides, such as digoxin, have similar effects on cardiac conduction.<sup>1,2</sup> Consequently, clinically significant adverse effects on cardiac conduction can occur even at therapeutic concentrations of cardiac glycosides in the setting of hypercalcemia.<sup>1</sup> Similarly, cardiac glycosides can exacerbate the negative cardiovascular effects of hypercalcemia. A case report describing an elderly patient who experienced a clinically significant bradyarrhythmia attributed to hypercalcemia (total calcium = 3.0 mmol/L [normal: 2.2-2.5 mmol/L]) and digoxin therapy (digoxin concentration = 1.5 ng/mL [normal/therapeutic: 0.5-2.0 ng/mL]) exemplifies this risk.<sup>1</sup> Other case reports describe cardiac arrhythmias that occurred during concomitant administration of cardiac glycosides and a calcium preparation (primarily IV calcium).<sup>3,4</sup> Though deaths were reported in one citation, a causal relationship was not firmly established.<sup>3</sup><br><br>The mechanism by which hypercalcemia and cardiac glycosides augment one another's effects on conduction involves both the Na+/K+-ATPase and the Ca2+/Na+-antiporter. Cardiac glycosides are known to inhibit Na+/K+-ATPase,<sup>2</sup> increasing intracellular sodium concentrations. This increase in intracellular sodium inhibits action of the Ca2+/Na+-antiporter, which normally transports sodium into the cell as it transports calcium out of the cell. The net effect of inhibiting this antiporter is increased intracellular calcium.<sup>1</sup> Both the cardiac glycosides and excess calcium (i.e., hypercalcemia) decrease the cardiac excitation threshold, shorten the effective refractory period, and increase the refractoriness of the AV node.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Vella A, Gerber TC, Hayes DL, et al, “Digoxin, Hypercalcemia, and Cardiac Conduction,” <i>Postgrad Med J</i>, 1999, 75:554-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10616693\">[PubMed 10616693]</a> </p>\n<p>2. Kelly RA, Smith TW, “Pharmacological Treatment of Heart Failure,” In: Hardman JG, Limbird LE, Molinoff PB, et al, eds, Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw-Hill, 1996:809-38.]</p>\n<p>3. Bower Jo and Mengle HAK, “The Additive Effects of Calcium and Digitalis. A Warning With a Report of Two Deaths,” <i>JAMA</i>, 1936, 106:1151.</p>\n<p>4. Nola GT, Pope S, and Harrison DC, “Assessment of the Synergistic Relationship Between Serum Calcium and Digitalis,” <i>Am Heart J</i>, 1970, 79(4):499-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5418023\">[PubMed 5418023]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7750":"<p><b>Title</b> Multivitamins/Minerals (with AE, No Iron) / Colchicine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Colchicine may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor clinical response to cyanocobalamin supplementation in patients receiving long-term colchicine.</p> \n<p><b>Discussion</b> Several reports describe pernicious anemia and/or vitamin B12 malabsorption in patients receiving colchicine.<sup>1,2,3</sup><br><br>Animal studies suggest that colchicine interferes with the expression of the intrinsic factor-vitamin B12 receptor, contributing to deficient vitamin B12 absorption.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Palopoli J, Waxman J, “Recurrent Aphthous Stomatitis and Vitamin B12 Deficiency,”<i> South Med J</i>, 1990, 83(4):475-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2321075\">[PubMed 2321075]</a></p>\n<p>2. Webb DI, Chodos RB, Mahar CQ, et al, “Mechanism of Vitamin B12 Malabsorption in Patients Receiving Colchicine,” <i>N Engl J Med</i>, 1968, 279(16):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5677718\">[PubMed 5677718]</a></p>\n<p>3. Race TF, Paes IC, Faloon WW, “Intestinal Malabsorption Induced by Oral Colchicine. Comparison with Neomycin and Cathartic Agents,” <i>Am J Med Sci</i>, 1970, 259(1):32-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5416781\">[PubMed 5416781]</a></p>\n<p>4. Polliotti BM, Panigel M, Miller RK, “Free Vitamin B12 and Transcobalamin II-Vitamin B12 Complex Uptake by the Visceral Yolk Sac of the Sprague-Dawley Rat: Effect of Inhibitors,” <i>Reprod Toxicol</i>, 1997, 11(4):617-26. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9241684\">[PubMed 9241684]</a></p>\n<p>5. Ramanujam KS, Seetharam S, Dahms NM, et al, “Functional Expression of Intrinsic Factor-Cobalamin Receptor by Renal Proximal Tubular Epithelial Cells,” <i>J Biol Chem</i>, 1991, 266(20):13135-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1649178\">[PubMed 1649178]</a></p>\n<p>6. Stopa EG, O'Brien R, Katz M, “Effect of Colchicine on Guinea Pig Intrinsic Factor-Vitamin B12 Receptor,” <i>Gastroenterology</i>, 1979, 76(2):309-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=759260\">[PubMed 759260]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7751":"<p><b>Title</b> CycloSPORINE (Systemic) / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased serum cyclosporine concentrations with initiation/dose increase of a vitamin E-containing multivitamin.</p> \n<p><b>Discussion</b> In three clinical studies of cyclosporine maintained transplant recipients, antioxidant regimens containing 267-500 mg/day vitamin E were associated with 24-30% lower trough cyclosporine concentrations compared to baseline values or placebo treatment.<sup>1,2,3</sup> All regimens also contained ascorbic acid (500-1000 mg/day), and one contained beta carotene (6 mg/day). The mechanism of this interaction is unknown, and it is unclear whether the observed changes may be attributable to vitamin E or the other supplements.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lake KD, Aaronson KD, Gorman LE, et al, “Effect of Oral Vitamin E and C Therapy on Calcineurin Inhibitor Levels in Heart Transplant Recipients,” <i>J Heart Lung Transplant</i>, 2005, 24(8):990-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16102431\">[PubMed 16102431]</a></p>\n<p>2. Blackhall ML, Fassett RG, Sharman JE, et al, “Effects of Antioxidant Supplementation on Blood Cyclosporine A and Glomerular Filtration Rate in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2005, 20(9):1970-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15998657\">[PubMed 15998657]</a></p>\n<p>3. de Vries AP, Oterdoom LH, Gans RO, et al, “Supplementation With Anti-oxidants Vitamin C and E Decreases Cyclosporine A Trough-Levels in Renal Transplant Recipients,” <i>Nephrol Dial Transplant</i>, 2006, 21(1):231-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16115840\">[PubMed 16115840]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7752":"<p><b>Title</b> Aspirin / Multivitamins/Fluoride (with ADE)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: The impact of aspirin on ascorbic acid absorption has only been demonstrated with aspirin doses 600 mg or greater.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Multivitamins/Fluoride (with ADE) may enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, aspirin may decrease the absorption of ascorbic acid. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients closely for evidence of increased platelet inhibition (e.g., bruising, bleeding) in patients receiving a multivitamin that contains vitamin E together with aspirin.</p> \n<p><b>Discussion</b> In vitro and animal studies have consistently demonstrated inhibition of platelet aggregation in the presence of vitamin E (primarily as alpha tocopherol, but also in gamma and delta forms).<sup>1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17</sup> Clinical data, however, have been less consistent. Some ex vivo studies in healthy volunteers show reduced platelet aggregation during vitamin E supplementation,<sup>3,18,19,20,21,22,23,24</sup> while others do not.<sup>25,26,27,28,29,30,31</sup> Studies in patient populations are also inconsistent, with most investigations showing inhibition of platelet aggregation during vitamin E supplementation,<sup>31,32,33,34,35,36</sup> but others detecting no inhibition.<sup>37,38,39</sup> Human studies with positive and negative findings do not clearly differentiate from one another in terms of patient population, vitamin E form, dose, or platelet aggregation assay.<br><br>In addition to the possible effects of vitamin E on platelet aggregation, in vitro data indicate lower expression of adhesion molecules and a decrease in platelet adhesion with the addition of vitamin E.<sup>40,41</sup> Ex vivo studies in healthy volunteers have shown decreased platelet adhesion during supplementation with vitamin E,<sup>21,42,43</sup> and in a study of patients with a history of cerebral ischemia, platelet adhesion was inhibited to a significantly greater extent with aspirin and vitamin E compared to aspirin alone.<sup>44</sup><br><br>Data demonstrating changes in clinical coagulation status with vitamin E supplementation are sparse, and effects seen may or may not be due to antiplatelet effects. Two case reports describe the reversal of platelet hyperaggregability in vitamin E deficient states by supplementation with vitamin E.<sup>45</sup> In a retrospective review, smokers who took vitamin E supplements were more likely to experience gingival bleeding than those who did not.<sup>46</sup> A large study of stroke incidence in male smokers showed a decrease in the incidence of ischemic stroke, a nonsignificant increase in the incidence of subarachnoid hemorrhage, and an almost 2 fold increase in the incidence of fatal subarachnoid hemorrhage in subjects randomly assigned to receive alpha tocopherol (50 mg daily).<sup>47</sup> In subgroup analyses, decreases in ischemic stroke and increases in subarachnoid hemorrhage were significant only in hypertensive patients, and the presence of diabetes in hypertensive patients was associated with a decreased incidence of hemorrhage.<sup>48</sup> In a study of patients with a history of transient ischemic attack, minor stroke, or residual ischemic neurologic deficit, rates of ischemic events were significantly reduced with vitamin E and aspirin compared to aspirin alone.<sup>44</sup><br><br>A number of possible mechanisms have been proposed for antiplatelet effects of vitamin E. Although results have varied, some in vitro data indicate inhibition of formation of thromboxane B2, prostaglandin D2, and other arachadonic acid metabolites in the presence of vitamin E.<sup>10,49,50</sup> Human data are also variable, but some indicate decreased circulating concentrations of thromboxane B2 in vitamin E supplemented patients.<sup>51</sup> In vitro data have shown inhibition of platelet aggregation in the absence of detectable increases in arachadonic acid products, and further inhibition of aggregation during aspirin treatment, both of which suggest an arachadonic acid independent pathway.<sup>12,13,14</sup> One in vitro study demonstrated that the vitamin E quinone metabolite was a more potent inhibitor of platelet aggregation than vitamin E, possibly acting via inhibition of phospholipase.<sup>52</sup> Other data have suggested decreased platelet counts,<sup>53</sup> diminished P-selectin response,<sup>54,55</sup> down-regulation of glycoprotein IIb expression,<sup>56</sup> enhancement of platelet nitric oxide release,<sup>57</sup> and impaired platelet factor 3 activity<sup>58</sup> as mechanisms for platelet inhibitory effects of vitamin E supplementation.<br><br>In addition, several observational and clinical studies, in both healthy volunteers and patients, have shown decreased ascorbate absorption and/or systemic concentrations during aspirin administration (from 600 mg single dose up to 3.9 g/day).<sup>59,60,61,62</sup> In contrast, one week of aspirin (3 g/day) had no effect on plasma ascorbate concentrations in healthy volunteers receiving varying dietary ascorbic acid content.<sup>63</sup><br><br>The mechanism and clinical importance of this interaction are unknown. Aspirin may decrease ascorbate absorption,<sup>59</sup> cause depletion of systemic ascorbate stores (e.g., in the gastric mucosa),<sup>60</sup> or both. Gastric ascorbate stores may be used in the process of neutralizing reactive oxygen species generated during aspirin treatment, which suggests a possible role in mediating the risk of aspirin induced gastric mucosal damage.<sup>64,65,66</sup> Ascorbic acid also may also decrease serum aspirin esterase activity,<sup>67</sup> but the clinical impact of this is likely low based on a study of choline salicylate.<sup>68</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Steiner M and Anastasi J, “Vitamin E. An inhibitor of the platelet release reaction,” <i> J Clin Invest</i>, 1976, 57(3):732-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1249206\">[PubMed 1249206]</a></p>\n<p>2. Diez Marques ML, Lucio Cazana FJ and Rodringuez Puyol M, “dl-Alpha-Tocopheryl Acetate Induces Hypocoagulability and Platelet Hypoaggregability in Rats,” <i> Int J Vitam Nutr Res</i>, 1987, 57(4):375-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3440712\">[PubMed 3440712]</a></p>\n<p>3. Freedman JE, Farhat JH, Loscalzo J, et al, “Alpha-Tocopherol Inhibits Aggregation of Human Platelets by a Protein Kinase C-Dependent Mechanism,” <i> Circulation</i>, 1996, 94(10):2434-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8921785\">[PubMed 8921785]</a></p>\n<p>4. Williams JC, Forster LA, Tull SP, “Effects of Vitamin E on Human Platelet and Mononuclear Cell Responses In Vitro,” <i>Int J Exp Pathol</i>, 1999, 80(4):227-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10583632\">[PubMed 10583632]</a></p>\n<p>5. Bakaltcheva I, Gyimah D, Reid T, et al, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i> Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>6. Freedman JE and Keaney JF Jr, “Vitamin E Inhibition of Platelet Aggregation is Independent of Antioxidant Activity,” <i>J Nutr</i>, 2001, 131(2):374S-7S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11160564\">[PubMed 11160564]</a></p>\n<p>7. Li D, Saldeen T, Romeo F, et al, “Different Isoforms of Rocopherols Enhance Nitric Oxide Synthase Phosphorylation and Inhibit Human Platelet Aggregation and Lipid Peroxidation: Implications in Therapy With Vitamin E,” <i>J Cardiovasc Pharmacol Ther</i>, 2001, 6(2):155-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11509922\">[PubMed 11509922]</a></p>\n<p>8. Celestini A, Pulcinelli FM, Pignatelli P, et al, “Vitamin E Potentiates the Antiplatelet Activity of Aspirin in Collagen-Stimulated Platelets,” <i>Haematologica</i>, 2002, 87(4):420-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11940487\">[PubMed 11940487]</a></p>\n<p>9. Fong JS, “Alpha-Tocopherol: Its Inhibition on Human Platelet Aggregation,” <i> Experientia</i>, 1976, 32(5):639-41. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1278322\">[PubMed 1278322]</a></p>\n<p>10. Rao GH, Gerrard JM, Eaton JW, et al, “Arachidonic Acid Peroxidation, Prostaglandin Synthesis and Platelet Function,” <i>Photochem Photobiol</i>, 1978, 28(4-5):845-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=733933\">[PubMed 733933]</a></p>\n<p>11. Agradi E, Petroni A, Socini A, et al, “In Vitro Effects of Synthetic Antioxidants and Vitamin E on Arachidonic Acid Metabolism and Thromboxane Formation in Human Platelets and on Platelet Aggregation,” <i> Prostaglandins</i>, 1981, 22(2):255-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6794104\">[PubMed 6794104]</a></p>\n<p>12. Srivastava KC, “Vitamin E Exerts Antiaggregatory Effects Without Inhibiting the Enzymes of the Arachidonic Acid Cascade in Platelets,” <i>Prostaglandins Leukot Med</i>, 1986, 21(2):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3083435\">[PubMed 3083435]</a></p>\n<p>13. Kakishita E, Suehiro A, Oura Y, et al, “Inhibitory Effect of Vitamin E (Alpha-Tocopherol) on Spontaneous Platelet Aggregation in Whole Blood,” <i>Thromb Res</i>, 1990, 60(6):489-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2082481\">[PubMed 2082481]</a></p>\n<p>14. Violi F, Pratico D, Ghiselli A, et al, “Inhibition of Cyclooxygenase-Independent Platelet Aggregation by Low Vitamin E Concentration,” <i>Atherosclerosis</i>, 1990, 82(3):247-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2115784\">[PubMed 2115784]</a></p>\n<p>15. Sheu JR, Lee CR, Hsiao G, et al, “Comparison of the Relative Activities of Alpha-Tocopherol and PMC on Platelet Aggregation and Antioxidative Activity,” <i>Life Sci</i>, 1999, 65(2):197-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10416825\">[PubMed 10416825]</a></p>\n<p>16. Bakaltcheva I, Gyimah D and Reid T, “Effects of Alpha-Tocopherol on Platelets and the Coagulation System,” <i>Platelets</i>, 2001, 12(7):389-94. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11674855\">[PubMed 11674855]</a></p>\n<p>17. Mardla V, Kobzar G and Samel N, “Potentiation of Antiaggregating Effect of Prostaglandins by Alpha-Tocopherol and Quercetin,” <i>Platelets</i>, 2004, 15(5):319-24. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15370103\">[PubMed 15370103]</a></p>\n<p>18. Calzada C, Bruckdorfer KR and Rice-Evans CA, “The Influence of Antioxidant Nutrients on Platelet Function in Healthy Volunteers,” <i>Atherosclerosis</i>, 1997, 128(1):97-105. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9051202\">[PubMed 9051202]</a></p>\n<p>19. Pignatelli P, Pulcinelli FM, Lenti L, et al, “Vitamin E Inhibits Collagen-Induced Platelet Activation by Blunting Hydrogen Peroxide,” <i> Arterioscler Thromb Vasc Biol</i>, 1999, 19(10):2542-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10521385\">[PubMed 10521385]</a></p>\n<p>20. Mabile L, Bruckdorfer KR and Rice-Evans C, “Moderate Supplementation With Natural Alpha-Tocopherol Decreases Platelet Aggregation and Low-Density Lipoprotein Oxidation,” <i> Atherosclerosis</i>, 1999, 147(1):177-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10525139\">[PubMed 10525139]</a></p>\n<p>21. Steiner M, “Effect of Alpha-Tocopherol Administration on Platelet Function in Man,” <i> Thromb Haemost</i>, 1983, 49(2):73-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6868015\">[PubMed 6868015]</a></p>\n<p>22. Liu M, Wallmon A, Olsson-Mortlock C, et al, “Mixed Tocopherols Inhibit Platelet Aggregation in Humans: Potential Mechanisms,” <i>Am J Clin Nutr</i>, 2003, 77(3):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12600864\">[PubMed 12600864]</a></p>\n<p>23. Kockmann V, Vericel E, Croset M, et al, “Vitamin E Fails to Alter the Aggregation and the Oxygenated Metabolism of Arachidonic Acid in Normal Human Platelets,” <i>Prostaglandins</i>, 1988, 36(5):607-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3148963\">[PubMed 3148963]</a></p>\n<p>24. Vucinic L, Singh I, Spargo FJ, et al, “Gamma Tocopherol Supplementation Prevents Exercise Induced Coagulation and Platelet Aggregation,” <i>Thromb Res</i>, 2010, 125(2):196-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20004007\">[PubMed 20004007]</a></p>\n<p>25. Huijgens PC, van den Berg CA, Imandt LM, et al, “Vitamin E and platelet aggregation,” <i> Acta Haematol</i>, 1981, 65(3):217-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6785976\">[PubMed 6785976]</a></p>\n<p>26. Stampfer MJ, Jakubowski JA, Faigel D, et al, “Vitamin E Supplementation Effect on Human Platelet Function, Arachidonic Acid Metabolism, and Plasma Prostacyclin Levels,” <i>Am J Clin Nutr</i>, 1988, 47(4):700-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3128100\">[PubMed 3128100]</a></p>\n<p>27. Silbert PL, Leong LL, Sturm MJ, et al, “Short Term Vitamin E Supplementation has no Effect on Platelet Function, Plasma Phospholipase A2 and Lyso-PAF in Male Volunteers,” <i> Clin Exp Pharmacol Physiol</i>, 1990, 17(9):645-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2279352\">[PubMed 2279352]</a></p>\n<p>28. Morinobu T, Ban R, Yoshikawa S, et al, “The Safety of High-Dose Vitamin E Supplementation in Healthy Japanese Male Adults,” <i> J Nutr Sci Vitaminol (Tokyo)</i>, 2002, 48(1):6-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12026191\">[PubMed 12026191]</a></p>\n<p>29. Clarke MW, Ward NC, Wu JH, et al, “Supplementation With Mixed Tocopherols Increases Serum and Blood Cell Gamma-Tocopherol but Does Not Alter Biomarkers of Platelet Activation in Subjects With Type 2 Diabetes,” <i>Am J Clin Nutr</i>, 2006, 83(1):95-102. [PMID:16400056]</p>\n<p>30. Kitagawa M and Mino M, “Effects of Elevated d-Alpha(RRR)-Tocopherol Dosage in Man,” <i>J Nutr Sci Vitaminol (Tokyo)</i>, 1989, 35(2):133-42. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2732807\">[PubMed 2732807]</a></p>\n<p>31. Szczeklik A, Gryglewski RJ, Domagala B, et al, “Dietary Supplementation With Vitamin E in Hyperlipoproteinemias: Effects on Plasma Lipid Peroxides, Antioxidant Activity, Prostacyclin Generation and Platelet Aggregability,” <i>Thromb Haemost</i>, 1985, 54(2):425-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3909500\">[PubMed 3909500]</a></p>\n<p>32. Williams JC, Forster LA, Tull SP, et al, “Dietary Vitamin E Supplementation Inhibits Thrombin-Induced Platelet Aggregation, but Not Monocyte Adhesiveness, in Patients With Hypercholesterolaemia,” <i>Int J Exp Pathol</i>, 1997, 78(4):259-66. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9505937\">[PubMed 9505937]</a></p>\n<p>33. Dmoszynska-Giannopoulou A, Janicka L, Sokolowska B, et al, “The Effect of Sulphinpyrazone and Alpha-Tocopherol on Platelet Activation and Function in Haemodialysed Patients,” <i>Int Urol Nephrol</i>, 1990, 22(6):561-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2093696\">[PubMed 2093696]</a></p>\n<p>34. Unchern S, Laoharuangpanya N, Phumala N, et al, “The Effects of Vitamin E on Platelet Activity in Beta-Thalassaemia Patients,” <i>Br J Haematol</i>, 2003, 123(4):738-44. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616980\">[PubMed 14616980]</a></p>\n<p>35. Renaud S, Ciavatti M, Perrot L, et al, “Influence of Vitamin E Administration on Platelet Functions in Hormonal Contraceptive Users,” <i>Contraception</i>, 1987, 36(3):347-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3677678\">[PubMed 3677678]</a></p>\n<p>36. Gisinger C, Jeremy J, Speiser P, et al, “Effect of Vitamin E Supplementation on Platelet Thromboxane A2 Production in Type I Diabetic Patients. Double-Blind Crossover Trial,” <i>Diabetes</i>, 1988, 37(9):1260-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3044891\">[PubMed 3044891]</a></p>\n<p>37. Dereska NH, McLemore EC, Tessier DJ, et al, “Short-Term, Moderate Dosage Vitamin E Supplementation May Have No Effect on Platelet Aggregation, Coagulation Profile, and Bleeding Time in Healthy Individuals,” <i> J Surg Res</i>, 2006, 132(1):121-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16337968\">[PubMed 16337968]</a></p>\n<p>38. Gomes JA, Venkatachalapathy D, and Haft JI, “The Effect of Vitamin E on Platelet Aggregation,” <i> Am Heart J</i>, 1976, 91(4):425-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1258749\">[PubMed 1258749]</a></p>\n<p>39. Mensink RP, van Houwelingen AC, Kromhout D, et al, “A Vitamin E Concentrate Rich in Tocotrienols had No Effect on Serum Lipids, Lipoproteins, or Platelet Function in Men With Mildly Elevated Serum Lipid Concentrations,” <i>Am J Clin Nutr</i>, 1999, 69(2):213-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9989682\">[PubMed 9989682]</a></p>\n<p>40. Szuwart T, Brzoska T, Luger TA, et al, “Vitamin E Reduces Platelet Adhesion to Human Endothelial Cells in Vitro,” <i>Am J Hematol</i>, 2000, 65(1):1-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10936856\">[PubMed 10936856]</a></p>\n<p>41. Ferber P, Moll K, Koschinsky T, et al, “High Dose Supplementation of RRR-Alpha-Tocopherol Decreases Cellular Hemostasis but Accelerates Plasmatic Coagulation in Type 2 Diabetes Mellitus,” <i> Horm Metab Res</i>, 1999, 31(12):665-71. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10668920\">[PubMed 10668920]</a></p>\n<p>42. Jandak J, Steiner M and Richardson PD, “Reduction of Platelet Adhesiveness by Vitamin E Supplementation in Humans,” <i>Thromb Res</i>, 1988, 49(4):393-404. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3381198\">[PubMed 3381198]</a></p>\n<p>43. Jandak J, Steiner M and Richardson PD, “Alpha-Tocopherol, an Effective Inhibitor of Platelet Adhesion,” <i> Blood</i>, 1989, 73(1):141-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2910355\">[PubMed 2910355]</a></p>\n<p>44. Steiner M, Glantz M and Lekos A, “Vitamin E Plus Aspirin Compared With Aspirin Alone in Patients With Transient Ischemic Attacks,” <i>Am J Clin Nutr</i>, 1995, 62(6 Suppl):1381S-1384S. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7495235\">[PubMed 7495235]</a></p>\n<p>45. Lake AM, Stuart MJ and Oski FA, “Vitamin E Deficiency and Enhanced Platelet Function: Reversal Following E Supplementation,” <i>J Pediatr</i>, 1977, 90(5):722-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=853335\">[PubMed 853335]</a></p>\n<p>46. Liede KE, Haukka JK, Saxen LM, et al, “Increased Tendency Towards Gingival Bleeding Caused by Joint Effect of Alpha-Tocopherol Supplementation and Acetylsalicylic Acid,” <i>Ann Med</i>, 1998, 30(6):542-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9920356\">[PubMed 9920356]</a></p>\n<p>47. Leppala JM, Virtamo J, Fogelholm R, et al, “Controlled Trial of Alpha-Tocopherol and Beta-Carotene Supplements on Stroke Incidence and Mortality in Male Smokers,” <i> Arterioscler Thromb Vasc Biol</i>, 2000, 20(1):230-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634823\">[PubMed 10634823]</a></p>\n<p>48. Leppala JM, Virtamo J, Fogelholm R, et al, “Vitamin E and Beta Carotene Supplementation in High Risk for Stroke: A Subgroup Analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study,” <i> Arch Neurol</i>, 2000, 57(10):1503-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11030804\">[PubMed 11030804]</a></p>\n<p>49. Ali M, Gudbranson CG and McDonald JW, “Inhibition of Human Platelet Cyclooxygenase by Alpha-Tocopherol,” <i>Prostaglandins Med</i>, 1980, 4(2):79-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6771778\">[PubMed 6771778]</a></p>\n<p>50. Mower R and Steiner M, “Biochemical Interaction of Arachidonic Acid and Vitamin E in Human Platelets,” <i>Prostaglandins Leukot Med</i>, 1983, 10(4):389-403. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6407031\">[PubMed 6407031]</a></p>\n<p>51. Jain SK, Krueger KS, McVie R, et al, “Relationship of Blood Thromboxane-B2 (TxB2) With Lipid Peroxides and Effect of Vitamin E and Placebo Supplementation on TxB2 and Lipid Peroxide Levels in Type 1 Diabetic Patients.,” <i>Diabetes Care</i>, 1998, 21(9):1511-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727900\">[PubMed 9727900]</a></p>\n<p>52. Rao GH, Cox CA, Gerrard JM, et al, “Alpha Tocopherol Quinone (Alpha TQ): A Potent Inhibitor of Platelet Function,” <i> Prog Lipid Res</i>, 1981, 549-52. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6804978\">[PubMed 6804978]</a></p>\n<p>53. Brown KM, Morrice PC and Duthie GG, “Vitamin E Supplementation Suppresses Indexes of Lipid Peroxidation and Platelet Counts in Blood of Smokers and Nonsmokers but Plasma Lipoprotein Concentrations Remain Unchanged,” <i>Am J Clin Nutr</i>, 1994, 60(3):383-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8074069\">[PubMed 8074069]</a></p>\n<p>54. Ferns GA, Forster LA, Williams JC, et al, “Effect of Vitamin E Supplementation on Circulating Cell Adhesion Molecules Pre- and Post-Coronary Angioplasty,” <i>Ann Clin Biochem</i>, 2000, 37 ( Pt 5):649-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11026517\">[PubMed 11026517]</a></p>\n<p>55. Murohara T, Ikeda H, Otsuka Y, et al, “Inhibition of Platelet Adherence to Mononuclear Cells by Alpha-Tocopherol: Role of P-Selectin,” <i>Circulation</i>, 2004, 110(2):141-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15197142\">[PubMed 15197142]</a></p>\n<p>56. Chang SJ, Lin JS and Chen HH, “Alpha-Tocopherol Downregulates the Expression of GPIIb Promoter in HEL Cells,” <i>Free Radic Biol Med</i>, 2000, 28(2):202-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11281287\">[PubMed 11281287]</a></p>\n<p>57. Freedman JE, Li L, Sauter R, et al, “Alpha-Tocopherol and Protein Kinase C Inhibition Enhance Platelet-Derived Nitric Oxide Release,” <i>FASEB J</i>, 2000, 14(15):2377-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11024007\">[PubMed 11024007]</a></p>\n<p>58. Korsan-Bengtsen K, Elmfeldt D and Holm T, “Prolonged Plasma Clotting Time and Decreased Fibrinolysis After Long Term Treatment With Alpha-Tocopherol,” <i>Thromb Diath Haemorrh</i>, 1974, 31(3):505-12. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4422949\">[PubMed 4422949]</a></p>\n<p>59. Basu TK, “Vitamin C-Aspirin Interactions,” <i>Int J Vitam Nutr Res Suppl</i>, 1982, 23:83-90. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6811490\">[PubMed 6811490]</a></p>\n<p>60. Schulz HU, Schurer M, Krupp S, et al, “Effects of Acetylsalicylic Acid on Ascorbic Acid Concentrations in Plasma, Gastric Mucosa, Gastric Juice and Urine--A Double-Blind Study in Healthy Subjects,” <i>Int J Clin Pharmacol Ther</i>, 2004, 42(9):481-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15487806\">[PubMed 15487806]</a></p>\n<p>61. Sahud MA and Cohen RJ, “Effect of Aspirin Ingestion on Ascorbic-Acid Levels in Rheumatoid Arthritis,” <i>Lancet</i>, 1971, 1(7706):937-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4102269\">[PubMed 4102269]</a></p>\n<p>62. Loh HS, Watters K and Wilson CW, “The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings,” <i>J Clin Pharmacol</i>, 1973, 13(11):480-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4490672\">[PubMed 4490672]</a></p>\n<p>63. Johansson U and Akesson B, “Interaction Between Ascorbic Acid and Acetylsalicylic Acid and Their Effects on Nutritional Status in Man,” <i>Int J Vitam Nutr Res</i>, 1985, 55(2):197-204. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4040504\">[PubMed 4040504]</a></p>\n<p>64. Pohle T, Brzozowski T, Becker JC, et al, “Role of Reactive Oxygen Metabolites in Aspirin-Induced Gastric Damage in Humans: Gastroprotection by Vitamin C,” <i>Aliment Pharmacol Ther</i>, 2001, 15(5):677-87. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11328262\">[PubMed 11328262]</a></p>\n<p>65. Konturek PC, Kania J, Hahn EG, et al, “Ascorbic Acid Attenuates Aspirin-Induced Gastric Damage: Role of Inducible Nitric Oxide Synthase,” <i>J Physiol Pharmacol</i>, 2006, 57 Suppl 5:125-36. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17218764\">[PubMed 17218764]</a></p>\n<p>66. Dammann HG, Saleki M, Torz M, et al, “Effects of Buffered and Plain Acetylsalicylic Acid Formulations With and Without Ascorbic Acid on Gastric Mucosa in Healthy Subjects,” <i>Aliment Pharmacol Ther</i>, 2004, 19(3):367-74. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14984384\">[PubMed 14984384]</a></p>\n<p>67. Gupta JD, Gruca M and Ablett W, “Effect of Other Drugs and Chemicals on the Degradation of Aspirin in Vitro: Possible Extrapolation to In Vivo Metabolism of Aspirin,” <i>Eur J Drug Metab Pharmacokinet</i>, 1979, 4(2):103-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=488131\">[PubMed 488131]</a></p>\n<p>68. Hansten PD and Hayton WL, “Effect of Antacid and Ascorbic Acid on Serum Salicylate Concentration,” <i>J Clin Pharmacol</i>, 1980, 20(5-6 Pt 1):326-31. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7400368\">[PubMed 7400368]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7753":"<p><b>Title</b> Deferoxamine / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Ascorbic acid (vitamin C) -- ascorbic acid may be used at doses of 200 mg/day or less under certain circumstances. Avoid ascorbic acid doses greater than 200 mg/day.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may enhance the adverse/toxic effect of Deferoxamine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid ascorbic acid/vitamin C doses greater than 200 mg/day in patients receiving deferoxamine, due to a potential risk of diminished left ventricular function. Though most multivitamins do not contain this amount of ascorbic acid, some products do contain close to or in excess of 200 mg per recommended dose. Ascorbic acid doses 200 mg/day or less may be administered to patients without cardiac failure, after one month of regular treatment with deferoxamine alone, ideally soon after setting up the infusion pump. Monitor cardiac function.</p> \n<p><b>Discussion</b> Ascorbic acid has been administered concomitantly with deferoxamine in some patients to increase the excretion of iron. However, prescribing information for deferoxamine recommends avoiding its use with ascorbic acid doses exceeding 200 mg/day.<sup>1</sup> Reports have been published of patients receiving 500 mg/day of ascorbic acid who experienced clinically important, transient deterioration of left ventricular function.<sup>2,3,4,5</sup><br><br>In contrast to the above cases, in a clinical study of 16 patients receiving iron chelation therapy with deferoxamine, 10 of the patients were given supplemental ascorbic acid (200 mg daily) 9-12 months after starting therapy, 9 of whom actually experienced increases in left ventricular ejection fraction (LVEF).<sup>6</sup> The one additional patient whose LVEF decreased while on ascorbic acid supplementation had pre-existing ischemic heart disease.<br><br>The reason for these effects has not been investigated. One group proposed that enhanced iron release from reticuloendothelial cells at higher ascorbic acid doses could enhance cardiac oxidative stress.<sup>6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Desferal (deferoxamine mesylate). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2010.</p>\n<p>2. Nienhaus AW, “Vitamin C and Iron,” <i>N Engl J Med</i>, 1981, 304:170-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442737\">[PubMed 7442737]</a></p>\n<p>3. Cohen A, Cohen U, and Schwartz E, “Scurvy and Altered Iron Stores in Thalassaemia Major,” <i>N Engl J Med</i>, 1981, 304(3):158-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7442735\">[PubMed 7442735]</a></p>\n<p>4. Henry W, “Echocardiographic Evaluation of the Heart in Thalassaemia Major,” <i>Ann Intern Med</i>, 1978:892-4.</p>\n<p>5. Schafer AI, Rabinowe S, LeBoff MS, et al, “Long-term Efficacy of Deferoxamine Iron Chelation Therapy in Patients With Acquired Transfusional Iron Overload,” <i>Arch Intern Med</i>, 1985, 145(7):1217-21. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3925909\">[PubMed 3925909]</a></p>\n<p>6. Jensen P, Olsen N, Bagger J, et al. “Cardiac Function During Iron Chelation Therapy in Adult Non-thalassaemic Patients With Transfusional Iron Overload,” <i>Eur J Haematol</i>, 1997, 59(4):221-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9338620\">[PubMed 9338620]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7754":"<p><b>Title</b> Deferiprone / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Deferiprone. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.</p> \n<p><b>Discussion</b> Deferiprone prescribing information recommends separating administration of deferiprone at least 4 hours from administration of medications or supplements that contain polyvalent cations.<sup>1</sup> Deferiprone chelates iron, with lower affinity for binding copper, aluminum, and zinc. Coadministration of any of these cations, or other polyvalent cations such as magnesium and calcium, with deferiprone could theoretically bind deferiprone in the gastrointestinal tract and limit its systemic exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Ferriprox (deferiprone). Rockville, MD: ApoPharma USA, Inc., 10/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7755":"<p><b>Title</b> Eltrombopag / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Eltrombopag. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any multivitamin containing polyvalent cations (e.g., calcium-, magnesium-, selenium-, or zinc-containing products).</p> \n<p><b>Discussion</b> The eltrombopag AUC was an average of 70% lower following administration of eltrombopag together with an antacid containing aluminum hydroxide, magnesium carbonate, and sodium alginate.<sup>1,2</sup> Similarly, eltrombopag AUC was an average of 75% lower following administration of eltrombopag with a high-calcium meal.<sup>1</sup> The eltrombopag AUC was 47% lower when administered 2 hours after a high-calcium meal, and the eltrombopag AUC was 20% lower when administered 2 hours before a high-calcium meal.<sup>1</sup><br><br>It is likely that this interaction represents chelation, where the polyvalent cation and eltrombopag bind to one another, forming a nonabsorbable complex.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Promacta (eltrombopag) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; August 2015.</p>\n<p>2. Williams DD, Peng B, Bailey CK, et al. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. <i>Clin Ther</i>. 2009;31(4):764-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19446149\">[PubMed 19446149]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7756":"<p><b>Title</b> Trientine / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Trientine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> The manufacturer of trientine recommends avoiding concurrent administration with oral mineral supplements to prevent an interaction in the gastrointestinal tract that would impair absorption of trientine. The recommendation is that trientine be taken at least one hour before or two hours after meals and at least one hour apart from any drug, food, or milk.</p> \n<p><b>Discussion</b> A case series notes that many of the 20 patients with Wilson's disease treated with trientine became iron deficient, an effect that was particularly common in female patients.<sup>1</sup> This iron deficiency was successfully treated with oral iron supplements given 4 hours apart from trientine doses. The manufacturer of trientine recognizes the potential interaction and recommends avoiding concurrent use with iron supplements or separating administration by at least 2 hours.<sup>2</sup> One Wilson's disease treatment guideline, however, recommends avoiding the combination altogether, noting that the resultant trientine-iron complex is toxic (though this assertion is not referenced or otherwise supported).<sup>3</sup><br><br>An evaluation of patients in the maintenance phase of treatment for Wilson's disease found evidence of a probable interaction between trientine and zinc, but it was reported that the suspected interaction had little effect on treatment response (copper balance).<sup>4</sup> Considering this report and the known ability of trientine to bind other minerals such as copper and iron, caution is warranted regarding combined administration of trientine with other minerals such as zinc (which along with trientine is a common treatment of Wilson's disease) or calcium in accordance with manufacturer recommendations.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Walshe JM, “Treatment of Wilson's Disease with Trientine (Triethylene Tetramine) Dihydrochloride,” <i>Lancet</i>, 1982, 1:643-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6121964\">[PubMed 6121964]</a></p>\n<p>2. Prescribing information. Syprine (trientine). West Point, PA: Merck and Co., Inc., May 2007.</p>\n<p>3. Roberts EA, Schlisky ML, “A Practice Guideline on Wilson Disease,” <i>Hepatology</i>, 2003, 37(6):1475-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12774027\">[PubMed 12774027]</a></p>\n<p>4. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al, “Treatment of Wilson's Disease with Zinc: Xi. Interaction with Other Anticopper Agents,” <i>J Am Coll Nutr</i>, 1993, 12:26-30. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8440814\">[PubMed 8440814]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7757":"<p><b>Title</b> CYP1A2 Substrates (High risk with Inhibitors) / Vemurafenib</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Vemurafenib may increase the serum concentration of CYP1A2 Substrates (High risk with Inhibitors). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of vemurafenib with any narrow therapeutic index drugs that are primarily metabolized by CYP1A2 is not recommended. Other drugs that are predominantly metabolized by CYP1A2 are also expected to interact significantly with vemurafenib, though the interaction may be of somewhat lower risk. Consider alternatives to such combinations whenever possible, particularly if the CYP1A2 substrate has a relatively narrow therapeutic index.</p>\n<div>\n <p><b>CYP1A2 Substrates (High risk with Inhibitors) Interacting Members</b> Acebrophylline, Acenocoumarol, Agomelatine, Alosetron, Aminophylline, Asenapine, Bromazepam, Caffeine, ClomiPRAMINE, CloZAPine, Cyclobenzaprine, Dacarbazine, DULoxetine, Flutamide, FluvoxaMINE, Kola Nut, Lidocaine (Systemic), Lidocaine (Topical), Melatonin, Mexiletine, Mirtazapine, OLANZapine, Pimozide, Pirfenidone, Pomalidomide, Propranolol, Ramelteon, Ramosetron, Rasagiline, ROPINIRole, Ropivacaine, Stiripentol, Tasimelteon, Theophylline, Thiothixene, TiZANidine, Trifluoperazine</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in vemurafenib prescribing information, administration of vemurafenib (960 mg twice daily for 15 days) was associated with a 2.6-fold increase in the AUC of caffeine (used as a marker of CYP1A2 activity) in a study of patients with cancer.<sup>1,2</sup> In another study of 18 patients, vemurafenib (960 mg twice daily for 20 days) increased the tizanidine (2 mg single oral dose) AUC and maximum serum concentration 4.2-fold and 2.2-fold, respectively.<sup>2</sup> As a result, the vemurafenib prescribing information states that concurrent use of drugs with a narrow therapeutic index that are primarily metabolized by CYP1A2 is not recommended.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zelboraf (vemurafenib) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015.</p>\n<p>2. Zelboraf (vemurafenib) [product monograph]. Mississauga, Ontario, Canada: Hoffmann-La Roche Limited; March 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7758":"<p><b>Title</b> Fosphenytoin-Phenytoin / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: This interaction is of most concern with products containing higher doses of pyridoxine (i.e., 80-200 mg/day).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Fosphenytoin-Phenytoin. Specifically, it has been reported that pyridoxine may decrease phenytoin concentrations. <b>Severity</b> Minor <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> No action required since this interaction is thought to be limited to high-dose pyridoxine (e.g., 80-200 mg/day). If patients may be receiving multiple pyridoxine-containing supplements, consider monitoring serum concentrations/effects of phenytoin more closely.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> Serum phenytoin concentrations were approximately halved in patients (also receiving chronic phenobarbital therapy) following 2-4 weeks of concomitant therapy with pyridoxine (80-200 mg/day).<sup>1</sup> The mechanism of this apparent interaction is unknown. The authors of the report suggest that pyridoxine might increase hepatic enzyme activity, and thus increase phenytoin metabolism. The ability of pyridoxine doses found in typical multiple vitamin preparations to produce these same effects is unknown, but presumed doubtful.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Hansson O and Sillanpaa M, “Pyridoxine and Serum Concentrations of Phenytoin and Phenobarbitone,” <i>Lancet</i>, 1976, i:256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=55569\">[PubMed 55569]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7759":"<p><b>Title</b> Levodopa / Multivitamins/Minerals (with AE, No Iron)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Additional drug/group</b> (Carbidopa): The significance of this interaction is substantially diminished with concurrent carbidopa (which is almost always used with levodopa).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may diminish the therapeutic effect of Levodopa. Specifically, pyridoxine may diminish the effects of levodopa, when used in the absence of a dopa decarboxylase inhibitor. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If levodopa is being used in the absence of a dopa decarboxylase inhibitor (DDI), concomitant use of a multivitamin containing pyridoxine (vitamin B6) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will largely eliminate the risk of this interaction.</p> \n<p><b>Discussion</b> The therapeutic effects of levodopa have been abolished in patients receiving concomitant pyridoxine in doses from 5-1000 mg/day.<sup>1,2,3,4,5</sup> When levodopa is administered with carbidopa (a dopa-decarboxylase inhibitor), no such interaction with pyridoxine occurs.<sup>6</sup> Pyridoxine enhances the conversion of levodopa to dopamine by increasing the concentration of a necessary cofactor, pyridoxal-5-phosphate. Excess pyridoxine increases the rate of conversion, and thus decreases the amount of levodopa available to cross the blood-brain barrier, and thus exert its therapeutic, anti-Parkinson's effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Carter AB, “Pyridoxine and Parkinsonism,” <i>Br Med J</i>, 1973, 4:236. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4758412\">[PubMed 4758412]</a></p>\n<p>2. Cotzias GC and Papavasiliou PS, “Blocking the Negative Effects of Pyridoxine on Patients Receiving Levodopa,” <i>JAMA</i>, 1971, 215:1504. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5107638\">[PubMed 5107638]</a></p>\n<p>3. Duvoisin RC, Yahr MD, and Cote LD, “Pyridoxine Reversal of L-Dopa Effects in Parkinsonism,” <i>Trans Am Neurol Ass</i>, 1969, 94:81. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5374494\">[PubMed 5374494]</a></p>\n<p>4. Hildick-Smith M, “Pyridoxine in Parkinsonism,” <i>Lancet</i>, 1973, ii:1029.</p>\n<p>5. Yahr MD and Duvoisin RC, “Pyridoxine and Levodopa in the Treatment of Parkinsonism,” <i>JAMA</i>, 1972, 220:861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5067358\">[PubMed 5067358]</a></p>\n<p>6. Papavasiliou PS, Cotzias GC, Duby SE, et al, “Levodopa in Parkinsonism: Potentiation of Central Effects With a Peripheral Inhibitor,” <i>N Engl J Med</i>, 1972, 285:8-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4550085\">[PubMed 4550085]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7760":"<p><b>Title</b> Multivitamins/Minerals (with AE, No Iron) / Mineral Oil</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mineral Oil may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant administration of mineral oil with a multivitamin to minimize the risk for an interaction, though specific recommendations regarding how much to separate administration of these agents are not available. If the multivitamin is being used to increase/maintain concentrations of a specific vitamin or mineral, increased monitoring of serum concentrations may be warranted after initiation of regular mineral oil use.</p> \n<p><b>Discussion</b> The prescribing information for several analogs of the fat-soluble vitamin D warn that mineral oil may interfere with their absorption.<sup>1,2,3,4</sup> Though specific recommendations regarding administration are not provided in the manufacturer labeling, it would seem prudent to separate the administration of vitamin D, and possibly other fat-soluble vitamins, from mineral oil by several hours to minimize the potential for an interaction. Similarly, the mineral oil prescribing information warns that chronic and abusive use may lead to potentially serious adverse events (e.g., bleeding, metabolic).<sup>5</sup><br><br>In contrast, a published case report describes a 17-year-old female with normal values for prothrombin time, vitamin A and E, alkaline phosphatase, calcium, and phosphorus, despite consuming mineral oil (up to 400 mL/day) for at least 5 months.<sup>6</sup> A study of 25 children who were treated with mineral oil (between meals) for up to 4 months for constipation similarly reported only minimal to moderate effects on serum concentrations of various fat-soluble vitamins.<sup>7</sup> Serum beta-carotene concentrations were reduced by an average of 35%, alpha-tocopherol concentrations were not significantly changed, and serum retinol concentrations were increased by an average of 50%. Others have also questioned the evidence supporting this potential interaction.<sup>8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Hectorol (doxercalciferol). Cambridge, MA: Genzyme Corporation, February 2011.</p>\n<p>2. Prescribing information. Drisdol (ergocalciferol). Bridgewater, NJ: Sanofi-Aventis U.S. LLC, March 2007.</p>\n<p>3. Prescribing information. Zemplar (paricalcitol). North Chicago, IL: Abbott Laboratories, June 2010. </p>\n<p>4. Product monograph. One-Alpha (alfacalcidol). Thornhill, Ontario:LEO Pharma Inc., March 2010.</p>\n<p>5. Prescribing information. Mineral oil. Greensville, SC: Pharmaceutical Associates, Inc., November 2002.</p>\n<p>6. Gal-Ezer S, Shaoul R, “The Safety of Mineral Oil in the Treatment of Constipation- A Lesson from Prolonged Overdose,” Clin Pediatr, 2006, 45:856-58. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17041175\">[PubMed 17041175]</a></p>\n<p>7. Clark JH, Russell GJ, Fitzgerald JF, et al, “Serum Beta-Carotene, Retinol, and Alpha-Tocopherol Levels During Mineral Oil Therapy for Constipation,” <i>Am J Dis Child</i>, 1987, 141(11):1210-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3673974\">[PubMed 3673974]</a></p>\n<p>8. Abi-Hanna A, Lake AM, “Constipation and Encopresis in Childhood,” <i>Pediatr Rev</i>, 1998, 19(1):23-30 <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9439166\">[PubMed 9439166]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7761":"<p><b>Title</b> Multivitamins/Minerals (with AE, No Iron) / Orlistat</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Orlistat may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, orlistat may impair absorption of fat-solube vitamins. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer oral fat soluble vitamins (such as vitamins A, D, E, and/or K that are contained in many multivitamin products) at least 2 hours before or after the administration of orlistat. Avoid concomitant administration due to the risk of impaired vitamin absorption. Similar precautions do not apply to parenterally administered fat soluble vitamins.</p> \n<p><b>Discussion</b> Orlistat prescribing information describes reduced absorption of supplemental beta carotene (30%) and vitamin E (60%) associated with its concomitant use.<sup>1</sup> The influence of orlistat on the absorption of other fat soluble vitamins including diet-derived vitamin K or supplemental vitamin A and D has not been demonstrated. As orlistat inhibits gastric and pancreatic lipase, it would seem prudent to anticipate a similar effect on the absorption of these fat soluble vitamins as well.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Xenical (orlistat). South San Francisco, CA: Genentech USA, Inc., May 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7762":"<p><b>Title</b> Retinoic Acid Derivatives / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may enhance the adverse/toxic effect of Retinoic Acid Derivatives. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Advise patients to avoid consuming vitamin A-containing supplements while taking retinoic acid derivatives. If supplements containing vitamin A are used, ensure vitamin A consumption does not exceed the recommended daily allowance of 4,000 to 5,000 units daily due to the risk for vitamin A toxicity.</p>\n<div>\n <p><b>Retinoic Acid Derivatives Interacting Members</b> Acitretin, Adapalene, Alitretinoin (Systemic), Alitretinoin (Topical), Bexarotene (Systemic), Bexarotene (Topical), ISOtretinoin (Systemic), Tretinoin (Systemic), Tretinoin (Topical)</p>\n</div> \n<p><b>Discussion</b> Due to the concern for an increased risk of vitamin A toxicity (eg, nausea, vomiting, headache, dizziness, blurred vision, skin and mucous disturbances), prescribing information for retinoic acid derivatives recommends to either strictly avoid all vitamin A supplements<sup>1,2,3,4</sup> or generally avoid vitamin A supplements, and if used, to not exceed the recommended daily allowance of 4,000 to 5,000 units daily.<sup>5</sup> <br><br>The likely mechanism of this potential interaction is retinoid overload resulting from the intake of both the specific retinoid derivative and vitamin A.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Soriatane</i> (acitretin) [prescribing information]. Research Triangle Park, NC: Stiefel Laboratories Inc; May 2014.</p>\n<p>2. <i>Accutane</i> (isotretinoin) [prescribing information]. Nutley, NJ: Roche Laboratories Inc; January 2010.</p>\n<p>3. Tretinoin [prescribing information]. Spring Valley, NY: Par Pharmaceutical Companies Inc; December 2011.</p>\n<p>4. <i>Toctino</i> (alitretinoin) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; January 2013.</p>\n<p>5. <i>Targretin</i> (bexarotene) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; November 2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7764":"<p><b>Title</b> Ceftibuten / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Ceftibuten. Specifically, the zinc contained in many multivitamins may decrease ceftibuten absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider administering oral zinc-containing multivitamins at least 3 hours after ceftibuten.</p> \n<p><b>Discussion</b> A study in rats found that concurrent administration of zinc with ceftibuten was associated with 50% inhibition of ceftibuten absorption, resulting in significant decreases in ceftibuten maximum concentration (Cmax) and prolonged time to maximum concentration (Tmax).<sup>1</sup> These results are consistent with the findings of an in vitro study where zinc was shown to inhibit the peptide transporter (PEPT1)-mediated uptake of the cephalosporins ceftibuten and cephradine in cultured cells.<sup>2</sup><br><br>Similarly, in a clinical study of 12 healthy volunteers, simultaneous coadministration of zinc sulfate (250 mg single oral dose) with the cephalosporin cephalexin (500 mg single oral dose), which is similarly dependent on PEPT1-mediated intestinal uptake, decreased cephalexin Cmax and AUC by 31% and 27%, respectively.<sup>3</sup> Cephalexin Cmax and AUC were decreased by 11% and 18%, respectively, when zinc sulfate was administered 3 hours before cephalexin, but there was no significant alteration of these variables when zinc sulfate was administered 3 hours after cephalexin.<br><br>This interaction appears to be at least partly attributable to zinc inhibition of PEPT1-mediated active uptake of ceftibuten from the gastrointestinal tract.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Okamura M, Terada T, Katsura T, et al, “Inhibitory effect of zinc on the absorption of beta-lactam antibiotic ceftibuten via the peptide transporters in rats,” <i>Drug Metab Pharmacokinet</i>, 2008, 23(6):464-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19122341\">[PubMed 19122341]</a></p>\n<p>2. Okamura M, Terada T, Katsura T, et al, “Inhibitory Effect of Zinc on PEPT1-Mediated Transport of Glycylsarcosine and Beta-Lactam Antibiotics in Human Intestinal Cell Line Caco-2,” <i>Pharm Res</i>, 2003, 20(9):1389-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14567632\">[PubMed 14567632]</a></p>\n<p>3. Ding Y, Jia Y, Li F, et al, “The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin,” <i>Br J Clin Pharmacol</i>, 2012, 73(3):422-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023069\">[PubMed 22023069]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7765":"<p><b>Title</b> Cephalexin / Multivitamins/Minerals (with AE, No Iron)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Multivitamins/Minerals (with AE, No Iron) may decrease the serum concentration of Cephalexin. Specifically, the zinc contained in many multivitamins may decrease cephalexin absorption. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider administering multivitamins at least 3 hours after cephalexin.</p> \n<p><b>Discussion</b> In a clinical study of 12 healthy volunteers, simultaneous coadministration of zinc sulfate (250 mg single oral dose) with cephalexin (500 mg single oral dose) decreased cephalexin maximum concentration (Cmax) and AUC by 31% and 27%, respectively.<sup>1</sup> Cephalexin Cmax and AUC were decreased by 11% and 18%, respectively, when zinc sulfate was administered 3 hours before cephalexin, but there was no significant alteration of these variables when zinc sulfate was administered 3 hours after cephalexin.<br><br>This interaction may be at least partly attributable to zinc inhibition of PEPT1-mediated active uptake of cephalexin from the gastrointestinal tract.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ding Y, Jia Y, Li F, et al, “The Effect of Staggered Administration of Zinc Sulfate on the Pharmacokinetics of Oral Cephalexin,” <i>Br J Clin Pharmacol</i>, 2012, 73(3):422-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22023069\">[PubMed 22023069]</a></p>\n<p>2. Okamura M, Terada T, Katsura T, et al, “Inhibitory Effect of Zinc on PEPT1-Mediated Transport of Glycylsarcosine and Beta-Lactam Antibiotics in Human Intestinal Cell Line Caco-2,” <i>Pharm Res</i>, 2003, 20(9):1389-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14567632\">[PubMed 14567632]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7766":"<p><b>Title</b> Multivitamins/Minerals (with AE, No Iron) / Thiazide and Thiazide-Like Diuretics</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Thiazide and Thiazide-Like Diuretics may increase the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, thiazide diuretics may decrease the excretion of calcium, and continued concomitant use can also result in metabolic alkalosis. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for toxic effects of calcium if a thiazide diuretic is initiated or the dose is increased.</p>\n<div>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> Case reports describe hypercalcemia, and signs and symptoms of the milk-alkali syndrome (including dizziness, weakness, hypercalcemia, metabolic and alkalosis with respiratory compensation), developing in conjunction with concomitant use of thiazide diuretics and calcium supplementation.<sup>1,2,3,4</sup> Thiazide diuretics inhibit the excretion of calcium, as well as bicarbonate. As such, calcium supplementation can result in the noted adverse effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Drinka PJ and Nolten WE, “Hazards of Treating Osteoporosis and Hypertension Concurrently With Calcium, Vitamin D, and Distal Diuretics,” <i>J Am Geriat Soc</i>, 1984, 32(5):405-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6715769\">[PubMed 6715769]</a></p>\n<p>2. Hakim R, Tolis G, Goltzman D, et al, “Severe Hypercalcemia Associated With Hydrochlorothiazide and Calcium Carbonate Therapy,” <i>Can Med Assoc J</i>, 1979, 121(5):591-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=497950\">[PubMed 497950]</a></p>\n<p>3. Gora ML, Seth SK, Bay WH, et al, “Milk-Alkali Syndrome Associated With Use of Cholorothiazide and Calcium Carbonate,” <i>Clin Pharm</i>, 1989, 8(3):227-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27006898\">[PubMed 27006898]</a></p>\n<p>4. Parfitt AM, “Chlorothiazide-Induced Hypercalcemia in Juvenile Osteoporosis and Hyperparathyroidism,” <i>N Engl J Med</i>, 1969, 281(2):55-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5305802\">[PubMed 5305802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7767":"<p><b>Title</b> Ezogabine / CarBAMazepine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CarBAMazepine may decrease the serum concentration of Ezogabine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Consider increasing the ezogabine dose when adding carbamazepine. Patients using this combination should be monitored closely for evidence of adequate ezogabine therapy. Conversely, patients stable on this combination may need to have their ezogabine dose reduced if carbamazepine is discontinued.</p> \n<p><b>Discussion</b> The ezogabine AUC was decreased by an average of 31% when administered with carbamazepine (600-1200 mg/d) in a study described in the ezogabine prescribing information.<sup>1</sup> As a result of this decrease in ezogabine exposure, the prescribing information recommends consideration of using increased ezogabine doses when used with carbamazepine.<br><br>The specific mechanism for this apparent interaction is unknown, but enhanced glucuronidation and/or acetylation of ezogabine is possible.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Potiga (ezogabine). Research Triangle Park, NC: GlaxoSmithKline, 06/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7769":"<p><b>Title</b> Ezogabine / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Ezogabine. Alcohol (Ethyl) may increase the serum concentration of Ezogabine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Caution patients that concurrent use with alcohol may increase the risks for and severity of ezogabine adverse effects. Also, concurrent use of these drugs may enhance the CNS depressant effects that are possible with each individual agent.</p> \n<p><b>Discussion</b> The ezogabine AUC was increased by an average of 36% when administered with alcohol (1 g/kg over 20 minutes) in a study of healthy volunteers (n=17).<sup>1</sup> Despite this apparent pharmacokinetic interaction, there was no detectable increase in subjective effects of either alcohol or ezogabine with the combination. However, due to the increase in ezogabine exposure, increased ezogabine effects are possible with the combination.<sup>2</sup><br><br>The specific mechanism for this apparent interaction is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Crean CS, Tompson DJ, “The Effects of Ethanol on the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ezogabine (Retigabine),” <i>Clin Ther</i>, 2013, 35(1):87-93. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23328270\">[PubMed 23328270]</a></p>\n<p>2. Prescribing information. Potiga (ezogabine). Research Triangle Park, NC: GlaxoSmithKline, 06/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7771":"<p><b>Title</b> LamoTRIgine / Ezogabine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ezogabine may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients receiving ezogabine and lamotrigine for evidence of enhanced CNS depression.</p> \n<p><b>Discussion</b> The lamotrigine AUC was decreased by an average of 18% with concurrent use of lamotrigine (200 mg/day) and ezogabine (600 mg/d) in a study described in the ezogabine prescribing information.<sup>1</sup> The clinical significance of this apparent interaction is uncertain but likely to be low considering the relatively small reduction in lamotrigine exposure. The specific mechanism for this apparent interaction is unknown, but given the average 22% increase in lamotrigine clearance reported in the study,<sup>1</sup> ezogabine may enhance the glucuronidation of lamotrigine. <br><br>Independent of the minor pharmacokinetic interaction between these agents, this combination is expected to increase the likelihood that patients will experience signs and symptoms of CNS depression.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Potiga (ezogabine). Research Triangle Park, NC: GlaxoSmithKline, 06/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7773":"<p><b>Title</b> Vemurafenib / Ipilimumab</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ipilimumab may enhance the hepatotoxic effect of Vemurafenib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. Use of this combination should only be undertaken with extra close monitoring of liver function (hepatic transaminases and bilirubin) and signs/symptoms of hepatotoxicity. As with all treatment decisions, carefully consider the increased risks for hepatotoxicity against any potential benefits.</p> \n<p><b>Discussion</b> In a study of two different vemurafenib plus ipilimumab dosing regimens, 6/10 patients experienced grade 3 elevation in hepatic transaminases, 13-36 days after the dose of ipilimumab (all patients had received ipilimumab 3 mg/kg; 6/10 received vemurafenib 960 mg twice/day, and 4/10 received vemurafenib 720 mg twice/day).<sup>1</sup> Additionally, another patient experienced a grade 2 elevation in hepatic transaminases, and 2 of the patients with elevated transaminases also experienced a grade 2 or 3 elevation in bilirubin. In all cases the transaminase/bilirubin elevations resolved within 4-20 days. Of the 6 patients with grade 3 transaminase elevations, 1 permanently discontinued both vemurafenib and ipilimumab, while 2/6 continued vemurafenib treatment with no further ipilimumab and 3/6 continued with both vemurafenib and ipilimumab (for 1-2 additional infusions). Of the 3 who continued with combination therapy, 1 experienced a relapse of elevated transaminases.<br><br>The findings from this study are in contrast to data for these drugs used outside of the combination. The reported incidence of significantly elevated transaminases and/or bilirubin with vemurafenib is 1.9-2.8%,<sup>2</sup> and the incidence of at least moderate hepatotoxicity with ipilimumab in the clinical study described in its prescribing information is 4.5%.<sup>3</sup><br><br>The specific mechanism for this possible interaction is not clear; however, the unexpectedly high rate of transaminase elevation suggests this goes beyond mere additive toxicity.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ribas A, Hodi FS, Callahan M, et al, “Hepatotoxicity with Combination of Vemurafenib and Ipilimumab,” <i>N Engl J Med</i>, 2013, 368(14):1365-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23550685\">[PubMed 23550685]</a></p>\n<p>2. Prescribing information. Zelboraf (vemurafenib). South San Francisco, CA: Genentech USA, Inc., 07/2013.</p>\n<p>3. Prescribing information. Yervoy (ipilimumab). Princeton, NJ: Bristol-Myers Squibb Company, May 2012.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7774":"<p><b>Title</b> Digoxin / Trimethoprim</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Trimethoprim may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor response to digoxin (i.e., signs/symptoms of response or toxicity, serum concentrations, etc.) more closely when used with trimethoprim, particularly when starting or stopping trimethoprim in patients previously stable on digoxin.</p> \n<p><b>Discussion</b> Digoxin serum concentrations were an average of 22% higher with concurrent trimethorpim in a group of older patients (n=9, ages 62-92 years).<sup>1</sup> Subsequent administration of the combination to healthy volunteers (n=6) found that the renal clearance of digoxin was decreased by an average of 17%.<sup>1</sup><br><br>The mechanism for this interaction is uncertain but seems to involve decreased renal clearance of digoxin, possibly via inhibition of renal transport by trimethoprim.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Petersen P, Kastrup J, Bartram R, et al, “Digoxin-Trimethoprim Interaction,” <i>Acta Med Scand</i>, 1985, 217(4):423-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4013832\">[PubMed 4013832]</a></p>\n<p>2. Prescribing information. Bactrim (sulfamethoxazole and trimethoprim). Philadelphia, PA: AR Scientific, Inc., June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7777":"<p><b>Title</b> Spironolactone / Triamterene</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Triamterene may enhance the hyperkalemic effect of Spironolactone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Spironolactone should not be given together with a potassium-sparing diuretic such as triamterene due to the risk for severe hyperkalemia.</p> \n<p><b>Discussion</b> The prescribing information for spironolactone cautions that concurrent use of spironolactone with other agents that increase serum potassium may increase the risk for severe hyperkalemia. The prescribing information goes on to state that spironolactone should not be given with potassium-sparing diuretics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aldactone (spironolactone). New York, NY: Pfizer, Inc, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7778":"<p><b>Title</b> Spironolactone / AMILoride</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> AMILoride may enhance the hyperkalemic effect of Spironolactone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Spironolactone should not be given together with a potassium-sparing diuretic such as amiloride due to the risk for severe hyperkalemia.</p> \n<p><b>Discussion</b> The prescribing information for spironolactone cautions that concurrent use of spironolactone with other agents that increase serum potassium may increase the risk for severe hyperkalemia. The prescribing information goes on to state that spironolactone should not be given with potassium-sparing diuretics.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Aldactone (spironolactone). New York, NY: Pfizer, Inc, June 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7779":"<p><b>Title</b> Lurasidone / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use of grapefruit juice or grapefruit with lurasidone should be avoided. Any such concurrent use could be expected to increase lurasidone absorption/bioavailability and overall exposure to lurasidone.</p> \n<p><b>Discussion</b> Lurasidone prescribing information cautions that use of grapefruit products with lurasidone should be avoided. Coadministration of diltiazem (240 mg/day), which is a relatively moderate CYP3A inhibitor like grapefruit/grapefruit juice, increased lurasidone maximum concentration and AUC by approximately 2-fold each, respectively.<sup>1</sup> The likely primary mechanism of this interaction is grapefruit-mediated inhibition of intestinal CYP3A4 metabolism of lurasidone.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Latuda (lurasidone). Marlborough, MA: Sunovion Pharmaceuticals Inc., 7/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7780":"<p><b>Title</b> Lurasidone / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Lurasidone. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Lurasidone should not be used together with St Johns wort (or any strong CYP3A4 inducers). Lurasidone US prescribing information specifically lists this as a contraindication.</p> \n<p><b>Discussion</b> In a study described in lurasidone prescribing information, coadministration of the CYP3A inducer rifampin (600 mg/day for 8 days) reduced single-dose lurasidone (40 mg) maximum concentration and AUC to 1/7th and 1/5th, respectively, of values achieved in the absence of rifampin.<sup>1</sup> The likely primary mechanism of this interaction is rifampin induction of CYP3A4 mediated lurasidone metabolism. Lurasidone prescribing information cautions that lurasidone should not be used together with St Johns wort.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7781":"<p><b>Title</b> Estazolam / Itraconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Itraconazole may increase the serum concentration of Estazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Avoid the use of itraconazole and estazolam in combination. Estazolam U.S. prescribing information specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Estazolam U.S. prescribing information lists its use in combination with itraconazole as contraindicated due to the potential for increased estazolam exposure and enhanced or prolonged sedative effects.<sup>1</sup> An interaction between these agents is expected based on data suggesting that CYP3A4 is a significant contributor to the 4-hydroxylation of estazolam, and that this reaction can be inhibited by CYP3A4 inhibitors including itraconazole.<sup>1,2</sup> In a clinical study of healthy volunteers, however, coadministration of itraconazole (100 mg/day for 7 days) had no impact on estazolam exposure or measures of psychomotor function (e.g., via digit symbol substitution test).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Estazolam. Sellersville, PA: Teva Pharmaceuticals USA, 6/2008.</p>\n<p>2. Miura M, Otani K and Ohkubo T, “Identification of Human Cytochrome P450 Enzymes Involved in the Formation of 4-Hydroxyestazolam From Estazolam,” <i>Xenobiotica</i>, 2005, 35(5):455-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16012077\">[PubMed 16012077]</a></p>\n<p>3. Otsuji Y, Okuyama N, Aoshima T, et al, “No Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Estazolam,” <i>Ther Drug Monit</i>, 2002, 24(3):375-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021628\">[PubMed 12021628]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7782":"<p><b>Title</b> Estazolam / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Estazolam. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> Avoid the use of ketoconazole and estazolam in combination. Estazolam U.S. prescribing information specifically lists this combination as contraindicated.</p> \n<p><b>Discussion</b> Estazolam U.S. prescribing information lists its use in combination with ketoconazole as contraindicated due to the potential for increased estazolam exposure and enhanced or prolonged sedative effects.<sup>1</sup> An interaction between these agents is expected based on data suggesting that CYP3A4 is a significant contributor to the 4-hydroxylation of estazolam, and that this reaction can be inhibited by CYP3A4 inhibitors including itraconazole (an azole antifungal agent closely related to ketoconazole).<sup>1,2</sup> In a clinical study of healthy volunteers, however, coadministration of itraconazole (100 mg/day for 7 days) had no impact on estazolam exposure or measures of psychomotor function (e.g., via digit symbol substitution test).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Estazolam. Sellersville, PA: Teva Pharmaceuticals USA, 6/2008.</p>\n<p>2. Miura M, Otani K and Ohkubo T, “Identification of Human Cytochrome P450 Enzymes Involved in the Formation of 4-Hydroxyestazolam From Estazolam,” <i>Xenobiotica</i>, 2005, 35(5):455-65. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16012077\">[PubMed 16012077]</a></p>\n<p>3. Otsuji Y, Okuyama N, Aoshima T, et al, “No Effect of Itraconazole on the Single Oral Dose Pharmacokinetics and Pharmacodynamics of Estazolam,” <i>Ther Drug Monit</i>, 2002, 24(3):375-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12021628\">[PubMed 12021628]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7783":"<p><b>Title</b> Pimozide / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> FLUoxetine may enhance the QTc-prolonging effect of Pimozide. FLUoxetine may increase the serum concentration of Pimozide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of pimozide and fluoxetine is contraindicated.</p> \n<p><b>Discussion</b> According to pimozide prescribing information, the pimozide AUC was increased by an average of 151%, and the pimozide maximum serum concentration (Cmax) was increased by an average of 62% when pimozide (2 mg x1) was administered with the strong CYP2D6 inhibitor paroxetine 60 mg.<sup>1</sup> The mechanism for this apparent interaction is described as being inhibition of the CYP2D6-mediated metabolism of pimozide by paroxetine.<sup>1</sup> As a result, pimozide prescribing information lists concurrent use of strong CYP2D6 inhibitors such as paroxetine or fluoxetine as contraindicated. The fluoxetine prescribing information also specifically contraindicates concurrent use with pimozide due to the potential for fluoxetine to inhibit the CYP2D6-mediated metabolism of pimozide and to increase the potential for QT interval prolongation.<sup>2</sup><br><br>These findings and conclusions are in conflict with both one in vivo study performed in CYP2D6 extensive and poor metabolizers that concluded CYP2D6 did not influence pimozide pharmacokinetics,<sup>3</sup> and two in vitro studies that each concluded that CYP2D6 and/or CYP2D6 inhibition had a minimal influence on pimozide metabolism.<sup>4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Orap (pimozide). Sellersville, PA: Teva Pharmaceuticals US, 08/2011.</p>\n<p>2. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Lilly USA, LLC, 07/2013.</p>\n<p>3. Desta Z, Kerbusch T, Flockhart DA, “Effect of Clarithromycin on the Pharmacokinetics and Pharmacodynamics of Pimozide in Healthy Poor and Extensive Metabolizers of Cytochrome P450 2D6 (CYP2D6),” <i>Clin Pharmacol Ther</i>, 1999, 65(1):10-20. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9951426\">[PubMed 9951426]</a></p>\n<p>4. Desta Z, Soukhova N, Flockhart DA, “In Vitro Inhibition of Pimozide N-Dealkylation by Selective Serotonin Reuptake Inhibitors and Azithromycin,” <i>J Clin Psychopharmacol</i>, 2002, 22(2):162-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11910261\">[PubMed 11910261]</a></p>\n<p>5. Desta Z, Kerbusch T, Soukhova N, et al, “Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide,” <i>J Pharmacol Exp Ther</i>, 1998, 285(2):428-37. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9580580\">[PubMed 9580580]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7784":"<p><b>Title</b> Thioridazine / FLUoxetine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> FLUoxetine may enhance the QTc-prolonging effect of Thioridazine. FLUoxetine may increase the serum concentration of Thioridazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of thioridazine and fluoxetine is contraindicated. Also, thioridazine should not be used within 5 weeks of stopping fluoxetine due to the long half-lives of fluoxetine and its active metabolite (and the resultant sustained risk for increased thioridazine concentrations and excessive QT interval prolongation).</p> \n<p><b>Discussion</b> The Cmax and AUC of thioridazine (25 mg single oral dose) increased 2.4-fold and 4.5-fold, respectively, in 6 healthy subjects labeled as “slow hydroxylators” as compared to 13 healthy subjects labeled as “rapid hydroxylators”.<sup>1</sup> Hydroxylation status was determined based on the speed at which these subjects metabolized debrisoquin, an agent extensively metabolized by CYP2D6. This information lends support to the potential impact of CYP2D6 inhibitor drugs. In addition, thioridazine has been shown to prolong QTc intervals in a dose-dependent fashion in healthy subjects<sup>2</sup>. Compared with placebo, thioridazine increased QTc intervals by 9 msec and 23 msec with 10 mg and 50 mg doses, respectively. As such, thioridazine prescribing information contraindicates the concomitant use of CYP2D6 inhibitors.<sup>1</sup> The prescribing information for fluoxetine, which is a strong CYP2D6 inhibitor, similarly specifically contraindicates use with thioridazine.<sup>3</sup> Given the long half-lives of fluoxetine and its active norfluoxetine metabolite, this warning specifically cautions that thioridazine should not be used with fluoxetine or within 5 weeks of stopping fluoxetine due to the risk for excessive QT interval prolongation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Thioridazine. Morgantown, WV: Mylan Pharmaceuticals Inc., April 2009. </p>\n<p>2. Hartigan-Go K, Bateman DN, Nyberg G, et al, “Concentration-Related Pharmacodynamic Effects of Thioridazine and its Metabolites in Humans,” <i>Clin Pharmacol Ther</i>, 1996, 60:543-53. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8941027\">[PubMed 8941027]</a></p>\n<p>3. Prescribing information. Prozac (fluoxetine). Indianapolis, IN: Lilly USA, LLC, 07/2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7787":"<p><b>Title</b> Hyoscyamine / Antacids</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: Dose separation recommendations for this interaction apply only to immediate release oral hyoscyamine dosage forms, and not to time release or sublingual preparations.</p></li>\n <li><p><b>Route</b>: This interaction is only expected with oral hyoscyamine.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antacids may decrease the serum concentration of Hyoscyamine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination.</p>\n<div>\n <p><b>Antacids Interacting Members</b> Almagate, Aluminum Hydroxide, Calcium Carbonate, Diomagnite, Magaldrate, Magnesium Carbonate, Magnesium Hydroxide, Magnesium Trisilicate, Potassium Bicarbonate, Sodium Bicarbonate</p>\n</div> \n<p><b>Discussion</b> U.S. prescribing information for immediate-release hyoscyamine formulations states that patients receiving these products and antacids in combination should take hyoscyamine before meals and antacids after meals, because antacids may interfere with hyoscyamine absorption.<sup>1,2,3</sup> No data are available characterizing the magnitude of interaction between these agents or the impact of the recommended dose separation. U.S. prescribing information for time release and sublingual hyoscyamine products highlights the potential for hyoscyamine to interact with antacids, but does not recommend any deviation from normal dose scheduling.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Anaspaz (hyoscyamine). Lenexa, KS: B. F. Ascher &amp; Compant, Inc., 6/2010.</p>\n<p>2. Prescribing information. Hyosyne (hyoscyamine). Spring Valley, NY: Silarx Pharmaceuticals, Inc., 4/2007.</p>\n<p>3. Prescribing information. Levsin (hyoscyamine). Marietta, GA: Alaven Pharmaceutical LLC, 2/2008.</p>\n<p>4. Prescribing information. Symax SR (hyoscyamine). Ft. Worth, TX: Capellon Pharmaceuticals, LLC, 9/2012.</p>\n<p>5. Prescribing information. Oscimin-SR (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</p>\n<p>6. Prescribing information. Oscimin (hyoscyamine). Canton, MS: Larken Laboratories, Inc., 6/2011.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7788":"<p><b>Title</b> Thyroid Products / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor thyroid function in patients receiving thyroid supplements following initiation, dose adjustment, or discontinuation of a selective serotonin reuptake inhibitor.</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n <p><b>Thyroid Products Interacting Members</b> Levothyroxine, Liothyronine, Liotrix, Thyroid, Desiccated</p>\n</div> \n<p><b>Discussion</b> Levothyroxine U.S. prescribing information states that administration of selective serotonin reuptake inhibitors (SSRIs) may increase levothyroxine dose requirements, specifically citing sertraline as a potentially interacting SSRI.<sup>1</sup> Several published case reports describe patients who exhibited laboratory evidence (with or without clinical evidence) of diminished thyroid function during treatment with selective serotonin reuptake inhibitors (SSRIs, including escitalopram, paroxetine, sertraline), and/or apparent increases in thyroid function following discontinuation of SSRIs.<sup>2,3,4,5</sup> U.S. prescribing information for several SSRIs also lists hypothyroidism and related conditions as potential rare adverse events associated with treatment.<sup>6,7,8</sup><br><br>Several reports of clinical studies have also described laboratory evidence consistent with small decreases in thyroid function during treatment with SSRIs (including fluoxetine, fluvoxamine, paroxetine, sertraline),<sup>9,10,11,12,13,14,15</sup> although several others have found no such evidence with SSRIs (including fluoxetine, fluvoxamine, sertraline) relative to baseline values or control groups.<sup>10,16,17,18,19,20,21</sup><br><br>The mechanism of this possible interaction is not clear, and based on clinical studies to date the incidence of hypothyroidism following initiation of selective serotonin reuptake inhibitors is low. However, most investigations have included few or no patients with histories of thyroid dysfunction and receiving thyroid hormone supplementation.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Synthroid (levothyroxine). North Chicago, IL: Abbott Laboratories, 7/2008.</p>\n<p>2. Eker SS, Akkaya C, Ersoy C, et al, “Reversible Escitalopram-Induced Hypothyroidism,” <i>Gen Hosp Psychiatry</i>, 2010, 32(5):559.e5-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20851281\">[PubMed 20851281]</a></p>\n<p>3. Takahashi M, Sawayama E, Sawayama T, et al, “Reversible Paroxetine-Induced Symptomatic Hypothyroidism,” <i>Pharmacopsychiatry</i>, 2007, 40(5):201-2. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17874352\">[PubMed 17874352]</a></p>\n<p>4. McCowen KC, Garber JR and Spark R, “Elevated Serum Thyrotropin in Thyroxine-Treated Patients With Hypothyroidism Given Sertraline,” <i>N Engl J Med</i>, 1997, 337(14):1010-1. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9312673\">[PubMed 9312673]</a></p>\n<p>5. Harel Z, Biro FM and Tedford WL, “Effects of Long Term Treatment With Sertraline (Zoloft) Simulating Hypothyroidism in an Adolescent,” <i>J Adolesc Health</i>, 1995, 16(3):232-4. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7779834\">[PubMed 7779834]</a></p>\n<p>6. Prescribing information. Celexa (citalopram). St. Louis, MO: Forest Laboratories, Inc., 12/2012.</p>\n<p>7. Prescribing information. Zoloft (sertraline). New York, NY: Pfizer Inc, 2/2013.</p>\n<p>8. Prescribing information. Paxil (paroxetine). Research Triangle Park, NC: GlaxoSmithKline, 12/2012.</p>\n<p>9. Hoflich G, Kasper S, Danos P, et al, “Thyroid Hormones, Body Temperature, and Antidepressant Treatment,” <i>Biol Psychiatry</i>, 1992, 31(8):859-62. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1643199\">[PubMed 1643199]</a></p>\n<p>10. de Carvalho GA, Bahls SC, Boeving A, et al, “Effects of Selective Serotonin Reuptake Inhibitors on Thyroid Function in Depressed Patients With Primary Hypothyroidism or Normal Thyroid Function,” <i>Thyroid</i>, 2009, 19(7):691-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19583486\">[PubMed 19583486]</a></p>\n<p>11. Eker SS, Akkaya C, Sarandol A, et al, “Effects of Various Antidepressants on Serum Thyroid Hormone Levels in Patients With Major Depressive Disorder,” <i>Prog Neuropsychopharmacol Biol Psychiatry</i>, 2008, 32(4):955-61. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18262705\">[PubMed 18262705]</a></p>\n<p>12. Gitlin M, Altshuler LL, Frye MA, et al, “Peripheral Thyroid Hormones and Response to Selective Serotonin Reuptake Inhibitors,” <i>J Psychiatry Neurosci</i>, 2004, 29(5):383-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15486607\">[PubMed 15486607]</a></p>\n<p>13. Gendall KA, Joyce PR, Mulder RT, et al, “Thyroid Indices and Response to Fluoxetine and Nortriptyline in Major Depression,” <i>J Psychopharmacol</i>, 2003, 17(4):431-7. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14870956\">[PubMed 14870956]</a></p>\n<p>14. Konig F, Hauger B, von Hippel C, et al, “Effect of Paroxetine on Thyroid Hormone Levels in Severely Depressed Patients,” <i>Neuropsychobiology</i>, 2000, 42(3):135-8. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11015031\">[PubMed 11015031]</a></p>\n<p>15. Fava M, Labbate LA, Abraham ME, et al, “Hypothyroidism and Hyperthyroidism in Major Depression Revisited,” <i>J Clin Psychiatry</i>, 1995, 56(5):186-92. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7737957\">[PubMed 7737957]</a></p>\n<p>16. Shelton RC, Winn S, Ekhatore N, et al, “The Effects of Antidepressants on the Thyroid Axis in Depression,” <i>Biol Psychiatry</i>, 1993, 33(2):120-6. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8439600\">[PubMed 8439600]</a></p>\n<p>16. Brady KT, Lydiard RB, Kellner CH, et al, “A Comparison of the Effects of Imipramine and Fluvoxamine on the Thyroid Axis,” <i>Biol Psychiatry</i>, 1994 36(11):778-9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7858077\">[PubMed 7858077]</a></p>\n<p>18. Bross R and Hoffer LJ, “Fluoxetine Increases Resting Energy Expenditure and Basal Body Temperature in Humans,” <i>Am J Clin Nutr</i>, 1995, 61(5):1020-5. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7733022\">[PubMed 7733022]</a></p>\n<p>19. Duval F, Mokrani MC, Crocq MA, et al, “Effect of Antidepressant Medication on Morning and Evening Thyroid Function Tests During a Major Depressive Episode,” <i>Arch Gen Psychiatry</i>, 1996, 53(9):833-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8792760\">[PubMed 8792760]</a></p>\n<p>20. Schule C, Baghai TC, Alajbegovic L, et al, “The Influence of 4-Week Treatment With Sertraline on the Combined T3/TRH Test in Depressed Patients,” <i>Eur Arch Psychiatry Clin Neurosci</i>, 2005, 255(5):334-40. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15747035\">[PubMed 15747035]</a></p>\n<p>21. Sagud M, Pivac N, Muck-Seler D, et al, “Effects of Sertraline Treatment on Plasma Cortisol, Prolactin and Thyroid Hormones in Female Depressed Patients,” <i>Neuropsychobiology</i>, 2002, 45(3):139-43. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11979064\">[PubMed 11979064]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7790":"<p><b>Title</b> Thiazide and Thiazide-Like Diuretics / Selective Serotonin Reuptake Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients receiving thiazide diuretics and selective serotonin reuptake inhibitors in combination closely for signs and symptoms of hyponatremia (e.g., nausea, headache, confusion, lethargy).</p>\n<div>\n <p><b>Selective Serotonin Reuptake Inhibitors Interacting Members</b> Citalopram, Dapoxetine, Escitalopram, FLUoxetine, FluvoxaMINE, PARoxetine, Sertraline, Vilazodone, Vortioxetine</p>\n <p><b>Thiazide and Thiazide-Like Diuretics Interacting Members</b> Bendroflumethiazide, Chlorothiazide, Chlorthalidone, Cyclopenthiazide, HydroCHLOROthiazide, Hydroflumethiazide, Indapamide, Methyclothiazide, MetOLazone, Xipamide</p>\n</div> \n<p><b>Discussion</b> The Canadian product monograph for cilazapril and hydrochlorothiazide states that concomitant use of thiazide diuretics with selective serotonin reuptake inhibitors (SSRIs) may potentiate hyponatremic effects of the drugs.<sup>1</sup> SSRIs and thiazide diuretics have both been widely reported as potential causes of hyponatremia, and three published case reports describe patients who developed hyponatremia while using drugs from these classes concomitantly.<sup>2,3</sup> <br><br>This interaction is suspected to result from the independent, and possibly complementary, sodium-lowering effects of thiazide diuretics and SSRIs. Thiazides may promote hyponatremia via a variety of mechanisms, most directly by promoting renal sodium excretion but also potentially via other mechanisms as well (e.g., antidiuretic hormone stimulation), while SSRIs more likely promote hyponatremia primarily via stimulation of antidiuretic hormone release.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Inhibace Plus (cilazapril and hydrochlorothiazide). Mississauga, ON: Hoffmann-La Roche Limited, June 2013.</p>\n<p>2. Adiga GU and Dharmarajan TS, “Renal Tubular Defects From Antidepressant Use in an Older Adult: An Uncommon but Reversible Adverse Drug Effect,” <i>Clin Drug Investig</i>, 2006, 26(10):607-10. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17163295\">[PubMed 17163295]</a></p>\n<p>3. Rosner MH, “Severe Hyponatremia Associated With the Combined Use of Thiazide Diuretics and Selective Serotonin Reuptake Inhibitors,” <i>Am J Med Sci</i>, 2004, 327(2):109-11. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14770031\">[PubMed 14770031]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7791":"<p><b>Title</b> PAZOPanib / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of P-glycoprotein inhibitors in combination with pazopanib whenever possible.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> Pazopanib U.S. prescribing information states that its use with inhibitors of P-glycoprotein (P-gp, also known as ABCB1) and/or breast cancer resistance protein (BCRP, also known as ABCG2) efflux transporters should be avoided when possible, because such agents could theoretically increase pazopanib exposure.<sup>1</sup> Pazopanib is a substrate of P-gp and BCRP in vitro, although the significance of these transporters to pazopanib pharmacokinetic characteristics in humans is unknown. In one study carried out in mice, coadministration of a single intravenous dose of pazopanib with inhibitors of both of these transporters increased pazopanib brain exposure without affecting its plasma concentrations.<sup>2</sup> Inhibitors of one of these transporters given without an inhibitor of the other, in contrast, had no impact on brain or plasma pazopanib exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Votrient (pazopanib). Research Triangle Park, NC: GlaxoSmithKline, August 2013.</p>\n<p>2. Minocha M, Khurana V, Qin B, et al, “Enhanced Brain Accumulation of Pazopanib by Modulating P-gp and Bcrp1 Mediated Efflux With Canertinib or Erlotinib,” <i>Int J Pharm</i>, 2012, 436(1-2):127-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22688250\">[PubMed 22688250]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7792":"<p><b>Title</b> PAZOPanib / BCRP/ABCG2 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> BCRP/ABCG2 Inhibitors may increase the serum concentration of PAZOPanib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the use of BCRP inhibitors in combination with pazopanib whenever possible.</p>\n<div>\n <p><b>BCRP/ABCG2 Inhibitors Interacting Members</b> Atazanavir, Cobicistat, CycloSPORINE (Systemic), Daclatasvir, Dasabuvir, Elbasvir, Eltrombopag, Glecaprevir and Pibrentasvir, Grazoprevir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Osimertinib, Regorafenib, Rolapitant, Tedizolid, Teriflunomide, Velpatasvir, Voxilaprevir</p>\n</div> \n<p><b>Discussion</b> Pazopanib U.S. prescribing information states that its use with inhibitors of P-glycoprotein (P-gp, also known as ABCB1) and/or breast cancer resistance protein (BCRP, also known as ABCG2) efflux transporters should be avoided when possible, because such agents could theoretically increase pazopanib exposure.<sup>1</sup> Pazopanib is a substrate of P-gp and BCRP in vitro, although the significance of these transporters to pazopanib pharmacokinetic characteristics in humans is unknown. In one study carried out in mice, coadministration of a single intravenous dose of pazopanib with inhibitors of both of these transporters increased pazopanib brain exposure without affecting its plasma concentrations.<sup>2</sup> Inhibitors of one of these transporters given without an inhibitor of the other, in contrast, had no impact on brain or plasma pazopanib exposure.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Prescribing information. Votrient (pazopanib). Research Triangle Park, NC: GlaxoSmithKline, August 2013.</p>\n<p>2. Minocha M, Khurana V, Qin B, et al, “Enhanced Brain Accumulation of Pazopanib by Modulating P-gp and Bcrp1 Mediated Efflux With Canertinib or Erlotinib,” <i>Int J Pharm</i>, 2012, 436(1-2):127-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22688250\">[PubMed 22688250]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7793":"<p><b>Title</b> Imatinib / Gemfibrozil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Gemfibrozil may decrease serum concentrations of the active metabolite(s) of Imatinib. Specifically N-desmethylimatinib concentrations may be decreased. Gemfibrozil may decrease the serum concentration of Imatinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Carefully monitor the clinical response to imatinib whenever given in combination with gemfibrozil, and seek alternatives to gemfibrozil whenever possible.</p> \n<p><b>Discussion</b> In a clinical study of 10 healthy volunteers, coadministration of gemfibrozil (600 mg twice daily for 6 days) with imatinib (200 mg single oral dose taken 1 h after gemfibrozil, on gemfibrozil day 3) decreased the imatinib maximum plasma concentration (Cmax) and AUC in the first 12 hours post-dose by 35% and 23%, respectively, without affecting the total estimated imatinib AUC.<sup>1</sup> N-desmethylimatinib (the primary active metabolite of imatinib) Cmax, AUC in the first 12 hours, and estimated total AUC were reduced by 56%, 57%, and 48%, respectively. Correspondingly, the estimates for total active imatinib (imatinib + N-desmethylimatinib) Cmax and total AUC were reduced by 38% and 14%, respectively.<br><br>The exact mechanisms of this interaction are unknown. The authors of the clinical study propose that gemfibrozil may cause the above pharmacokinetic changes via inhibition of both imatinib active intestinal absorption and its CYP2C8 mediated conversion to N-desmethylimatinb.<sup>1</sup> The clinical impact of these pharmacokinetic changes is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Filppula AM, Tornio A, Niemi M, et al, “Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite,” <i>Clin Pharmacol Ther</i>, 2013 May 8. Epub. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23657159\">[PubMed 23657159]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7797":"<p><b>Title</b> Ulipristal / CYP3A4 Inhibitors (Strong)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Significance of this interaction is greater when ulipristal is used for treatment of uterine fibroid signs/symptoms (Canadian indication).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of ulipristal together with a moderate or strong CYP3A4 inhibitor is not recommended when ulipristal is being used as treatment for signs/symptoms of uterine fibroids (Canadian indication). No such recommendation to avoid is specifically included in the U.S. prescribing information, where the only approved indication is as an emergency contraceptive. If this combination is used, monitor patients for evidence of increased ulipristal effects/toxicity.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> According to the ulipristal product monograph, the ulipristal AUC increased an average of 5.9-fold when administered with the strong CYP3A4 inhibitor ketoconazole (400 mg/day x 7 days).<sup>1</sup> The AUC of the active mono-N-demethylated active metabolite, PGL4002, was also increased by an average of 2.4-fold.<br><br>Similarly, the ulipristal AUC increased an average of 2.9-fold when administered with the moderate CYP3A4 inhibitor erythromycin propionate (500 mg twice/day x 9 days).<sup>1</sup> The PGL4002 AUC was increased by an average of 1.5-fold.<br><br>Since ulipristal is a known substrate of CYP3A4,<sup>1,2</sup> the likely mechanism for this interaction is inhibition of the CYP3A-mediated metabolism of ulipristal.<br><br>The Canadian product monograph for ulipristal cautions that concurrent use with a moderate or strong CYP3A4 inhibitor is not recommended.<sup>1</sup> The U.S. prescribing information, however, does not include any specific warning about such a combination,<sup>2</sup> likely because the current U.S. indication (emergency contraception) requires only single-dose ulipristal treatment. Caution and increased monitoring for adverse effects still appears prudent with any such concurrent use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Product monograph. Fibristal (ulipristal acetate). Mississauga, Ontario, Canada: Actavis Specialty Pharmaceuticals Co., June 2013.</p>\n<p>2. Prescribing information. ella (ulipristal acetate). Morristown, NJ: Watson Pharma, Inc., 8/2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7798":"<p><b>Title</b> Ulipristal / CYP3A4 Inhibitors (Moderate)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Significance of this interaction is greater when ulipristal is used for treatment of uterine fibroid signs/symptoms (Canadian indication).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of ulipristal together with a moderate or strong CYP3A4 inhibitor is not recommended when ulipristal is being used as treatment for signs/symptoms of uterine fibroids (Canadian indication). No such recommendation to avoid is specifically included in the US prescribing information, where the only approved indication is as an emergency contraceptive. If this combination is used, monitor patients for evidence of increased ulipristal effects/toxicity.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to the ulipristal Canadian product monograph, the ulipristal AUC increased an average of 5.9-fold when administered with the strong CYP3A4 inhibitor ketoconazole (400 mg/day x 7 days).<sup>1</sup> The AUC of the active mono-N-demethylated active metabolite, PGL4002, was also increased by an average of 2.4-fold. AUCs of ulipristal and PGL 4002 also increased an average of 3.3 and 1.7-fold, respectively, when administered with the moderate CYP3A4 inhibitor erythromycin propionate (500 mg twice/day x 9 days) in a published clinical study of 18 healthy female volunteers.<sup>2</sup><br><br>The suspected primary mechanism of these interactions is inhibition of CYP3A-mediated ulipristal metabolism.<br><br>The Canadian product monograph for ulipristal cautions that concurrent use with a moderate or strong CYP3A4 inhibitor is not recommended.<sup>1</sup> The US prescribing information, however, does not include any specific warning about such a combination,<sup>3</sup> likely because the current US indication (emergency contraception) requires only single-dose ulipristal treatment. Caution and increased monitoring for adverse effects still appear prudent with any such concurrent use.</p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, ON: Actavis Specialty Pharmaceuticals Co; June 2013.</p>\n<p>2. Pohl O, Osterloh I, Gotteland JP. Effects of erythromycin at steady-state concentrations on the pharmacokinetics of ulipristal acetate. <i>J Clin Pharm Ther</i>. 2013;38(6):512-517. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24102384\">[PubMed 24102384]</a> </p>\n<p>3. <i>ella</i> (ulipristal acetate) [prescribing information]. Morristown, NJ: Watson Pharma Inc; August 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","7799":"<p><b>Title</b> Ulipristal / Progestins</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Progestins may diminish the therapeutic effect of Ulipristal. Ulipristal may diminish the therapeutic effect of Progestins. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Patients should avoid co-administration of uliprital with a hormonal contraceptive according to the U.S. prescribing information, where the only approved indication is as an emergency contraceptive (single-dose). Patients wishing to start or resume a hormone containing contraceptive should wait at least 5 days following the ulipristal dose before starting the progestin-containing contraceptive and should use a barrier contraceptive untl the next menstrual cycle. Patients using ulipristal as treatment for signs/symptoms of uterine fibroids (Canadian indication) should avoid use of any progestin-containing product within 12 days of stopping ulipristal therapy, and patients using hormonal contraceptive products should use a non-hormonal, barrier-type of contraceptive until their next menstrual period.</p>\n<div>\n <p><b>Progestins Interacting Members</b> Chlormadinone, Cyproterone, Desogestrel, Dienogest, Drospirenone, Dydrogesterone, Ethynodiol Diacetate, Etonogestrel, Gestodene, HYDROXYprogesterone Caproate, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Megestrol, Norelgestromin, Norethindrone, Norgestimate, Norgestrel, Progesterone</p>\n</div> \n<p><b>Discussion</b> Ulipristal, which acts as a tissue-specific partial antagonist of progestin receptors, may interfere with the effects of progestins, and progestin-containing products may likewise interfere with effects of ulipristal.<sup>1,2</sup> As a result, both the U.S. and Canadian labeling for ulipristal products caution that concurrent use of progestin-containing products should be avoided and that patients should wait at least 5 days (U.S.) or 12 days (Canada) after stopping ulipristal before resuming or starting any hormonal contraceptive.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. <i>Fibristal</i> (ulipristal acetate) [product monograph]. Mississauga, Ontario, Canada: Actavis Specialty Pharmaceuticals Co., June 2013.</p>\n<p>2. <i>ella</i> (ulipristal acetate) [prescribing information]. Charleston, SC: Afaxys, Inc.; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}